Original Article
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
N Engl J Med 2005; 353:1659-1672October 20, 2005
- Abstract
Background
Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy.
Methods
This international, multicenter, randomized trial compared one or two years of trastuzumab given every three weeks with observation in patients with HER2-positive and either node-negative or node-positive breast cancer who had completed locoregional therapy and at least four cycles of neoadjuvant or adjuvant chemotherapy.
Results
Data were available for 1694 women randomly assigned to two years of treatment with trastuzumab, 1694 women assigned to one year of trastuzumab, and 1693 women assigned to observation. We report here the results only of treatment with trastuzumab for one year or observation. At the first planned interim analysis (median follow-up of one year), 347 events (recurrence of breast cancer, contralateral breast cancer, second nonbreast malignant disease, or death) were observed: 127 events in the trastuzumab group and 220 in the observation group. The unadjusted hazard ratio for an event in the trastuzumab group, as compared with the observation group, was 0.54 (95 percent confidence interval, 0.43 to 0.67; P<0.0001 by the log-rank test, crossing the interim analysis boundary), representing an absolute benefit in terms of disease-free survival at two years of 8.4 percentage points. Overall survival in the two groups was not significantly different (29 deaths with trastuzumab vs. 37 with observation). Severe cardiotoxicity developed in 0.5 percent of the women who were treated with trastuzumab.
Conclusions
One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer. (ClinicalTrials.gov number, NCT00045032.)
Media in This Article
Figure 1
Consolidated Standards of Reporting Trials (CONSORT) Chart of the Herceptin Adjuvant (HERA) Trial.Figure 2
Kaplan–Meier Curves Showing Disease-free Survival (Panel A), Time to Distant Recurrence (Panel B), and Overall Survival (Panel C).Article Activity
- Article
Her2/neu (hereafter referred to as HER2) belongs to a family of four transmembrane receptor tyrosine kinases that mediate the growth, differentiation, and survival of cells.1,2 Overexpression of the HER2 protein, amplification of the HER2 gene, or both occur in approximately 15 to 25 percent of breast cancers, and are associated with aggressive behavior in the tumor.3,4
Trastuzumab (Herceptin, Roche), a humanized monoclonal antibody against the extracellular domain of HER2, has been shown to benefit patients with HER2-positive metastatic breast cancer when administered weekly or every three weeks, alone5,6 or in combination with chemotherapy.7,8 Trastuzumab is not associated with the adverse events that typically occur with chemotherapy, such as alopecia, myelosuppression, and severe nausea and vomiting.9 With the exception of hypersensitivity, which has been seen mainly and occasionally with the first infusion, cardiotoxicity (principally congestive heart failure) is the most important adverse effect of trastuzumab. Cardiotoxicity has been reported in 1.4 percent of women who received the drug as a single agent for metastatic disease.5,6 The adverse effect of the interaction between trastuzumab and anthracyclines on the heart7 and the lesser adverse effect of the interaction between trastuzumab and taxanes7,8 are concerns in the design and conduct of studies of adjuvant therapy, given the established activity and central role of anthracyclines and taxanes in the treatment of breast cancer. For this reason, investigations of trastuzumab in the adjuvant setting require careful cardiac monitoring and stopping rules specified for cardiotoxicity.
Our group investigated whether the administration of trastuzumab was effective as adjuvant treatment for HER2-positive breast cancer if used after completion of the primary treatment (e.g., surgery, radiotherapy, and chemotherapy given preoperatively [neoadjuvant], postoperatively [adjuvant], or both). The administration of trastuzumab after chemotherapy permits the application of our findings to the wide variety of chemotherapy regimens used throughout the world.10 In our trial, one group of women received trastuzumab for one year and another group received the drug for two years. We included these two groups for three reasons: a major peak in the rate of relapse occurs 18 to 24 months after surgery,11 effective treatment of HER2-positive breast cancer may require prolonged attenuation of HER2 activity,12 and tamoxifen, which is an effective targeted therapy for breast cancer, is most beneficial when given for longer than one year.13 We report a comparison of the results obtained with observation or with one year of trastuzumab after primary treatment of breast cancer.
Methods
Study Design
The Herceptin Adjuvant (HERA) (Breast International Group [BIG] 01-01) Trial is an international, intergroup, open-label, phase 3 randomized trial involving women with HER2-positive (overexpressing or amplified) early-stage invasive breast cancer who completed locoregional therapy (surgery with or without radiotherapy) and a minimum of four courses of chemotherapy (administered as adjuvant treatment postoperatively among 89 percent of the women, or as neoadjuvant treatment preoperatively among 5 percent of the women, or as both adjuvant and neoadjuvant chemotherapy among 6 percent of the women) (Figure 1Figure 1
Consolidated Standards of Reporting Trials (CONSORT) Chart of the Herceptin Adjuvant (HERA) Trial.). The HER2-positive status of the tumors was centrally confirmed in all cases before randomization. The trial included three groups: women who had observation alone; those treated with trastuzumab, given as adjuvant treatment (at a dose of 8 mg per kilogram of body weight intravenously once, then at a dose of 6 mg per kilogram every three weeks) for two years; and those treated with trastuzumab at the same dose and on the same schedule for one year. Random assignment to one of the three groups was performed within seven weeks from day 1 of the last chemotherapy cycle or six weeks from the end of radiotherapy or definitive surgery, whichever was last. A minimization procedure, according to the methods of Pocock and Simon,14 was used with stratification according to region of the world, age, nodal status, type of chemotherapy, and hormone-receptor status together with intention to use endocrine therapy (Table 1Table 1
Baseline characteristics of the Patients, Tumors, and Primary Treatments (Intention-to-Treat Groups).).The primary end point was disease-free survival, defined as time from randomization to the first occurrence of any of the following disease-free–survival events: recurrence of breast cancer at any site; the development of ipsilateral or contralateral breast cancer, including ductal carcinoma in situ but not lobular carcinoma in situ; second nonbreast malignant disease other than basal-cell or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix; or death from any cause without documentation of a cancer-related event. Secondary end points included cardiac safety, overall survival, site of first disease-free–survival event, and time to distant recurrence, defined as the time between randomization and the date of the first distant tumor recurrence, ignoring locoregional recurrences and second breast or nonbreast cancers and taking into account deaths before recurrence of distant breast cancer as censoring events.
The study was conducted under the auspices of the BIG and involved the collaboration of 17 BIG groups, 9 other cooperative groups, 91 independent centers, and the pharmaceutical sponsor, Roche, all of which were represented in the steering committee of the HERA trial. The study was designed by members of the steering committee. The database resided in a system of the sponsor, and access was restricted to data managers of the Breast European Adjuvant Study Team data center and statisticians of Frontier Science (Scotland). The sponsor had no access to the database or the interim analyses. The analyses were presented by the independent statisticians to the independent data monitoring committee without disclosure to the data center, the investigators, or the sponsor. The HERA steering committee was responsible for the decision to publish and for the content of the manuscript. The sponsor provided the drug and financial support.
The institutional review board at each of the 478 participating institutions in 39 countries approved the study protocol. All patients gave written informed consent.
Eligibility Criteria
Eligible patients had histologically confirmed, completely excised invasive breast cancer with HER2 overexpression or HER2 amplification as assessed in the participating institution and verified in the central laboratory of the trial (Kassel, Germany). A result on immunohistochemical analysis (IHC) at the central laboratory (Herceptest, Dako) of 3+ (IHC 3+), in a range from 0 to 3+ with higher values indicating increased overexpression, was required for confirmation of the status of tumors assessed at the participating institution as IHC 3+, and a positive result on fluorescence in situ hybridization (FISH) for HER2 amplification (PathVision, Vysis) at the central laboratory was required for tumors that were assessed in the participating institution as IHC 2+ or FISH-positive.
The hormone-receptor status of the tumor was determined and the tumor tissue was accessible for central review. Eligible patients had node-positive disease (irrespective of pathological tumor size) or node-negative disease (including only a negative sentinel node) if on pathological examination the tumor size was larger than 1 cm.
Adjuvant chemotherapy, neoadjuvant chemotherapy, or both, selected from a list of approved regimens consisting of at least four cycles (described in detail in Supplementary Appendix 1, available with the full text of this article at www.nejm.org), was completed before randomization. Adjuvant endocrine therapy, primarily tamoxifen, was given after chemotherapy to women with hormone-receptor–positive disease unless contraindicated. During the course of the trial, an amendment to the protocol allowed aromatase inhibitors to be used instead of, or in sequence with, tamoxifen.
Patients were required to have adequate baseline hepatic, renal, and bone marrow function. Patients were required to use adequate non–hormone-based contraceptive measures, if indicated. Patients were excluded if they had distant metastases, a previous invasive breast carcinoma, or a neoplasm not involving the breast, except for curatively treated basal-cell or squamous-cell carcinoma of the skin or in situ carcinoma of the cervix. Patients with clinical stage T4 tumors, including inflammatory breast cancers or involvement of supraclavicular nodes, were not eligible. Suspicious internal mammary nodes were an exclusion criterion, unless they were subjected to radiotherapy. Prior mediastinal irradiation (except internal mammary-node irradiation for the present breast cancer) and cumulative doses of anthracycline exceeding 360 mg per square meter of body-surface area for doxorubicin, or 720 mg per square meter for epirubicin or stem-cell support for chemotherapy were also exclusion criteria.
Only patients who, after completion of all chemotherapy and radiotherapy, had a normal left ventricular ejection fraction (LVEF) (≥55 percent as measured on echocardiography or multiple gated acquisition [MUGA] scanning) were eligible. Cardiac exclusion criteria included a history of documented congestive heart failure, coronary artery disease with previous Q-wave myocardial infarction, angina pectoris requiring medication, uncontrolled hypertension, clinically significant valvular disease, and unstable arrhythmias.
Administration of Trastuzumab
Trastuzumab was administered intravenously over a 90-minute period at all doses. Patients were closely observed for at least six hours after the start of the first dose of 8 mg per kilogram of body weight of trastuzumab. The second and all subsequent maintenance doses were 6 mg per kilogram given every three weeks. Actual body weight was used to calculate the dose. If the administration of trastuzumab was delayed by more than seven days, treatment was restarted at the level of the initial dose of 8 mg per kilogram, which was followed by the usual maintenance dose (6 mg per kilogram every three weeks).
If nonhematologic grade 3 or 4 toxic effects occurred, trastuzumab was temporarily withheld until recovery to grade 2 or lower; it was discontinued if the recovery took more than five weeks, if the severe side effect recurred on readministration of trastuzumab, or if symptomatic congestive heart failure and an LVEF of 45 percent or less developed or an LVEF of less than 50 percent with an absolute reduction of at least 10 percent from baseline developed. In patients without symptoms of congestive heart failure, the same criteria for left ventricular function were used to withhold treatment. Trastuzumab was discontinued if, in asymptomatic patients, left ventricular function did not return to a level above the criteria for withholding treatment after the therapy was stopped for three weeks.
Follow-up Procedures
All patients adhered to the same schedule of follow-up visits, which required the recording of symptoms, side effects (graded according to the National Cancer Institute Common Toxicity Criteria [NCI-CTC] version 2.0), and findings on clinical examination every three months for the first two years, with hematologic and chemistry studies performed every six months. These assessments are scheduled to occur annually for year 3 to year 10. Annual chest radiography is required to year 5 and annual mammography to year 10.
Cardiac Monitoring
Cardiac monitoring in the trastuzumab group and the observation group included responses to a cardiac questionnaire, physical examination, 12-lead electrocardiogram, and an assessment of LVEF by echocardiography15 or MUGA scanning at baseline and 3, 6, 12, 18, 24, 30, 36, and 60 months after randomization. Cardiac events are described in Table 2Table 2
Adverse Events, with a Special Focus on Cardiotoxicity, among Patients Included in the Safety Analysis.. A core laboratory reviewed the echocardiograms, and data management and clinical science staff reviewed the MUGA scan results of the first 900 patients who were followed for six months.Three prespecified interim cardiac safety analyses were performed after 300, 600, and 900 patients had been enrolled and treated for at least six months. An absolute difference of more than 4 percentage points in the incidence of severe congestive heart failure or cardiac death between the trastuzumab group and the observation group would have triggered a recommendation by the independent data-monitoring committee to stop or modify the trial.
Statistical Analysis
Enrollment of 4482 patients was planned to detect a 23 percent relative reduction in the risk of a disease-free–survival event with 80 percent power, with the use of a two-sided significance level of 2.5 percent for each comparison: two years of trastuzumab versus observation and one year of trastuzumab versus observation. A total of 951 disease-free–survival events were required for the final analysis. One interim efficacy analysis was planned after 475 events, with a specified significance level of P≤0.001 required, with the use of a sequential plan according to the O'Brien–Fleming boundary as implemented by Lan and DeMets.16 The independent data-monitoring committee reviewed data on patient enrollment, deaths, compliance, and safety every six months and conducted the interim cardiac safety and efficacy reviews as preplanned.
The efficacy analyses were conducted according to the intention-to-treat principle. Chi-square tests for categorical data and log-rank tests for time-to-event end points provided two-sided P values. Kaplan–Meier curves are presented. Cox proportional-hazards regression analysis was used to estimate hazard ratios and 95 percent confidence intervals.
Results
Interim Efficacy Analysis
The 475 disease-free-survival events needed for the interim efficacy analysis were recorded in the database on March 29, 2005, and the database was locked on April 8, 2005; results were reviewed by the independent data-monitoring committee on April 25, 2005. The independent data-monitoring committee recommended release of the results because improvements in disease-free survival were highly significant, crossing the sequential boundary for both one year and two years of trastuzumab, as compared with observation. After a median follow-up period of 1 year (range, 0 to 36 months), the independent data-monitoring committee released detailed information only for the groups assigned to 1 year of treatment with trastuzumab or observation. These groups are the focus of this report; evaluation of the group assigned to two years of treatment with trastuzumab is ongoing.
Study Population
Between December 2001 and March 2005, 5081 women for whom information was available for analysis were enrolled in the study. Of these, 1694 women were assigned to the trastuzumab group receiving the drug for one year and 1693 women were assigned to the observation group (Figure 1). HER2-positive status as assessed by the central laboratory was IHC 3+ without FISH testing among 67 percent of the patients. Table 1 lists baseline characteristics of the patients, tumors, and primary treatment. The baseline characteristics of the two groups were well balanced (Table 1). The median age was 49 years, one third of the patients had node-negative disease, and 48 percent of the patients had hormone-receptor–negative tumors.
Chemotherapy was anthracycline-based in 94 percent of patients; 26 percent received a taxane, 76 percent received radiotherapy, and tamoxifen was the predominant endocrine therapy. The median time between diagnosis of breast cancer and the initiation of trastuzumab was 8.4 months (interquartile range, 7.1 to 9.6 months).
There were major eligibility violations in 11 patients (8 patients in the trastuzumab group and 3 patients in the observation group): LVEF less than 55 (4 patients), status of HER2-positive not centrally confirmed (3 patients), microinvasive breast cancer (3 patients), and metastatic disease (1 patient). In addition, 39 patients in the trastuzumab group and 52 patients in the observation group had node-negative disease with tumors 1 cm in diameter or less.
Adverse Effects and Cardiac Safety
Twenty patients assigned to one year of trastuzumab did not receive treatment, and three patients assigned to observation received trastuzumab. These 23 patients are included in the alternative group for the safety analyses (Figure 1 and Table 2). Table 2 shows a higher incidence of NCI-CTC grade 3 or 4 adverse events and serious adverse events in the trastuzumab group than in the observation group. There were six fatal adverse events in the trastuzumab group and three in the observation group (Table 2).
There was one cardiac death in the observation group, and nine patients (0.54 percent) in the trastuzumab group had severe congestive heart failure (as defined in Table 2). Symptomatic congestive heart failure, including the nine severe cases (as defined in Table 2), occurred in 1.7 percent of patients in the trastuzumab group and 0.06 percent of patients in the observation group; a decrease in LVEF (as defined in Table 2) was noted on at least one assessment among 7.1 percent of patients in the trastuzumab group and among 2.2 percent of those in the observation group.
Treatment Compliance
Trastuzumab was stopped before completion of the planned one-year treatment among 143 patients (8.5 percent) for reasons other than relapse. Reasons included an adverse event among 5.5 percent of patients, the patient's refusal among 2.5 percent, and other reasons among 0.5 percent.
Efficacy
A total of 127 disease-free–survival events were reported in the trastuzumab group and 220 in the observation group (Table 3Table 3
Efficacy End-Point Events (Intention-to-Treat Groups).). The unadjusted hazard ratio for the risk of an event in the trastuzumab group, as compared with the observation group, was 0.54 (95 percent confidence interval, 0.43 to 0.67; P<0.0001 by the log-rank test, crossing the interim-analysis boundary) (Figure 2AFigure 2Kaplan–Meier Curves Showing Disease-free Survival (Panel A), Time to Distant Recurrence (Panel B), and Overall Survival (Panel C).), which corresponded to an absolute benefit in disease-free survival of 8.4 percentage points at two years (95 percent confidence interval, 2.1 to 14.8).Approximately two thirds of the reported first events were distant metastases (Table 3). The hazard ratio for time to a distant recurrence in the trastuzumab group, as compared with the observation group, was 0.49 (95 percent confidence interval, 0.38 to 0.63; P<0.0001) (Figure 2B). With 29 deaths in the trastuzumab group and 37 in the observation group, the estimated reduction in the hazard ratio for death (24 percent) was not statistically significant (Figure 2C). There was no evidence of substantial heterogeneity in the relative treatment effect among the subgroups (Figure 3Figure 3
Analyses of Disease-free Survival According to Subgroup.).Discussion
This study shows that trastuzumab can benefit women with HER2-positive breast cancer when given after completion of adjuvant chemotherapy. As compared with observation after primary therapy (including surgery with or without radiotherapy and neoadjuvant or adjuvant chemotherapy), trastuzumab given after primary therapy reduced the rate of recurrence, particularly distant recurrence, by approximately 50 percent. This degree of benefit in early breast cancer is the largest to be reported since the introduction of tamoxifen in hormone-receptor–positive disease. This trial is the culmination of a collaboration between basic research scientists and clinical investigators over the past two decades.1-4,17-33
The interpretation of our results must take into account the very short follow-up period — a median of 12 months and a maximum of 36 months. However, the pattern of early, and largely distant, relapse found among patients with HER2-positive breast cancer, and the clinically and statistically significant reduction in the risk of relapse achieved with trastuzumab, justified release of the results of the interim efficacy analysis.
We acknowledge that we have only an incomplete picture of the risks associated with trastuzumab. The risk of cardiotoxicity is currently low in our trial, but this could change with longer follow-up. Another concern is that longer follow-up may show that trastuzumab is not effective in reducing the incidence of disease recurrence in the central nervous system. Brain metastases developed in approximately one third of the women receiving trastuzumab as treatment for advanced breast cancer, despite control of systemic disease.34 It is not clear whether such central nervous system metastases reflect aggressive disease or poor penetration of trastuzumab into the brain.
Will the benefit of adjuvant trastuzumab accrue to all women who have HER2-positive breast cancer who are treated outside clinical trials? Women with small (≤1 cm in diameter), node-negative invasive tumors were not eligible for this trial. Although at a median of one year of follow-up, trastuzumab improved the disease-free survival in all subgroups (Figure 3), further follow-up may show that the magnitudes of absolute benefit differ across subgroups. For example, almost 60 percent of the disease-free–survival events observed so far occurred in the hormone-receptor–negative cohort (48 percent of the patients), but we cannot rule out the possibility that in the future disease-free–survival events may occur disproportionately more often among patients in the subgroup with hormone-receptor–positive tumors. By design, women with cardiac risk factors and an LVEF of less than 55 percent after completion of chemotherapy with or without radiotherapy were excluded from the study, and our data are not applicable to the treatment of such women.
In our study, HER2 overexpression or HER2 amplification had to be confirmed by a central laboratory before randomization, thereby reducing the risk of false positive results. It is our view that adjuvant trastuzumab should be considered only if the HER2-positive status of the tumor has been determined by a high-volume laboratory with quality-control procedures.35
The results of the HERA trial should be widely applicable to women with HER2-positive breast cancer for the following reasons: different types of neoadjuvant or adjuvant chemotherapy were allowed before the initiation of trastuzumab; the schedule of administration of one dose every three weeks, which was shown in the metastatic setting to have efficacy, side effects, and pharmacokinetics similar to those of the weekly schedule,6 was used; and patients with node-negative disease were included. It appears that trastuzumab is effective regardless of the type of chemotherapeutic regimens received before treatment with trastuzumab and the extent of nodal involvement.
We do not know if introducing trastuzumab early in the course of adjuvant systemic therapy, concomitantly with chemotherapy, could further improve the outcome. The question of timing is likely to remain unanswered, because early administration of trastuzumab, as studied in ongoing trials,36,37 requires the drug to be used concurrently with specific chemotherapy regimens that are hypothesized to enhance the effectiveness of trastuzumab.30,32
The results of this trial indicate that one year of adjuvant trastuzumab should be considered a standard option on completion of locoregional therapy and neoadjuvant or adjuvant chemotherapy for women who fulfill the study eligibility criteria used in the HERA trial.
Supported by F. Hoffmann–La Roche (Roche), Basel, Switzerland.
Dr. Piccart-Gebhart reports having received consulting fees from GlaxoSmithKline and, on behalf of the Breast International Group [BIG], an unrestricted educational grant from Roche; Dr. Leyland-Jones, consulting fees from Genentech and Roche and lecture fees and grant support from Roche; Dr. Goldhirsch, consulting fees from GlaxoSmithKline; Dr. Untch, consulting fees from Roche and GlaxoSmithKline and lecture fees from Roche and AstraZeneca; Dr. Smith, consulting and lecture fees from Roche; Dr. Gianni, consulting fees from Genentech and Roche and lecture fees and grant support from Roche; Dr. Baselga, consulting fees from Roche; Dr. Bell, consulting and lecture fees from Roche and AstraZeneca and grant support from AstraZeneca; Dr. Jackisch, lecture fees from Roche; Dr. Cameron, consulting fees, lecture fees, and grant support from Roche; Dr. Dowsett, consulting fees, lecture fees, and grant support from Roche; Dr. Steger, consulting fees and lecture fees from AstraZeneca and Roche and lecture fees from Merck; Dr. Andersson, lecture fees from GlaxoSmithKline and Roche; Dr. Láng, consulting fees, lecture fees, and grant support from Roche; Dr. Nitz, lecture fees from Chugai and grant support from Roche; Dr. Thomssen, consulting fees from Roche and AstraZeneca and lecture fees from Roche; Dr. Suter, consulting fees and grant support from Roche; Dr. Rüschoff, fees for serving on the advisory board to Roche and for central diagnostic services from Roche. Dr. Süto”is an employee of Roche and holds equity in the company. Ms. Greatorex and Ms. Ward are employees of Roche.
We are indebted to the women who participated in the study; to the Breast European Adjuvant Study Team (BrEAST) data center; to the Frontier Science Team of data-entry operators, data managers, medical fellows, information-technology specialists, and secretaries, in particular, E. Azambuja, M.D., J. Bines, M.D., G. Castro, M.D., L. Dal Lago, M.D., G. Demonty, M.D., M. Mano, M.D., M. Zavettieri, M.D., C. Bernard, M.D., D. Antoine, S. Da Silva, S. Guillaume, S. Jonas, E. Kabanga, A. Spence, A. Lange, and S. Gelber; to the Breast International Group (BIG) Secretariat for its vital role in the coordination of the study; to the HERA steering committee; to the independent data-monitoring committee; to the cardiac advisory board; to Cardio Analytics, Plymouth, United Kingdom; the Pathology Laboratory, Kassel, Germany; and to the doctors and the steering committee representatives (in parentheses) from the following: the 17 BIG groups — the National Cancer Research Institute (NCRI), Breast Clinical Studies Group (336) (I. Smith); the International Breast Cancer Study Group (IBCSG) (276) (O. Pagani); the Austrian Breast and Colorectal Cancer Study Group (ABCSG) (200) (R. Jakesz); the European Organization for Research and Treatment of Cancer (EORTC) (189) (R. Coleman); the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) (160) (K. Gelmon); the German Adjuvant Breast Group (GABG) (159) (C. Jackisch); the Danish Breast Cancer Cooperative Group (DBCG) (133) (M. Andersson); BrEAST (128) (M. Piccart); Grupo Español de Investigacion en Cancer de Mama (GEICAM) (112) (P. Sanchez Rovira); the Australian New Zealand Breast Cancer Trial Group (ANZ BCTG) (110) (N. Wilcken); the Swedish Breast Cancer Group (SBCG) (103) (J. Bergh); the International Collaborative Cancer Group (ICCG) (95) (P. Hupperets); the Anglo Celtic Co-operative Oncology Group (ACCOG) (71) (D. Cameron); the Yorkshire Breast Cancer Research Group (YBCRG) (61) (D. Dodwell); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) (48) (R. Passalacqua); Gruppo Oncologico Nord Ovest (GONO) (41) (L. Del Mastro); Borstkanker Onderzoeksgroep Nederland (BOOG) (38) (J.G.M. Klijn); to the 9 groups not affiliated with BIG — Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-NEO), Adjuvant Study Group, Westdeutsche Studiengruppe and (ASG&WSG), and Biomed-2 Node Negative (BIOMED N0) (732) (M. Untch, M. Frick, C. Thomssen); Solid Tumor Intensification (SOLTI) (242) (M.A. Climent); Taiwan Cooperative Oncology Group (TCOG) (162) (J. Whang-Pen); MICHELANGELO (157) (L. Gianni); Israeli Breast Cancer Group (IBCG) (126) (M. Inbar); Gruppo Italiano Mammella (GIM) (95) (S. Deplacido); Norwegian Breast Cancer Group (NBCG) (28) (E. Wist); and to the 91 independent sites — Asia Pacific (R. Bell); Central and Eastern Europe (M. Lichinitser); Japan (M. Toi); and Central and South America (C. Barrios). Additional acknowledgements can be found in Supplementary Appendix 2 (available with the full text of this article at www.nejm.org).
Source Information
The authors' affiliations are listed in the Appendix.
Address reprint requests to Dr. Piccart-Gebhart at the Medicine Department, Jules Bordet Institute, Blvd. de Waterloo 125, 1000 Brussels, Belgium, or at martine.piccart@bordet.be.
Appendix
The authors' affiliations are as follows: the Department of Medicine (M.J.P.-G.), the Breast International Group Secretariat (C.S.), and the Breast European Adjuvant Study Team Data Centre (M.S.D.), Jules Bordet Institute, Université Libre de Bruxelles, Brussels; Frontier Science (Scotland), Kingussie, Scotland (M.P., E.M., R.D.G.); the Department of Oncology, Gerald Bronfman Centre for Clinical Research in Oncology, McGill University, Montreal (B.L.-J.); the Department of Medicine, the European Institute of Oncology, Milan, and the Oncology Institute of Southern Switzerland, Bellinzona, Switzerland (A.G.); Klinik für Frauenheilkunde und Geburtshilfe, Ludwig-Maximilians-Universität München, Grosshadern, Munich, Germany (M.U.); the Breast Unit, Royal Marsden Hospital and the Institute of Cancer Research, London (I.S.); Struttura Complessa Oncologia Medica 1, Istituto Nazionale per lo Studie e la Cura dei Tumori, Milan (L.G.); the Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona (J.B.); the Andrew Love Cancer Centre, Geelong Hospital, Geelong, Australia (R.B.); the Department of Gynecology, Philipps University of Marburg, Marburg, Germany (C.J.); the Department of Oncology, Western General Hospital, Edinburgh (D.C.); the Department of Academic Biochemistry, the Royal Marsden National Health Service Trust, London (M.D.); Hospital São Lucas, Pontifìcia Universidad Catòlica do Rio Grande do Sul School of Medicine, Porto Alegre, Brazil (C.H.B.); the Department of Internal Medicine, Medical University of Vienna, Vienna (G.S.); the Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei (C.-S.H.); the Department of Oncology, Finsen Center, Rigshospitalet University Hospital, Copenhagen (M.A.); the Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (M.I.); N.N. Blokhin Cancer Research Center, Moscow (M.L.); the Department of Oncology, National Institute of Oncology, Budapest, Hungary (I.L.); Frauenklinik der Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany (U.N.); Department of Breast Oncology, Aichi Cancer Center, Aichi, Japan (H.I.); Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany (C.T.); Department of Medical Oncology, British Columbia Cancer Agency, Vancouver Centre, Vancouver, B.C., Canada (C.L.); Swiss Cardiovascular Center, Bern, Switzerland (T.M.S.); Institut für Pathologie, Klinikum Kassel, Kassel, Germany (J.R.); F. Hoffmann–La Roche, Basel, Switzerland (T.S., V.G., C.W.); and the Department of Biostatistics and Computational Biology, Dana–Farber Cancer Institute, Boston (R.D.G.).
- References
References
1
Yarden Y ,Sliwkowski M . Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137
CrossRef | Web of Science | Medline2
Gschwind A ,Fischer OM ,Ullrich A . The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004;4:361-370
CrossRef | Web of Science | Medline3
Slamon DJ ,Clark GM ,Wong SG , et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
CrossRef | Web of Science | Medline4
Slamon DJ ,Godolphin W ,Jones LA , et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712
CrossRef | Web of Science | Medline5
Vogel CL ,Cobleigh MA ,Tripathy D , et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726
CrossRef | Web of Science | Medline6
Baselga J ,Carbonell X ,Castaneda-Soto NJ , et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23:2162-2171
CrossRef | Web of Science | Medline7
Slamon DJ ,Leyland-Jones B ,Shak S , et al. Concurrent administration of anti-HER2 monoclonal antibody and first-line chemotherapy for HER2-overexpressing metastatic breast cancer. A phase III, multinational, randomized controlled trial. N Engl J Med 2001;344:783-792
Full Text | Web of Science | Medline8
Marty M ,Cognetti F ,Maraninchi D , et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 2005;23:4265-4274
CrossRef | Web of Science | Medline9
Bell R . What can we learn from Herceptin trials in metastatic breast cancer? Oncology 2002;63:Suppl 1:39-46
CrossRef | Web of Science | Medline10
Goldhirsch A ,Wood WC ,Gelber RD ,Coates AS ,Thurlimann B ,Senn H-J . Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-3365
CrossRef | Web of Science | Medline11
Menard S ,Calini P ,Tomasic G , et al. Pathologic identification of two distinct breast carcinoma subsets with diverging clinical behaviours. Breast Cancer Res Treat 1999;55:169-177
CrossRef | Web of Science | Medline12
Pietras RJ ,Pegram MD ,Finn RS ,Maneval DA ,Slamon DJ . Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER2 receptor and DNA-reactive drugs. Oncogene 1998;17:2235-2249
CrossRef | Web of Science | Medline13
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
CrossRef | Web of Science | Medline14
Pocock SJ ,Simon R . Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-115
CrossRef | Web of Science | Medline15
Schiller NB ,Shah PM ,Crawford M , et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989;2:358-365
Medline16
Lan KKG ,DeMets DL . Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-663
CrossRef | Web of Science17
Coussens L ,Yang-Feng TL ,Liao YC , et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-1139
CrossRef | Web of Science | Medline18
King CR ,Kraus MH ,Aaronson SA . Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985;229:974-976
CrossRef | Web of Science | Medline19
Akiyama T ,Sudo C ,Ogawara H ,Toyoshima K ,Yamamoto T . The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644-1646
CrossRef | Web of Science | Medline20
Hudziak RM ,Schlessinger J ,Ulrich A . Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A 1987;84:7159-7163
CrossRef | Web of Science | Medline21
Di Fiore PP ,Pierce JH ,Kraus MH ,Segatto O ,King CR ,Aaronson SA . ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987;237:178-182
CrossRef | Web of Science | Medline22
Lacroix H ,Iglehart JD ,Skinner MA , et al. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene 1989;4:145-151
Web of Science | Medline23
Hudziak RM ,Lewis GD ,Winget M ,Fendly BM ,Shepard HM ,Ullrich A . p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9:1165-1172
Web of Science | Medline24
Shepard HM ,Lewis GD ,Sarup JC , et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 1991;11:117-127
CrossRef | Web of Science | Medline25
Guy CT ,Webster MA ,Schaller M ,Parsons TJ ,Cardiff RD ,Muller W . Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 1992;89:10578-10582
CrossRef | Web of Science | Medline26
Pietras RJ ,Arboleda J ,Reese DM , et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1992;7:1859-1866
Web of Science | Medline27
Carter P ,Presta L ,Gorman CM , et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285-4289
CrossRef | Web of Science | Medline28
Sliwkowski MX ,Schaefer G ,Akita RW , et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994;269:14661-14665
Web of Science | Medline29
Baselga J ,Tripaty D ,Mendelsohn J , et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-744
Web of Science | Medline30
Baselga J ,Norton L ,Albanell J ,Kim YM ,Mendelsohn J . Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-2831
Web of Science | Medline31
Pegram MD ,Lipton A ,Hayes DF , et al. Phase II study of receptor enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-2671
Web of Science | Medline32
Pegram M ,Hsu S ,Lewis G , et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-2251
CrossRef | Web of Science | Medline33
Cobleigh MA ,Vogel CL ,Tripathy D , et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648
Web of Science | Medline34
Bendell JC ,Domchek SM ,Burstein HJ , et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972-2977
CrossRef | Web of Science | Medline35
Paik S ,Bryant J ,Tan-Chi E , et al. Real world performance of HER2 testing: National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-854
CrossRef | Web of Science | Medline36
Tan-Chiu E ,Piccart M . Moving forward: Herceptin in the adjuvant setting. Oncology 2002;63:Suppl 1:57-63
CrossRef | Web of Science | Medline37
Romond EH ,Perez EA ,Bryant J , et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684
Full Text | Web of Science | Medline
- Citing Articles (983)
Citing Articles
1
Robert Whitfield, James Kollias, Primali De Silva, Helen Zorbas, Guy Maddern. (2012) Use of trastuzumab in Australia and New Zealand: results from the National Breast Cancer Audit. ANZ Journal of Surgeryno-no
CrossRef2
N. Lynn Henry, Daniel F. Hayes. (2012) Cancer Biomarkers. Molecular Oncology
CrossRef3
Martin C Chang, Janet I Malowany, Julita Mazurkiewicz, Martha Wood. (2012) ‘Genetic heterogeneity’ in HER2/neu testing by fluorescence in situ hybridization: a study of 2522 cases. Modern Pathology
CrossRef4
Carlos H. Barrios. (2012) The Role of Capecitabine in Early Stage Breast Cancer. Current Breast Cancer Reports
CrossRef5
Stefan A. Lange, Bernd Ebner, Astrid Wess, Matthias Kögel, Mieczyslaw Gajda, Thomas Hitschold, Jens Jung. (2012) Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy. Clinical Research in Cardiology
CrossRef6
J Cohen, A Wilson, K Manzolillo. (2012) Clinical and economic challenges facing pharmacogenomics. The Pharmacogenomics Journal
CrossRef7
Fengjuan Fan, Alexander Schimming, Dirk Jaeger, Klaus Podar. (2012) Targeting the Tumor Microenvironment: Focus on Angiogenesis. Journal of Oncology 2012, 1-16
CrossRef8
Hung-Wen Lai, Su-Yu Chien, Shou-Jen Kuo, Ling-Ming Tseng, Hui-Yi Lin, Chin-Wen Chi, Dar-Ren Chen. (2012) The Potential Utility of Curcumin in the Treatment of HER-2-Overexpressed Breast Cancer: An In Vitro and In Vivo Comparison Study with Herceptin. Evidence-Based Complementary and Alternative Medicine 2012, 1-12
CrossRef9
K.A.B. Goddard, S. Weinmann, K. Richert-Boe, C. Chen, J. Bulkley, C. Wax. (2012) <i>HER2</i> Evaluation and Its Impact on Breast Cancer Treatment Decisions. Public Health Genomics 15:1, 1-10
CrossRef10
Carmel Pezaro, Mun Sem Liew, Ian D Davis. (2012) Urothelial cancers: using biology to improve outcomes. Expert Review of Anticancer Therapy 12:1, 87-98
CrossRef11
Alex Walsh, Rebecca S. Cook, Brent Rexer, Carlos L. Arteaga, Melissa C. Skala. (2012) Optical imaging of metabolism in HER2 overexpressing breast cancer cells. Biomedical Optics Express 3:1, 75
CrossRef12
Yu Zhou, James D. Marks. 2012. Discovery of Internalizing Antibodies to Tumor Antigens from Phage Libraries. , 43-66.
CrossRef13
István Láng, Zsuzsanna Kahán, Erika Hitre, Magdolna Dank, Gábor Rubovszky, Zsolt Horváth, Miklós Kásler. (2012) Az emlőrák korszerű gyógyszeres kezelése. Orvosi Hetilap 153:2, 56-65
CrossRef14
Eleri Lloyd Davies. (2012) Breast cancer. Medicine 40:1, 5-9
CrossRef15
Stella Wanjugu Karuri, Richard Simon. (2012) A two-stage Bayesian design for co-development of new drugs and companion diagnostics. Statistics in Medicinen/a-n/a
CrossRef16
Paolo Carli, Elisa Turchet, Daniela Quitadamo, Antonella Spada, Gianmaria Miolo, Elda Lamaj, Simon Spazzapan, Vincenzo Di Lauro, Riccardo Dolcetti, Andrea Veronesi, Diana Crivellari. (2012) Target therapy in elderly breast cancer patients. Critical Reviews in Oncology/Hematology
CrossRef17
Anupama Sharma, Ursula Koldovsky, Shuwen Xu, Rosemarie Mick, Robert Roses, Elizabeth Fitzpatrick, Susan Weinstein, Harvey Nisenbaum, Bruce L. Levine, Kevin Fox, Paul Zhang, Gary Koski, Brian J. Czerniecki. (2012) HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancern/a-n/a
CrossRef18
Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, Laslo Roman, Ling-Ming Tseng, Mei-Ching Liu, Ana Lluch, Elżbieta Staroslawska, Juan de la Haba-Rodriguez, Seock-Ah Im, Jose Luiz Pedrini, Brigitte Poirier, Paolo Morandi, Vladimir Semiglazov, Vichien Srimuninnimit, Giulia Bianchi, Tania Szado, Jayantha Ratnayake, Graham Ross, Pinuccia Valagussa. (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. The Lancet Oncology 13:1, 25-32
CrossRef19
Phuong Khanh Morrow, Rashmi K. Murthy, Joe D. Ensor, Gilad S. Gordon, Kim A. Margolin, Anthony D. Elias, Walter J. Urba, David E. Weng, Hope S. Rugo, Gabriel N. Hortobagyi. (2012) An open-label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer. Cancern/a-n/a
CrossRef20
Casey Shuptrine, Rishi Surana, Louis M. Weiner. (2012) Monoclonal antibodies for the treatment of cancer. Seminars in Cancer Biology
CrossRef21
Enrico Pegolo, Piernicola Machin, Franca Riosa, Anna Bassini, Laura Deroma, Carla Di Loreto. (2012) Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma. Cancer Cytopathologyn/a-n/a
CrossRef22
N. Hedhli, L. W. Dobrucki, A. Kalinowski, Z. W. Zhuang, X. Wu, R. R. Russell, A. J. Sinusas, K. S. Russell. (2011) Endothelial Derived Neuregulin is an Important Mediator of Ischemic Induced Angiogenesis and Arteriogenesis. Cardiovascular Research
CrossRef23
Hope S. Rugo, A. Jo Chien, Sandra X. Franco, Alison T. Stopeck, Alexa Glencer, Soumi Lahiri, Michael C. Arbushites, Janet Scott, John W. Park, Clifford Hudis, Ben Nulsen, Maura N. Dickler. (2011) A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Research and Treatment
CrossRef24
Rosalie Fisher, James Larkin, Charles Swanton. (2011) Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. The EPMA Journal
CrossRef25
Nadia Harbeck. (2011) Breast cancer: Increasing therapy options for HER2-positive early breast cancer. Nature Reviews Clinical Oncology 9:1, 10-12
CrossRef26
Guopei Luo, Jiang Long, Bo Zhang, Chen Liu, Shunrong Ji, Jin Xu, Xianjun Yu, Quanxing Ni. (2011) Quantum dots in cancer therapy. Expert Opinion on Drug Delivery47-58
CrossRef27
J. D. Jensen, A. Knoop, A. V. Laenkholm, M. Grauslund, M. B. Jensen, E. Santoni-Rugiu, M. Andersson, M. Ewertz. (2011) PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Annals of Oncology
CrossRef28
Rosa Lerose, Pellegrino Musto, Michele Aieta, Carla Papa, Alfredo Tartarone. (2011) Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience. European Journal of Clinical Pharmacology
CrossRef29
E. A. Perez, A. C. Dueck, A. E. McCullough, M. M. Reinholz, K. S. Tenner, N. E. Davidson, J. Gralow, L. N. Harris, L. A. Kutteh, D. W. Hillman, R. B. Jenkins, B. Chen. (2011) Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria. JNCI Journal of the National Cancer Institute
CrossRef30
Alexandre Cochet, Gaetan Quilichini, Inna Dygai-Cochet, Claude Touzery, Michel Toubeau, Alina Berriolo-Riedinger, Bruno Coudert, Yves Cottin, Pierre Fumoleau, François Brunotte. (2011) Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Research and Treatment 130:3, 845-854
CrossRef31
C.B. Moelans, R.A. de Weger, E. Van der Wall, P.J. van Diest. (2011) Current technologies for HER2 testing in breast cancer. Critical Reviews in Oncology/Hematology 80:3, 380-392
CrossRef32
J. Kenneth Burkus, Matthew F. Gornet, Steven D. Glassman, Paul J. Slosar, Michael K. Rosner, Jeffrey E. Deckey, John Nowak, Brian M. Hatcher. (2011) Blood Serum Antibody Analysis and Long-Term Follow-up of Patients Treated With Recombinant Human Bone Morphogenetic Protein-2 in the Lumbar Spine. Spine 36:25, 2158-2167
CrossRef33
Flora Zagouri, Christos A. Papadimitriou, Meletios-Athanassios Dimopoulos, Dimitrios Pectasides. (2011) Molecularly targeted therapies in unresectable-metastatic gastric cancer. A systematic review. Cancer Treatment Reviews 37:8, 599-610
CrossRef34
E. Voulgaris, G. Pentheroudakis, N. Pavlidis. (2011) Cancer and pregnancy: A comprehensive review. Surgical Oncology 20:4, e175-e185
CrossRef35
Gunter Minckwitz, Sibylle Loibl, Andrea Maisch, Michael Untch. (2011) Incorporating Agents that Target HER2 in the Neoadjuvant Setting. Current Breast Cancer Reports 3:4, 190-196
CrossRef36
Stephane Ederhy, Hassan Izzedine, Christophe Massard, Ghislaine Dufaitre, Jean Philippe Spano, Gerard Milano, Catherine Meuleman, Benjamin Besse, Franck Boccara, David Kahyat, Ariel Cohen, Jean Charles Soria. (2011) Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists. Critical Reviews in Oncology/Hematology 80:3, 369-379
CrossRef37
Pilar Eroles, Ana Bosch, J. Alejandro Pérez-Fidalgo, Ana Lluch. (2011) Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treatment Reviews
CrossRef38
S. P. Bueno Angela, R. M. Viero, C. T. Soares. (2011) Fine needle aspirate cell blocks are reliable for detection of hormone receptors and HER-2 by immunohistochemistry in breast carcinoma. Cytopathologyno-no
CrossRef39
Hye Jin Kim, Hwang-Phill Kim, Young-Kwang Yoon, Maeng-Sup Kim, Gwan-Sun Lee, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Do-Youn Oh, Yung-Jue Bang. (2011) Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells. Anti-Cancer Drugs1
CrossRef40
Luigi Tarantini, Giovanni Cioffi, Stefania Gori, Fausto Tuccia, Lidia Boccardi, Daniella Bovelli, Chiara Lestuzzi, Nicola Maurea, Stefano Oliva, Giulia Russo, Pompilio Faggiano. (2011) Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer. Journal of Cardiac Failure
CrossRef41
Carlo Palmieri, Alison Jones. (2011) The 2011 EBCTCG polychemotherapy overview. The Lancet
CrossRef42
M. Pegram, J. Liao. (2011) Trastuzumab Treatment in Multiple Lines: Current Data and Future Directions. Clinical Breast Cancer
CrossRef43
Serena Di Cosimo. (2011) Heart to heart with trastuzumab: a review on cardiac toxicity. Targeted Oncology
CrossRef44
Carlos L. Arteaga, Mark X. Sliwkowski, C. Kent Osborne, Edith A. Perez, Fabio Puglisi, Luca Gianni. (2011) Treatment of HER2-positive breast cancer: current status and future perspectives. Nature Reviews Clinical Oncology
CrossRef45
Yanan Kong, Shuqin Dai, Xinhua Xie, Xiangsheng Xiao, Ning Lv, Jiaoli Guo, Laisheng Li, Weihua Jia, Yin Zhang, Wanli Liu, Weidong Wei, Xiaoming Xie. (2011) High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. Journal of Cancer Research and Clinical Oncology
CrossRef46
Naoki Niikura, Morihiko Kimura, Takayuki Iwamoto, Naoki Hayashi, Junichi Shintoku, Yuki Saito, Yasuhiro Suzuki, Yutaka Tokuda. (2011) Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment. Breast Cancer
CrossRef47
R M Webster, J Abraham, N Palaniappan, A Caley, B Jasani, P Barrett-Lee. (2011) Exploring the use and impact of adjuvant Trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. British Journal of Cancer
CrossRef48
Fuh Yong Wong, Connie Siew Poh Yip, Eu Tiong Chua. (2011) Implications of HER2 Amplification in Small, Node-Negative Breast Cancers: Do Asians Differ?. World Journal of Surgery
CrossRef49
Luc Ceugnart, Bruno Coudert, Florence Dalenc, Jean-Marc Guinebretiere, Philippe Rouanet, Alain Toledano. (2011) Les traitements néoadjuvants (hors cancer du sein inflammatoire). Oncologie
CrossRef50
M. -P. Chauvet, M. Debled, C. Decanter, A. Goncalves, R. Largillier, P. Pujol, P. Saltel, P. Taourel. (2011) Prise en charge du cancer du sein infiltrant de la femme âgée de 40 ans ou moins. Oncologie
CrossRef51
S A Watt, C Pourreyron, K Purdie, C Hogan, C L Cole, N Foster, N Pratt, J-C Bourdon, V Appleyard, K Murray, A M Thompson, X Mao, C Mein, L Bruckner-Tuderman, A Evans, J A McGrath, C M Proby, J Foerster, I M Leigh, A P South. (2011) Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma. Oncogene 30:46, 4666-4677
CrossRef52
Jin Cheon Kim, Jong Han Yu, Yoon Kyung Cho, Choon Sik Jung, Sei Hyun Ahn, Gyungyub Gong, Yong Sung Kim, Dong-Hyung Cho. (2011) Expression of SPRR3 is associated with tumor cell proliferation in less advanced stages of breast cancer. Breast Cancer Research and Treatment
CrossRef53
Giampietro Gasparini, Raffaele Longo. (2011) The paradigm of personalized therapy in oncology. Expert Opinion on Therapeutic Targets1-10
CrossRef54
Gabrielle Rocque, Adedayo Onitilo, Jessica Engel, Erica Pettke, Alice Boshoven, KyungMann Kim, Shailly Rishi, Bonnie Waack, Kari B. Wisinski, Amye Tevaarwerk, Mark E. Burkard. (2011) Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity. Breast Cancer Research and Treatment
CrossRef55
Agustí Barnadas, Laura G. Estévez, Ana Lluch-Hernández, Álvaro Rodriguez-Lescure, César Rodriguez-Sanchez, Pedro Sanchez-Rovira. (2011) An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer. Advances in Therapy
CrossRef56
D. M. Collins, N. O'Donovan, P. M. McGowan, F. O'Sullivan, M. J. Duffy, J. Crown. (2011) Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Annals of Oncology
CrossRef57
D. Rayson, T. M. Suter, C. Jackisch, S. van der Vegt, B. Bermejo, J. van den Bosch, G. L. Vivanco, A. M. van Gent, H. Wildiers, A. Torres, L. Provencher, M. Temizkan, J. Chirgwin, J. L. Canon, G. Ferrandina, S. Srinivasan, L. Zhang, D. J. Richel. (2011) Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial. Annals of Oncology
CrossRef58
Elisabeth Luporsi, Fabrice André, Frédérique Spyratos, Pierre-Marie Martin, Jocelyne Jacquemier, Frédérique Penault-Llorca, Nicole Tubiana-Mathieu, Brigitte Sigal-Zafrani, Laurent Arnould, Anne Gompel, Caroline Egele, Bruno Poulet, Krishna B. Clough, Hubert Crouet, Alain Fourquet, Jean-Pierre Lefranc, Carole Mathelin, Nicolas Rouyer, Daniel Serin, Marc Spielmann, Margaret Haugh, Marie-Pierre Chenard, Etienne Brain, Patricia de Cremoux, Jean-Pierre Bellocq. (2011) Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Research and Treatment
CrossRef59
Umut Demirci, Suleyman Buyukberber, Guldal Yılmaz, Mustafa Kerem, Ugur Coskun, Aytug Uner, Meltem Baykara, Hatice Pasali, Mustafa Benekli. (2011) Hepatotoxicity associated with lapatinib in an experimental rat model. European Journal of Cancer
CrossRef60
Hee Jeong Kim, Wonshik Han, On Vox Yi, Hee Chul Shin, Soo-Kyung Ahn, Beom Seok Koh, Hyeong-Gon Moon, Jong Han You, Byung Ho Son, Sei Hyun Ahn, Dong-Young Noh. (2011) Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype. Breast Cancer Research and Treatment 130:2, 499-505
CrossRef61
Giorgio Valabrega, Sonia Capellero, Giuliana Cavalloni, Gianluca Zaccarello, Annalisa Petrelli, Giorgia Migliardi, Andrea Milani, Caterina Peraldo-Neia, Loretta Gammaitoni, Anna Sapino, Carla Pecchioni, Aldo Moggio, Silvia Giordano, Massimo Aglietta, Filippo Montemurro. (2011) HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Research and Treatment 130:1, 29-40
CrossRef62
Sarah Barton, Charles Swanton. (2011) Recent Developments in Treatment Stratification for Metastatic Breast Cancer. Drugs 71:16, 2099-2113
CrossRef63
C. M. Kelly, K. I. Pritchard, M. Trudeau, E. Andreopoulou, K. Hess, L. Pusztai. (2011) Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?. Annals of Oncology 22:11, 2387-2393
CrossRef64
K. Tanaka, H. Kawaguchi, Y. Nakamura, K. Taguchi, K. Nishiyama, S. Ohno. (2011) Effect of HER2 status on risk of recurrence in women with small, node-negative breast tumours. British Journal of Surgery 98:11, 1561-1565
CrossRef65
Alan K Sears, Sonia A Perez, Guy T Clifton, Linda C Benavides, Jeremy D Gates, Kevin S Clive, Jarrod P Holmes, Nathan M Shumway, David C Van Echo, Mark G Carmichael, Sathibalan Ponniah, Constantin N Baxevanis, Elizabeth A Mittendorf, Michael Papamichail, George E Peoples. (2011) AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert Opinion on Biological Therapy 11:11, 1543-1550
CrossRef66
Thomas A Buchholz. (2011) Radiotherapy and survival in breast cancer. The Lancet 378:9804, 1680-1682
CrossRef67
Min A Kim, Hyuk-Joon Lee, Han-Kwang Yang, Yung-Jue Bang, Woo Ho Kim. (2011) Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 59:5, 822-831
CrossRef68
Mark R. Trusheim, Breon Burgess, Sean Xinghua Hu, Theresa Long, Steven D. Averbuch, Aiden A. Flynn, Alfons Lieftucht, Abhijit Mazumder, Judy Milloy, Peter M. Shaw, David Swank, Jian Wang, Ernst R. Berndt, Federico Goodsaid, Michael C. Palmer. (2011) Quantifying factors for the success of stratified medicine. Nature Reviews Drug Discovery 10:11, 817-833
CrossRef69
Rebecca L. Hirsh, Angela DeMichele. (2011) The Role of Lapatinib in the Preoperative Therapy of Breast Cancer. Current Oncology Reports
CrossRef70
T Shiroiwa, T Fukuda, K Shimozuma. (2011) Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. British Journal of Cancer 105:9, 1273-1278
CrossRef71
Kunal S. Taskar, Vinay Rudraraju, Rajendar K. Mittapalli, Ramakrishna Samala, Helen R. Thorsheim, Julie Lockman, Brunilde Gril, Emily Hua, Diane Palmieri, Joseph W. Polli, Stephen Castellino, Stephen D. Rubin, Paul R. Lockman, Patricia S. Steeg, Quentin R. Smith. (2011) Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer. Pharmaceutical Research
CrossRef72
M.K. Magnusson, R. Kraaij, R.M. Leadley, C.M.A. De Ridder, W.M. van Weerden, K.A.J. Van Schie, M. Van der Kroeg, R.C. Hoeben, N.J. Maitland, L. Lindholm. (2011) A Transductionally Retargeted Adenoviral Vector for Virotherapy of Her2/neu-Expressing Prostate Cancer. Human Gene Therapy111012121242004
CrossRef73
Slamon, Dennis, Eiermann, Wolfgang, Robert, Nicholas, Pienkowski, Tadeusz, Martin, Miguel, Press, Michael, Mackey, John, Glaspy, John, Chan, Arlene, Pawlicki, Marek, Pinter, Tamas, Valero, Vicente, Liu, Mei-Ching, Sauter, Guido, von Minckwitz, Gunter, Visco, Frances, Bee, Valerie, Buyse, Marc, Bendahmane, Belguendouz, Tabah-Fisch, Isabelle, Lindsay, Mary-Ann, Riva, Alessandro, Crown, John, . (2011) Adjuvant Trastuzumab in HER2-Positive Breast Cancer. New England Journal of Medicine 365:14, 1273-1283
Full Text74
Daniel F. Hayes. (2011) Clinical trials: The silent minority—unpublished data on cancer care. Nature Reviews Clinical Oncology 8:11, 631-632
CrossRef75
Michaela J. Higgins, José Baselga. (2011) Targeted therapies for breast cancer. Journal of Clinical Investigation 121:10, 3797-3803
CrossRef76
Sarah J. Storr, Caroline M. Woolston, Fabricio F.T. Barros, Andrew R. Green, Mohamed Shehata, Stephen Y. Chan, Ian O. Ellis, Stewart G. Martin. (2011) Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy. International Journal of Cancer 129:7, 1773-1780
CrossRef77
Josep M. Llovet, Valerie Paradis, Masatoshi Kudo, Jessica Zucman-Rossi. (2011) Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Liver Transplantation 17:S2, S67-S71
CrossRef78
Robert C. Seeger. (2011) Immunology and immunotherapy of neuroblastoma. Seminars in Cancer Biology 21:4, 229-237
CrossRef79
Rachel L. Theriault, Jennifer K. Litton, Elizabeth A. Mittendorf, Huiqin Chen, Funda Meric-Bernstam, Mariana Chavez-MacGregor, Phuong K. Morrow, Wendy A. Woodward, Aysegul Sahin, Gabriel N. Hortobagyi, Ana M. Gonzalez-Angulo. (2011) Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype. Clinical Breast Cancer 11:5, 325-331
CrossRef80
Kenji Shibuta, Hiroaki Ueo, Hidemi Furusawa, Kansei Komaki, Yoshiaki Rai, Yoshiatsu Sagara, Yoshihiko Kamada, Nobumitsu Tamaki. (2011) The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer. Breast Cancer 18:4, 292-298
CrossRef81
Jiannan Wu, Shunrong Li, Weijuan Jia, Fengxi Su. (2011) Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. Journal of Cancer Research and Clinical Oncology 137:10, 1505-1510
CrossRef82
Scott A. Waldman, Andre Terzic. (2011) Widening the Path to Personalized Medicine. Clinical and Translational Science 4:5, 392-394
CrossRef83
Sofiya Reicher, Fatih Z. Boyar, Maher Albitar, Vladimira Sulcova, Sally Agersborg, Visal Nga, Ying Zhou, Gang Li, Rose Venegas, Samuel W. French, David S. Chung, Bruce E. Stabile, Viktor E. Eysselein, Arturo Anguiano. (2011) Fluorescence In Situ Hybridization and K-ras Analyses Improve Diagnostic Yield of Endoscopic Ultrasound-Guided Fine-Needle Aspiration of Solid Pancreatic Masses. Pancreas 40:7, 1057-1062
CrossRef84
Elena B. Elkin, Deborah A. Marshall, Nathalie A. Kulin, Ilia L. Ferrusi, Michael J. Hassett, Uri Ladabaum, Kathryn A. Phillips. (2011) Economic evaluation of targeted cancer interventions: Critical review and recommendations. Genetics in Medicine 13:10, 853-860
CrossRef85
Nehmat Houssami, Petra Macaskill, Rosemary L. Balleine, Michael Bilous, Mark D. Pegram. (2011) HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Research and Treatment 129:3, 659-674
CrossRef86
Kalipso Chalkidou, Sir Michael Rawlins. (2011) Pharmacogenetics and cost-effectiveness analysis: a two-way street. Drug Discovery Today 16:19-20, 873-877
CrossRef87
Pierre Miossec. (2011) Biomarqueurs et médecine personnalisée au cours de la polyarthrite rhumatoïde : vers un changement historique. Revue du Rhumatisme 78, S154-S156
CrossRef88
C. Hennequin, D. Azria. (2011) L’avenir de la radiothérapie du cancer du sein : de la taille unique au sur-mesure. Cancer/Radiothérapie 15:6-7, 455-459
CrossRef89
Zhiyuan Xu, Nicholas F. Marko, Sam T. Chao, Lilyana Angelov, Michael A. Vogelbaum, John H. Suh, Gene H. Barnett, Robert J. Weil. (2011) Relationship Between HER2 Status and Prognosis in Women with Brain Metastases from Breast Cancer. International Journal of Radiation Oncology*Biology*Physics
CrossRef90
M. Valentini, A. Milesi, A. Bettini, C. Tondini, A. Nicolucci. (2011) Type and trends in outcomes research in breast cancer between 2000 and 2007. Annals of Oncology 22:10, 2160-2165
CrossRef91
Edith A. Perez. (2011) New treatment strategies in the management of breast cancer. European Journal of Cancer Supplements 9:2, 22-29
CrossRef92
L.M. Tho, N. Bose, L. Robertson, S. Bhattacharya, L. McClue, L. Anderson, E. Fraser, K. Graham, H. Yosef, G. Lumsden. (2011) Trastuzumab-related Palmar Plantar Erythrodysaesthesia. Clinical Oncology
CrossRef93
Kamal S. Saini, Hatem A. Azim Jr, Otto Metzger-Filho, Sherene Loi, Christos Sotiriou, Evandro de Azambuja, Martine Piccart. (2011) Beyond trastuzumab: New treatment options for HER2-positive breast cancer. The Breast 20, S20-S27
CrossRef94
Bohuslav Melichar, Mario Plebani. (2011) Targeted therapy for HER-2: personalized medicine for her, too. Clinical Chemistry and Laboratory Medicine---
CrossRef95
Eugene R. Ahn, Charles L. Vogel. (2011) Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Research and Treatment
CrossRef96
Barbara Bernasconi, Anna Maria Chiaravalli, Giovanna Finzi, Katia Milani, Maria Grazia Tibiletti. (2011) Genetic heterogeneity in HER2 testing may influence therapy eligibility. Breast Cancer Research and Treatment
CrossRef97
Vinochani Pillay, Hui K. Gan, Andrew M. Scott. (2011) Antibodies in oncology. New Biotechnology 28:5, 518-529
CrossRef98
M. Bates, J. Sperinde, W. J. Kostler, S. M. Ali, K. Leitzel, E. M. Fuchs, A. Paquet, Y. Lie, T. Sherwood, R. Horvat, C. F. Singer, J. Winslow, J. M. Weidler, W. Huang, A. Lipton. (2011) Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab. Annals of Oncology 22:9, 2014-2020
CrossRef99
Daliah Tsoref, Amit M. Oza. (2011) Recent advances in systemic therapy for advanced endometrial cancer. Current Opinion in Oncology 23:5, 494-500
CrossRef100
Abigail S. Caudle, Kelly K. Hunt, Henry M. Kuerer, Funda Meric-Bernstam, Anthony Lucci, Isabelle Bedrosian, Gildy V. Babiera, Rosa F. Hwang, Merrick I. Ross, Barry W. Feig, Karen Hoffman, Jennifer K. Litton, Aysegul A. Sahin, Wei Yang, Gabriel N. Hortobagyi, Thomas A. Buchholz, Elizabeth A. Mittendorf. (2011) Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing Trial. Annals of Surgical Oncology 18:9, 2407-2412
CrossRef101
, Harald Choritz, Guntram Büsche, Hans Kreipe. (2011) Quality assessment of HER2 testing by monitoring of positivity rates. Virchows Archiv 459:3, 283-289
CrossRef102
Juan José Grau, Miguel Caballero, Andrea Tagliapetra. (2011) Nuevos fármacos antineoplásicos antidiana. Indicaciones clínicas en el tratamiento de tumores sólidos. Medicina Clínica 137:8, 370-376
CrossRef103
Katharina Pachmann, O. Camara, T. Kroll, M. Gajda, A. K. Gellner, J. Wotschadlo, I. B. Runnebaum. (2011) Efficacy control of therapy using circulating epithelial tumor cells (CETC) as “Liquid Biopsy”: trastuzumab in HER2/neu-positive breast carcinoma. Journal of Cancer Research and Clinical Oncology 137:9, 1317-1327
CrossRef104
Susana Banerjee, Stan Kaye. (2011) The role of targeted therapy in ovarian cancer. European Journal of Cancer 47, S116-S130
CrossRef105
Gretchen Kimmick. (2011) Adjuvant Chemotherapy for Breast Cancer in Older Women: Emerging Evidence to Aid in Decision Making. Current Treatment Options in Oncology 12:3, 286-301
CrossRef106
Jennifer R. Bellon, Eleanor E. R. Harris, Douglas W. Arthur, Lisa Bailey, Lisa Carey, Sharad Goyal, Michele Y. Halyard, Kathleen C. Horst, Meena S. Moran, Shannon M. MacDonald, Bruce G. Haffty. (2011) ACR Appropriateness Criteria® Conservative surgery and Radiation - Stage I and II Breast Carcinoma. The Breast Journal 17:5, 448-455
CrossRef107
H. Joensuu, J. Sperinde, M. Leinonen, W. Huang, J. Weidler, P. Bono, V. Kataja, R. Kokko, T. Turpeenniemi-Hujanen, S. Jyrkkio, J. Isola, P.- L. Kellokumpu-Lehtinen, A. Paquet, Y. Lie, M. Bates. (2011) Very high quantitative tumor HER2 content and outcome in early breast cancer. Annals of Oncology 22:9, 2007-2013
CrossRef108
S. Aebi, T. Davidson, G. Gruber, F. Cardoso, . (2011) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 22:Supplement 6, vi12-vi24
CrossRef109
Ulas Darda Bayraktar, Tae Kon Kim, Katherine Drews-Elger, Cara Benjamin, Dorraya El-Ashry, Eric Wieder, Krishna V. Komanduri. (2011) Simultaneous measurement of ERα, HER2, and PhosphoERK1/2 in breast cancer cell lines by flow cytometry. Breast Cancer Research and Treatment 129:2, 623-628
CrossRef110
Joshua Cohen. (2011) Dearth of clinically useful diagnostics limits growth of personalized medicine. Expert Review of Clinical Pharmacology 4:5, 527-529
CrossRef111
J. Huober, P.A. Fasching, M. Barsoum, L. Petruzelka, D. Wallwiener, C. Thomssen, T. Reimer, S. Paepke, H.A. Azim, V. Ragosch, E. Kubista, A.K. Baumgärtner, M.W. Beckmann, C. May, I. Nimmrich, N. Harbeck. (2011) Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial. The Breast
CrossRef112
Sanjay P. Bagaria, Partha S. Ray, Jinhua Wang, Luisa Kropcho, Alice Chung, Myung-Shin Sim, Jaime M. Shamonki, Silvana Martino, Xiaojiang Cui, Armando E. Giuliano. (2011) Prognostic Value of Basal Phenotype in HER2-overexpressing Breast Cancer. Annals of Surgical Oncology
CrossRef113
Kazuhiro Araki, Shigehira Saji, Michelle Gallas, Mark Pegram, Yasutsuna Sasaki. (2011) Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer. Breast Cancer
CrossRef114
Nicholas B. La Thangue, David J. Kerr. (2011) Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nature Reviews Clinical Oncology 8:10, 587-596
CrossRef115
C. Serrano, J. Cortes, L. De Mattos-Arruda, M. Bellet, P. Gomez, C. Saura, J. Perez, M. Vidal, E. Munoz-Couselo, M. J. Carreras, G. Sanchez-Olle, J. Tabernero, J. Baselga, S. Di Cosimo. (2011) Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Annals of Oncology
CrossRef116
Y. Belkacémi, A. Fourquet, B. Cutuli, C. Bourgier, M. Hery, G. Ganem, H. Marsiglia, M. Namer, J. Gligorov, D. Azria. (2011) Radiotherapy for invasive breast cancer: Guidelines for clinical practice from the French expert review board of Nice/Saint-Paul de Vence. Critical Reviews in Oncology/Hematology 79:2, 91-102
CrossRef117
Roscoe Atkinson, Jens Mollerup, Anne-Vibeke Lænkholm, Mark Verardo, Debra Hawes, Deborah Commins, Birte Engvad, Adrian Correa, Charlotte Cort Ehlers, Kirsten Vang Nielsen. (2011) Effects of the Change in Cutoff Values for Human Epidermal Growth Factor Receptor 2 Status by Immunohistochemistry and Fluorescence In Situ Hybridization: A Study Comparing Conventional Brightfield Microscopy, Image Analysis-Assisted Microscopy, and Interobserver Variation. Archives of Pathology & Laboratory Medicine 135:8, 1010-1016
CrossRef118
L. Munck, M. Schaapveld, S. Siesling, J. Wesseling, A. C. Voogd, V. C. G. Tjan-Heijnen, R. Otter, P. H. B. Willemse. (2011) Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands. Breast Cancer Research and Treatment 129:1, 229-233
CrossRef119
F. Charles Brunicardi, Richard A. Gibbs, David A. Wheeler, John Nemunaitis, William Fisher, John Goss, Changyi Chen. (2011) Overview of the Development of Personalized Genomic Medicine and Surgery. World Journal of Surgery 35:8, 1693-1699
CrossRef120
Virginia Arrazubi, Roberto Pazo, Dolores Isla, José Luis Pérez Gracia. (2011) SEOM clinical guidelines for using molecular markers in clinical practice. Clinical and Translational Oncology 13:8, 587-591
CrossRef121
A. Goldhirsch, W. C. Wood, A. S. Coates, R. D. Gelber, B. Thurlimann, H.- J. Senn, . (2011) Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology 22:8, 1736-1747
CrossRef122
Ramazan Mercan, Ozgur Oktem, Zeki Salar, Alp Nuhoglu, Basak Balaban, Bulent Urman. (2011) Conjoined twins after intracytoplasmic sperm injection and transfer of day-3 embryos. Fertility and Sterility 96:2, e111-e114
CrossRef123
M. Tahir, T. Robinson, A. Stotter. (2011) How not to neglect the care of elderly breast cancer patients?. The Breast 20:4, 293-296
CrossRef124
Hironori Shindo, Jisu Park, Makoto Taniguchi. (2011) Effect of amino group density for prevention of mammary gland tissue detachment from coated glass surface. Journal of Bioscience and Bioengineering 112:2, 180-183
CrossRef125
Hyeong-Gon Moon, Ki-Tae Hwang, Jeong-Ah Kim, Hee Sung Kim, Min-Joo Lee, Eun-Mi Jung, Eunyoung Ko, Wonshik Han, Dong-Young Noh. (2011) NFIB is a potential target for estrogen receptor-negative breast cancers. Molecular Oncology
CrossRef126
S Ladoire, L Arnould, G Mignot, L Apetoh, C Rébé, F Martin, P Fumoleau, B Coudert, F Ghiringhelli. (2011) T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. British Journal of Cancer 105:3, 366-371
CrossRef127
H. K. Chew, G. Somlo, P. C. Mack, B. Gitlitz, R. Gandour-Edwards, S. Christensen, H. Linden, L. J. Solis, X. Yang, A. M. Davies. (2011) Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Annals of Oncology
CrossRef128
Simona F. Shaitelman, Leonard H. Kim, Di Yan, Alvaro A. Martinez, Frank A. Vicini, Inga S. Grills. (2011) Continuous Arc Rotation of the Couch Therapy for the Delivery of Accelerated Partial Breast Irradiation: A Treatment Planning Analysis. International Journal of Radiation Oncology*Biology*Physics 80:3, 771-778
CrossRef129
Sylvain Ladoire, Grégoire Mignot, Sandrine Dabakuyo, Laurent Arnould, Lionel Apetoh, Cedric Rébé, Bruno Coudert, Francois Martin, Marie Hélène Bizollon, André Vanoli, Charles Coutant, Pierre Fumoleau, Franck Bonnetain, François Ghiringhelli. (2011) In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. The Journal of Pathology 224:3, 389-400
CrossRef130
Elda Tagliabue, Manuela Campiglio, Serenella M. Pupa, Sylvie Ménard, Andrea Balsari. (2011) Activity and resistance of trastuzumab according to different clinical settings. Cancer Treatment Reviews
CrossRef131
Milayna Subar, WenLong Lin, William Chen, Donald G. Pittman. (2011) Lack of Uniformity in Cardiac Assessment during Trastuzumab Therapy. The Breast Journal 17:4, 383-390
CrossRef132
Teemu T. Junttila, Guangmin Li, Kathryn Parsons, Gail Lewis Phillips, Mark X. Sliwkowski. (2011) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Research and Treatment 128:2, 347-356
CrossRef133
Su Wei Wong, Kai Hung Tiong, Weng Yip Kong, Yuen Chee Yue, Choon Hooi Chua, Jae Ying Lim, Chai Yuin Lee, Sean I. Quah, Cindy Fow, Cyril Chung, Irene So, Boon Shing Tan, Heng Lungh Choo, Rozita Rosli, Soon-Keng Cheong, Chee-Onn Leong. (2011) Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. Breast Cancer Research and Treatment 128:2, 301-313
CrossRef134
Vladimir Tolmachev, Joachim Feldwisch, Malin Lindborg, Barbro Baastrup, Mattias Sandström, Anna Orlova. (2011) Influence of an aliphatic linker between DOTA and synthetic ZHER2:342 Affibody molecule on targeting properties of the 111In-labeled conjugate. Nuclear Medicine and Biology 38:5, 697-706
CrossRef135
Jaclyn Yoong, Michael Michael, Trevor Leong. (2011) Targeted Therapies for Gastric Cancer. Drugs 71:11, 1367-1384
CrossRef136
Patrizia Paterlini-Bréchot. (2011) Organ-specific markers in circulating tumor cell screening: an early indicator of metastasis-capable malignancy. Future Oncology 7:7, 849-871
CrossRef137
Janneke P.C. Grutters, Shanly C. Seferina, Vivianne C.G. Tjan-Heijnen, Roel J.W. van Kampen, Wim G. Goettsch, Manuela A. Joore. (2011) Bridging Trial and Decision: A Checklist to Frame Health Technology Assessments for Resource Allocation Decisions. Value in Health 14:5, 777-784
CrossRef138
Giuseppe Bogina, Laura Bortesi, Marcella Marconi, Marco Venturini, Gianluigi Lunardi, Francesca Coati, Alberto Massocco, Erminia Manfrin, Cristina Pegoraro, Giuseppe Zamboni. (2011) Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Archiv 459:1, 1-10
CrossRef139
Krishna K. Singh, Praphulla C. Shukla, Adrian Quan, Fina Lovren, Yi Pan, Jesse I. Wolfstadt, Milan Gupta, Mohammed Al-Omran, Howard Leong-Poi, Hwee Teoh, Subodh Verma. (2011) Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death. Biochemical and Biophysical Research Communications 411:2, 421-426
CrossRef140
Brigitte Rack, Julia Jückstock, Maria Günthner-Biller, Ulrich Andergassen, Julia Neugebauer, Philip Hepp, Alexandra Schoberth, Doris Mayr, Thomas Zwingers, Christian Schindlbeck, Klaus Friese, Wolfgang Janni. (2011) Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. Archives of Gynecology and Obstetrics
CrossRef141
Akiyo Horio, Takashi Fujita, Hironori Hayashi, Masaya Hattori, Naoto Kondou, Mai Yamada, Eri Adachi, Aya Ushio, Naomi Gondou, Aiko Sueta, Yasushi Yatabe, Hiroji Iwata. (2011) High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers. International Journal of Clinical Oncology
CrossRef142
Kathryn C. Amirikia, Paul Mills, Jason Bush, Lisa A Newman. (2011) Higher population-based incidence rates of triple-negative breast cancer among young African-American women. Cancer 117:12, 2747-2753
CrossRef143
Elizabeth A Mittendorf, Gheath Alatrash, Haile Xiao, G Travis Clifton, James L Murray, George E Peoples. (2011) Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials. Expert Review of Vaccines 10:6, 755-774
CrossRef144
Wilson Gonsalves, Apar Kishor Ganti. (2011) Targeted anti-cancer therapy in the elderly. Critical Reviews in Oncology/Hematology 78:3, 227-242
CrossRef145
J.K. Raikhelkar, R.M. Steingart, C.L. Chen. (2011) Role of echocardiography in cancer care. Herz 36:4, 333-339
CrossRef146
N. Harbeck, M. S. Ewer, M. De Laurentiis, T. M. Suter, S. M. Ewer. (2011) Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Annals of Oncology 22:6, 1250-1258
CrossRef147
Cyrus Chargari, Krassen M. Kirov, Marc A. Bollet, Nicolas Magné, Lionel Védrine, Serge Cremades, Philippe Beuzeboc, Alain Fourquet, Youlia M. Kirova. (2011) Cardiac toxicity in breast cancer patients: From a fractional point of view to a global assessment. Cancer Treatment Reviews 37:4, 321-330
CrossRef148
François Bertucci, Nathalie Borie, Henri Roche, Thomas Bachelot, Jean-Marc Doussal, Gaëtan Macgrogan, Stéphane Debono, Agnès Martinec, Isabelle Treilleux, Pascal Finetti, Benjamin Esterni, Jean-Marc Extra, Jean Geneve, Fabienne Hermitte, Christian Chabannon, Jocelyne Jacquemier, Anne-Laure Martin, Michel Longy, Dominique Maraninchi, Vincent Fert, Daniel Birnbaum, Patrice Viens. (2011) Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. Breast Cancer Research and Treatment 127:2, 363-373
CrossRef149
Elżbieta Senkus, Jacek Jassem. (2011) Cardiovascular effects of systemic cancer treatment. Cancer Treatment Reviews 37:4, 300-311
CrossRef150
Jonathan R. Walker, Anita Sharma, Matthew Lytwyn, Sheena Bohonis, James Thliveris, Pawan K. Singal, Davinder S. Jassal. (2011) The Cardioprotective Role of Probucol Against Anthracycline and Trastuzumab-Mediated Cardiotoxicity. Journal of the American Society of Echocardiography 24:6, 699-705
CrossRef151
Rosalba Amodio, Maurizio Zarcone, Rosanna Cusimano, Ildegarda Campisi, Cecilia Dolcemascolo, Adele Traina, Biagio Agostara, Nino Romano. (2011) Target Therapy in HER2-Overexpressing Breast Cancer Patients. OMICS: A Journal of Integrative Biology 15:6, 363-367
CrossRef152
K. Tamura, C. Shimizu, T. Hojo, S. Akashi-Tanaka, T. Kinoshita, K. Yonemori, T. Kouno, N. Katsumata, M. Ando, K. Aogi, F. Koizumi, K. Nishio, Y. Fujiwara. (2011) Fc R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Annals of Oncology 22:6, 1302-1307
CrossRef153
Rexxi D. Prasasya, Dan Tian, Pamela K. Kreeger. (2011) Analysis of cancer signaling networks by systems biology to develop therapies. Seminars in Cancer Biology 21:3, 200-206
CrossRef154
Jonathan Krell, Colin R. James, Deep Shah, Ondrej Gojis, Adrian Lim, Pippa Riddle, Riz Ahmad, Andreas Makris, Andrew Cowdray, Angela Chow, Tamerlan Babayev, Peter Madden, Robert Leonard, Susan Cleator, Carlo Palmieri. (2011) Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Relapsing Post-Adjuvant Trastuzumab: Pattern of Recurrence, Treatment and Outcome. Clinical Breast Cancer 11:3, 153-160
CrossRef155
Richard Eglen, Terry Reisine. (2011) Drug discovery and the human kinome: Recent trends. Pharmacology & Therapeutics 130:2, 144-156
CrossRef156
Peter S. Hall, Claire Hulme, Christopher McCabe, Yemi Oluboyede, Jeff Round, David A. Cameron. (2011) Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer. PharmacoEconomics 29:5, 415-432
CrossRef157
Joshua P Cohen. (2011) Personalized medicine: are payers the weak link?. Personalized Medicine 8:3, 293-296
CrossRef158
Thor Edvardsen. (2011) Can Modern Echocardiographic Techniques Predict Drug-Induced Cardiotoxicity?
Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 57:22, 2271-2272
CrossRef159
Tallal Younis, Chris Skedgel. (2011) Adjuvant Trastuzumab for Breast Cancer. PharmacoEconomics 29:5, 361-365
CrossRef160
H. J. Chang, S.-W. Han, D.-Y. Oh, S.-A. Im, Y. K. Jeon, I. A. Park, W. Han, D.-Y. Noh, Y.-J. Bang, T.-Y. Kim. (2011) Discordant Human Epidermal Growth Factor Receptor 2 and Hormone Receptor Status in Primary and Metastatic Breast Cancer and Response to Trastuzumab. Japanese Journal of Clinical Oncology 41:5, 593-599
CrossRef161
Augusto Villanueva, Josep M. Llovet. (2011) Targeted Therapies for Hepatocellular Carcinoma. Gastroenterology 140:5, 1410-1426
CrossRef162
M. Sawaki, N. Tokudome, T. Mizuno, T. Nakayama, N. Taira, H. Bando, S. Murakami, Y. Yamamoto, M. Kashiwaba, H. Iwata, Y. Uemura, Y. Ohashi. (2011) Evaluation of Trastuzumab Without Chemotherapy as a Post-operative Adjuvant Therapy in HER2-positive Elderly Breast Cancer Patients: Randomized Controlled Trial [RESPECT (N-SAS BC07)]. Japanese Journal of Clinical Oncology 41:5, 709-712
CrossRef163
T. Zander, M. Hallek. (2011) Thyrosinkinaseinhibitoren in der Onkologie. Der Internist 52:5, 595-600
CrossRef164
Francesca Orlandi, José A. Guevara-Patiño, Taha Merghoub, Jedd D. Wolchok, Alan N. Houghton, Polly D. Gregor. (2011) Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice. Vaccine 29:20, 3646-3654
CrossRef165
Michael Gnant, Martine Piccart-Gebhart, Aron Goldhirsch, Jose Baselga, David Cameron, Angelo Di Leo, Mitchell Dowsett, Richard Gelber, Gunter von Minckwitz, Cecilia Waldvogel, Carolyn Straehle. (2011) Developing an international network for breast cancer research: the BIG experience. Clinical Investigation 1:5, 623-628
CrossRef166
Roger Y. Tsang, Richard S. Finn. (2011) HER2-positive breast cancer: trastuzumab, lapatinib and emerging therapies. Drug Discovery Today: Therapeutic Strategies
CrossRef167
Javier Cortés, Cristina Saura, Meritxell Bellet, Eva Muñoz-Couselo, Natalia Ramírez-Merino, Virginia Calvo, Jose Pérez, María Vidal. (2011) HER2 and hormone receptor-positive breast cancer—blocking the right target. Nature Reviews Clinical Oncology 8:5, 307-311
CrossRef168
Nazanin Fallah-Rad, Jonathan R. Walker, Anthony Wassef, Matthew Lytwyn, Sheena Bohonis, Tielan Fang, Ganhong Tian, Iain D.C. Kirkpatrick, Pawan K. Singal, Marianne Krahn, Debjani Grenier, Davinder S. Jassal. (2011) The Utility of Cardiac Biomarkers, Tissue Velocity and Strain Imaging, and Cardiac Magnetic Resonance Imaging in Predicting Early Left Ventricular Dysfunction in Patients With Human Epidermal Growth Factor Receptor II–Positive Breast Cancer Treated With Adjuvant Trastuzumab Therapy. Journal of the American College of Cardiology 57:22, 2263-2270
CrossRef169
S. Guiu, I. Adoubi, J. C. Kouassi Comoe, P. Fumoleau, B. Coudert. (2011) Trastuzumab et lapatinib dans la prise en charge du cancer du sein HER2 positif. Journal Africain du Cancer / African Journal of Cancer 3:2, 128-140
CrossRef170
Jona A. Hattangadi-Gluth, Jennifer Y. Wo, Paul L. Nguyen, Rita F. Abi Raad, Meera Sreedhara, Andrzej Niemierko, Phoebe E. Freer, Dianne Georgian-Smith, Jennifer R. Bellon, Julia S. Wong, Barbara L. Smith, Jay R. Harris, Alphonse G. Taghian. (2011) Basal Subtype of Invasive Breast Cancer is Associated with a Higher Risk of True Recurrence After Conventional Breast-Conserving Therapy. International Journal of Radiation Oncology*Biology*Physics
CrossRef171
Masataka Sawaki, Hirofumi Mukai, Nahomi Tokudome, Takahiro Nakayama, Naruto Taira, Toshiro Mizuno, Yutaka Yamamoto, Akiyo Horio, Toru Watanabe, Yukari Uemura, Yasuo Ohashi. (2011) Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study. Breast Cancer
CrossRef172
Ji-Yu Li, Zhou-Luo Ou, San-Jian Yu, Xiao-Li Gu, Chen Yang, Ao-Xiang Chen, Gen-Hong Di, Zhen-Zhou Shen, Zhi-Ming Shao. (2011) The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer. Breast Cancer Research and Treatment
CrossRef173
Alicia Okines, David Cunningham, Ian Chau. (2011) Targeting the human EGFR family in esophagogastric cancer. Nature Reviews Clinical Oncology 8:8, 492-503
CrossRef174
Alessandra Buja, Egle Perissinotto, Antonio Compostella, Andrea Tramarin, Vincenzo Rebba, Davide Pastorelli, Francesco Grigoletto, Costantino Gallo, Giuseppe Rausa, Dario Gregori. (2011) Taking decisions on expenditure for high-cost drugs at the regional level: a model for evaluating the overall impact of Trastuzumab in the Veneto Region of Italy. Journal of Evaluation in Clinical Practice 17:2, 298-303
CrossRef175
Christopher M. Booth, Pavlo Ohorodnyk, Liting Zhu, Dongsheng Tu, Ralph M. Meyer. (2011) Randomised controlled trials in oncology closed early for benefit: Trends in methodology, results, and interpretation. European Journal of Cancer 47:6, 854-863
CrossRef176
Timo T. Purmonen, Emma Pänkäläinen, Juha H. O. Turunen, Christian Asseburg, Janne A. Martikainen. (2011) Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncologica 50:3, 344-352
CrossRef177
R. Tanz, T. Mahfoud, A. Bazine, R. Khmamouch, Y. Bensouda, N. Ismaili, N. Benjaafar, B.K. El Gueddari, M. Ichou, H. Errihani. (2011) Tolérance cardiaque du trastuzumab en adjuvant : revue à travers 53 observations. Journal de Gynécologie Obstétrique et Biologie de la Reproduction 40:2, 144-148
CrossRef178
S. Samuel Kim, Jennifer Klemp, Carol Fabian. (2011) Breast cancer and fertility preservation. Fertility and Sterility 95:5, 1535-1543
CrossRef179
Carlo Palmieri, Deep Shah, Jonathan Krell, Ondrej Gojis, Katy Hogben, Pippa Riddle, Riz Ahmad, Tri Tat, Kevin Fox, Andrew Porter, Sarah Mahmoud, Stephanie Kirschke, Sami Shousha, Mihir Gudi, R. Charles Coombes, Robert Leonard, Susan Cleator. (2011) Management and Outcome of HER2-Positive Early Breast Cancer Treated With or Without Trastuzumab in the Adjuvant Trastuzumab Era. Clinical Breast Cancer 11:2, 93-102
CrossRef180
Paul W. Sperduto, Norbert Kased, David Roberge, Zhiyuan Xu, Ryan Shanley, Xianghua Luo, Penny K. Sneed, Samuel T. Chao, Robert J. Weil, John Suh, Amit Bhatt, Ashley W. Jensen, Paul D. Brown, Helen A. Shih, John Kirkpatrick, Laurie E. Gaspar, John B. Fiveash, Veronica Chiang, Jonathan P.S. Knisely, Christina Maria Sperduto, Nancy Lin, Minesh Mehta. (2011) Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases. International Journal of Radiation Oncology*Biology*Physics
CrossRef181
D H Roukos. (2011) Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. The Pharmacogenomics Journal 11:2, 81-92
CrossRef182
Vaishali Bagalkot, Mi Kyung YU, Sangyong Jon. 2011. Nanoparticles for Combined Cancer Imaging and Therapy. , 565-592.
CrossRef183
F. Fang, S. Turcan, A. Rimner, A. Kaufman, D. Giri, L. G. T. Morris, R. Shen, V. Seshan, Q. Mo, A. Heguy, S. B. Baylin, N. Ahuja, A. Viale, J. Massague, L. Norton, L. T. Vahdat, M. E. Moynahan, T. A. Chan. (2011) Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis. Science Translational Medicine 3:75, 75ra25-75ra25
CrossRef184
George Dranitsaris, Ilse Truter, Martie S. Lubbe, Eitan Amir, William Evans. (2011) Advances in Cancer Therapeutics and Patient Access to New Drugs. PharmacoEconomics 29:3, 213-224
CrossRef185
Sigrun Ressler, Brigitte Mlineritsch, Richard Greil. (2011) Zoledronic acid for adjuvant use in patients with breast cancer. Expert Review of Anticancer Therapy 11:3, 333-349
CrossRef186
Vishal Rana, Ramona F. Swaby. (2011) Targeted Therapies for HER2 Breast Cancer: A View of the Landscape. Current Breast Cancer Reports 3:1, 55-62
CrossRef187
Ivana Bozovic-Spasojevic, Hatem A Azim, Marianne Paesmans, Thomas Suter, Martine J Piccart, Evandro de Azambuja. (2011) Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?. The Lancet Oncology 12:3, 209-211
CrossRef188
Natalie Galanina, Veerle Bossuyt, Lyndsay N. Harris. (2011) Molecular Predictors of Response to Therapy for Breast Cancer. The Cancer Journal 17:2, 96-103
CrossRef189
J. -P. Spano, J. -C. Thery. (2011) Place des thérapies ciblées chez la patiente âgée atteinte de cancer du sein. Oncologie 13:2-3, 97-101
CrossRef190
Marc Buyse, Stefan Michiels, Daniel J Sargent, Axel Grothey, Alastair Matheson, Aimery de Gramont. (2011) Integrating biomarkers in clinical trials. Expert Review of Molecular Diagnostics 11:2, 171-182
CrossRef191
Heikki Joensuu. (2011) HERA crosses over. The Lancet Oncology 12:3, 203-204
CrossRef192
Leroy Hood, Stephen H. Friend. (2011) Predictive, personalized, preventive, participatory (P4) cancer medicine. Nature Reviews Clinical Oncology 8:3, 184-187
CrossRef193
Roshawn G. Watson, Howard L. McLeod. (2011) Pharmacogenomic Contribution to Drug Response. The Cancer Journal 17:2, 80-88
CrossRef194
Pyung-Hwan Kim, Joo-Hyuk Sohn, Joung-Woo Choi, Yukyung Jung, Sung Wan Kim, Seungjoo Haam, Chae-Ok Yun. (2011) Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin. Biomaterials 32:9, 2314-2326
CrossRef195
Valentina Rossi, Stefania Redana, Andrea Milani, Elena Geuna, Giorgio Valabrega, Massimo Aglietta, Filippo Montemurro. (2011) Trastuzumab in the adjuvant setting: a practical review. Therapy 8:2, 161-177
CrossRef196
Luca Gianni, Urania Dafni, Richard D Gelber, Evandro Azambuja, Susanne Muehlbauer, Aron Goldhirsch, Michael Untch, Ian Smith, José Baselga, Christian Jackisch, David Cameron, Max Mano, José Luiz Pedrini, Andrea Veronesi, Cesar Mendiola, Anna Pluzanska, Vladimir Semiglazov, Eduard Vrdoljak, Michael J Eckart, Zhenzhou Shen, George Skiadopoulos, Marion Procter, Kathleen I Pritchard, Martine J Piccart-Gebhart, Richard Bell. (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. The Lancet Oncology 12:3, 236-244
CrossRef197
Guodong Shen, Hui Huang, Anli Zhang, Ting Zhao, Siyi Hu, Liansheng Cheng, Jing Liu, Weihua Xiao, Bin Ling, Qiang Wu, Lihua Song, Wei Wei. (2011) In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models. Cancer Immunology, Immunotherapy 60:3, 339-348
CrossRef198
Rupninder Sandhu, Ashley G. Rivenbark, William B. Coleman. (2011) Enhancement of chemotherapeutic efficacy in hypermethylator breast cancer cells through targeted and pharmacologic inhibition of DNMT3b. Breast Cancer Research and Treatment
CrossRef199
Pietro Sanpaolo, Viviana Barbieri, Piernicola Pedicini, Vincenzo Fusco. (2011) Her-2 prognostic value in very early-stage breast cancer: a single-institution retrospective analysis. Medical Oncology
CrossRef200
Hideya Onishi, Takashi Morisaki, Yuji Nakafusa, Yutaka Nakashima, Kazunori Yokohata, Mitsuo Katano. (2011) Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer. International Journal of Clinical Oncology
CrossRef201
Florian Lordick. (2011) Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. Future Oncology 7:2, 187-199
CrossRef202
M. Aapro, C. Bernard-Marty, E. G. C. Brain, G. Batist, F. Erdkamp, K. Krzemieniecki, R. Leonard, A. Lluch, S. Monfardini, M. Ryberg, P. Soubeyran, U. Wedding. (2011) Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Annals of Oncology 22:2, 257-267
CrossRef203
Robert O. Dillman. (2011) Cancer Immunotherapy. Cancer Biotherapy & Radiopharmaceuticals 26:1, 1-64
CrossRef204
Shaheenah Dawood, Rong Hu, Michelle D. Homes, Laura C. Collins, Stuart J. Schnitt, James Connolly, Graham A. Colditz, Rulla M. Tamimi. (2011) Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Research and Treatment 126:1, 185-192
CrossRef205
S. Guiu, M. Liegard, L. Favier, I. van Praagh, R. Largillier, B. Weber, D. Coeffic, L. Moreau, F. Priou, M. Campone, J. Gligorov, L. Vanlemmens, V. Trillet-Lenoir, L. Arnould, B. Coudert. (2011) Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy. Annals of Oncology 22:2, 321-328
CrossRef206
Rena Callahan, Sara Hurvitz. (2011) Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease. Current Opinion in Obstetrics and Gynecology 23:1, 37-43
CrossRef207
Takayuki Iwamoto, Giampaolo Bianchini, Yuan Qi, Massimo Cristofanilli, Anthony Lucci, Wendy A. Woodward, James M. Reuben, Junji Matsuoka, Yun Gong, Savitri Krishnamurthy, Vicente Valero, Gabriel N. Hortobagyi, Fredika Robertson, W. Fraser Symmans, Lajos Pusztai, Naoto T. Ueno. (2011) Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Research and Treatment 125:3, 785-795
CrossRef208
Aleix Prat, Charles M. Perou. (2011) Deconstructing the molecular portraits of breast cancer. Molecular Oncology 5:1, 5-23
CrossRef209
Lopa Mishra. (2011) Health care reform: How personalized medicine could help bundling of care for liver diseases. Hepatology 53:2, 379-381
CrossRef210
Devika Gajria, Sarat Chandarlapaty. (2011) HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Review of Anticancer Therapy 11:2, 263-275
CrossRef211
Sandra A OʼToole, Christina I Selinger, Ewan K A Millar, Trina Lum, Jane M Beith. (2011) Molecular assays in breast cancer pathology. Pathology 43:2, 116-127
CrossRef212
Sabine Riethdorf, Bernhard Hoegel, Birgit John, German Ott, Peter Fritz, Susanne Thon, Thomas Loening, Klaus Pantel. (2011) Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients. Journal of Cancer Research and Clinical Oncology 137:2, 261-269
CrossRef213
Yan Lu, Hua Zhou, Wantao Chen, Yuexing Zhang, Anne W. Hamburger. (2011) The ErbB3 binding protein EBP1 regulates ErbB2 protein levels and tamoxifen sensitivity in breast cancer cells. Breast Cancer Research and Treatment 126:1, 27-36
CrossRef214
Jiyoung Rhee, Sae-Won Han, Yongjun Cha, Hye Seon Ham, Hwang-phill Kim, Do-Youn Oh, Seock-Ah Im, Jong-Wan Park, Jungsil Ro, Keun Seok Lee, In Hae Park, Young-Hyuck Im, Yung-Jue Bang, Tae-You Kim. (2011) High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer. Breast Cancer Research and Treatment 125:1, 107-114
CrossRef215
Montserrat Solá, Mireia Margelí, Eva Castellá, Juan F Julian, Miquel Rull, Josep M Gubern, Antonio Mariscal, Agustí Barnadas, Manuel Fraile. (2011) Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: A prospective observational study. BMC Cancer 11:1, 252
CrossRef216
Jan Hysing, Erik Wist. (2011) Kardiotoksiske effekter av trastuzumab. Tidsskrift for Den norske legeforening 131:22, 2239-2241
CrossRef217
Ashley Davidson, Karen Gelmon. (2011) Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer?. Future Oncology 7:1, 37-55
CrossRef218
Sarah Lee, Woohee Jung, Soon-Won Hong, Ja Seung Koo. (2011) Evaluation of Intratumoral HER-2 Heterogeneity by Fluorescence In Situ Hybridization in Invasive Breast Cancer: A Single Institution Study. Journal of Korean Medical Science 26:8, 1001
CrossRef219
Toru Mukohara. (2011) Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Science 102:1, 1-8
CrossRef220
T. Eschenhagen, T. Force, M. S. Ewer, G. W. de Keulenaer, T. M. Suter, S. D. Anker, M. Avkiran, E. de Azambuja, J.-L. Balligand, D. L. Brutsaert, G. Condorelli, A. Hansen, S. Heymans, J. A. Hill, E. Hirsch, D. Hilfiker-Kleiner, S. Janssens, S. de Jong, G. Neubauer, B. Pieske, P. Ponikowski, M. Pirmohamed, M. Rauchhaus, D. Sawyer, P. H. Sugden, J. Wojta, F. Zannad, A. M. Shah. (2011) Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure 13:1, 1-10
CrossRef221
Nicholas Robert, Lea Krekow, Chris Stokoe, Alicia Clawson, Jose Iglesias, Joyce O’Shaughnessy. (2011) Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study. Breast Cancer Research and Treatment 125:1, 115-120
CrossRef222
Wataru Onozato, Keishi Yamashita, Kazuya Yamashita, Tatsuru Kuba, Hiroshi Katoh, Takatoshi Nakamura, Takeo Sato, Atsushi Ihara, Isao Okayasu, Masahiko Watanabe. (2011) Genetic alterations of K-ras may reflect prognosis in stage III colon cancer patients below 60 years of age. Journal of Surgical Oncology 103:1, 25-33
CrossRef223
Günter Mayer, Jens Müller, Christina E. Lünse. (2011) RNA diagnostics: real-time RT-PCR strategies and promising novel target RNAs. Wiley Interdisciplinary Reviews: RNA 2:1, 32-41
CrossRef224
Anthony S.-Y. Leong, Zhengping Zhuang. (2011) The Changing Role of Pathology in Breast Cancer Diagnosis and Treatment. Pathobiology 78:2, 99-114
CrossRef225
Karim S. ElSahwi, Alessandro D. Santin. (2011) erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy. Obstetrics and Gynecology International 2011, 1-5
CrossRef226
Jae Myoung Noh, Doo Ho Choi, Seung Jae Huh, Won Park, Jung Hyun Yang, Seok Jin Nam, Young Hyuck Im, Jin Seok Ahn. (2011) Patterns of Recurrence after Breast-Conserving Treatment for Early Stage Breast Cancer by Molecular Subtype. Journal of Breast Cancer 14:1, 46
CrossRef227
Rohit Bhargava, Nicole N. Esposito, David J. Dabbs. 2011. Immunohistology of the Breast. , 763-819.
CrossRef228
K.P.S. Raghav, A.M. Gonzalez-Angulo. (2011) Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Breast Diseases: A Year Book Quarterly 22:2, 156-158
CrossRef229
Ana P. Kiess, Heather L. McArthur, Kathleen Mahoney, Sujata Patil, Patrick G. Morris, Alice Ho, Clifford A. Hudis, Beryl McCormick. (2011) Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. Cancern/a-n/a
CrossRef230
Gunter Minckwitz, Michael Untch, Eveline Nüesch, Sibylle Loibl, Manfred Kaufmann, Sherko Kümmel, Peter A. Fasching, Wolfgang Eiermann, Jens-Uwe Blohmer, Serban Dan Costa, Keyur Mehta, Jörn Hilfrich, Christian Jackisch, Bernd Gerber, Andreas Bois, Jens Huober, Claus Hanusch, Gottfried Konecny, Werner Fett, Elmar Stickeler, Nadia Harbeck, Volkmar Müller, Peter Jüni. (2011) Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Research and Treatment 125:1, 145-156
CrossRef231
Dok Hyun Yoon, Yoon-Koo Kang. (2011) Results and implications of the Trastuzumab for Gastric Cancer (ToGA) trial. Clinical Investigation 1:1, 87-95
CrossRef232
Ralf Gutzmer, Elke Jäger, Dirk Vordermark. (2011) Adjuvante Therapieansätze in der Onkologie: Eine kritische Nutzen-Risiko-Abwägung. Onkologie 34:s2, 10-12
CrossRef233
Kyoji Ogoshi. (2011) Effective and ineffective personalized therapy based on serum HLA from a 30-year odyssey. Annals of Cancer Research and Therapy 19:2, 44-53
CrossRef234
David Khayat. (2011) Innovative cancer therapies. Cancern/a-n/a
CrossRef235
Masahiro Takada, Hiroshi Terunuma, Xuewen Deng, Md. Zahidunnabi Dewan, Shigehira Saji, Katsumasa Kuroi, Naoki Yamamoto, Masakazu Toi. (2011) Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer 18:1, 64-67
CrossRef236
Alfonso Sánchez-Muñoz, Elisabeth Pérez-Ruiz, Jose Manuel Jurado, Nuria Ribelles, Antonia Márquez, Jose Miramón, Maria Maíz, Bella Pajares, Elena Gallego, Victoria Scholtz, Begona Jiménez, Concepcion Soler, Manuel Molina, Isabel García-Ríos, Emilio Alba. (2011) Outcome of Small Invasive Breast Cancer with No Axillary Lymph Node Involvement. The Breast Journal 17:1, 32-38
CrossRef237
Gilberto de Lima Lopes. (2011) Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore. BMC Cancer 11:1, 178
CrossRef238
Hervé Wallerand, Jean-Christophe Bernhard, Stéphane Culine, Philippe Ballanger, Grégoire Robert, Robert E. Reiter, Jean-Marie Ferrière, Alain Ravaud. (2011) Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways. Urologic Oncology: Seminars and Original Investigations 29:1, 4-11
CrossRef239
M. Joerger, B. Thurlimann, J. Huober. (2011) Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?. Annals of Oncology 22:1, 17-23
CrossRef240
Soley Bayraktar, Ana M. Gonzalez-Angulo, Xiudong Lei, Aman U. Buzdar, Vicente Valero, Amal Melhem-Bertrandt, Henry M. Kuerer, Gabriel N. Hortobagyi, Aysegul A. Sahin, Funda Meric-Bernstam. (2011) Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancern/a-n/a
CrossRef241
Henry Lin, Marija Balic, Siyang Zheng, Ram Datar, Richard J. Cote. (2011) Disseminated and circulating tumor cells: Role in effective cancer management. Critical Reviews in Oncology/Hematology 77:1, 1-11
CrossRef242
Toru Mukohara. (2011) Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer. Chemotherapy Research and Practice 2011, 1-12
CrossRef243
Michael L Gatza, Hsiu-Ni Kung, Kimberly L Blackwell, Mark W Dewhirst, Jeffrey R Marks, Jen-Tsan Chi. (2011) Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Research 13:3, R62
CrossRef244
Anthony Jarkowski, Ashley E Glode, Edward J Spangenthal, Michael K. K Wong. (2011) Heart Failure Caused by Molecularly Targeted Therapies for Cancer. Pharmacotherapy 31:1, 62-75
CrossRef245
Elmar Stickeler. (2011) Prognostic and Predictive Markers for Treatment Decisions in Early Breast Cancer. Breast Care 6:3, 193-198
CrossRef246
Thommey P. Thomas, Yu-Chung Chang, Jing Yong Ye, Alina Kotlyar, Zhengyi Cao, Rameshwer Shukla, Suyang Qin, Theodore B. Norris, James R. Baker. (2011) Optical fiber-based in vivo quantification of growth factor receptors. Cancern/a-n/a
CrossRef247
Lorenzo Livi, Icro Meattini, Calogero Saieva, Ciro Franzese, Vanessa Di Cataldo, Daniela Greto, Davide Franceschini, Vieri Scotti, Pierluigi Bonomo, Jacopo Nori, Luis Sanchez, Vania Vezzosi, Simonetta Bianchi, Luigi Cataliotti, Giampaolo Biti. (2011) Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer. Cancern/a-n/a
CrossRef248
Bo-Gun Jang, Woo Ho Kim. (2011) Molecular Pathology of Gastric Carcinoma. Pathobiology 78:6, 302-310
CrossRef249
Heather L. McArthur, Kathleen M. Mahoney, Patrick G. Morris, Sujata Patil, Lindsay M. Jacks, Jane Howard, Larry Norton, Clifford A. Hudis. (2011) Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancern/a-n/a
CrossRef250
F. Pandolfi, R. Cianci, D. Pagliari, F. Casciano, C. Bagalà, A. Astone, R. Landolfi, C. Barone. (2011) The Immune Response to Tumors as a Tool toward Immunotherapy. Clinical and Developmental Immunology 2011, 1-12
CrossRef251
Jean-Paul Guastalla, Olivier Tredan, Isabelle Ray-Coquard, Sana Intidhar Labidi-Galy, Aude Duret, Philippe Cassier, Thomas Bachelot. 2011. Traitements adjuvants du cancer du sein. , 93-105.
CrossRef252
Katsutoshi Ando, Norio Masumoto, Masaaki Sakamoto, Kou Teraoka, Takako Suzuki, Terumasa Kurihara, Satoko Abe, Mitsuhiro Tozaki, Eisuke Fukuma, Kazuei Hoshi. (2011) Parotid Gland Metastasis of Breast Cancer: Case Report and Review of the Literature. Breast Care 6:6, 471-473
CrossRef253
Daniela Sia, Augusto Villanueva. (2011) Signaling Pathways in Hepatocellular Carcinoma. Oncology 81:s1, 18-23
CrossRef254
Kyeongmee Park, Sehwan Han, Jung-Yeon Kim, Hyun-Jung Kim, Ji Eun Kwon, Geumhee Gwak. (2011) Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer. Journal of Breast Cancer 14:4, 276
CrossRef255
Martijn Arns, Jay Gunkelman, Sebastian Olbrich, Christian Sander, Ulrich Hegerl. 2011. EEG Vigilance and Phenotypes in NeuropsychiatryImplications for Intervention. , 79-435.
CrossRef256
Mark D. Danese, Deepa Lalla, Melissa Brammer, Quan Doan, Kevin Knopf. (2010) Estimating recurrences prevented from using trastuzumab in HER-2/neu-positive adjuvant breast cancer in the United States. Cancer 116:24, 5575-5583
CrossRef257
Sallie-Anne Pearson, Melvin Chin, Margaret Faedo, Robyn Ward. (2010) Rationale for treatment durations of targeted cancer agents. The Lancet Oncology 11:12, 1113-1115
CrossRef258
T Kanazawa, M Nokubi, K Takizawa, S Matsuzawa, A Shinnabe, H Mineta, Y Iino. (2010) KIT and platelet-derived growth factor receptor α gene expression in laryngeal small cell carcinoma. The Journal of Laryngology & Otology 124:12, 1340-1343
CrossRef259
Debora Fumagalli, Christine Desmedt, Martine Piccart, Christos Sotiriou. (2010) Strategies to Incorporate Translational Research Science into Clinical Trials in Breast Cancer. Current Breast Cancer Reports 2:4, 208-213
CrossRef260
Nobuyoshi Kittaka, Ichiro Takemasa, Shigeto Seno, Yutaka Takeda, Shogo Kobayashi, Shigeru Marubashi, Keizo Dono, Koji Umeshita, Hiroaki Nagano, Hideo Matsuda, Morito Monden, Masaki Mori, Yuichiro Doki. (2010) Exploration of Potential Genomic Portraits Associated with Intrahepatic Recurrence in Human Hepatocellular Carcinoma. Annals of Surgical Oncology 17:12, 3145-3154
CrossRef261
Susana Banerjee, Ian E Smith. (2010) Management of small HER2-positive breast cancers. The Lancet Oncology 11:12, 1193-1199
CrossRef262
R. Webster, N. Palaniappan, J. Abraham, G. Bertelli, B. Jasani, P. Barrett-Lee. (2010) HER2 Testing, Adjuvant Trastuzumab Use and Results. Our Experience in South Wales. Clinical Oncology 22:10, 894
CrossRef263
Hideo Shigematsu, Yoshiaki Nakamura, Kimihiro Tanaka, Satoko Shiotani, Chinami Koga, Hidetoshi Kawaguchi, Sumiko Nishimura, Kenichi Taguchi, Kenichi Nishiyama, Shinji Ohno. (2010) A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment. International Journal of Clinical Oncology 15:6, 615-620
CrossRef264
N. S. Bese, C. Umay, S. Serdengecti, N. Kepil, N. Sut, T. Altug, A. Ober. (2010) The impact of trastuzumab on radiation-induced pulmonary fibrosis: results of an experimental study. Medical Oncology 27:4, 1415-1419
CrossRef265
L. Tookman, R. Roylance. (2010) New drugs for breast cancer. British Medical Bulletin 96:1, 111-129
CrossRef266
Nicolas Magné, Cyrus Chargari, Dhara MacDermed, Rosa Conforti, Lionel Védrine, Jean-Philippe Spano, David Khayat. (2010) Tomorrow's targeted therapies in breast cancer patients: What is the risk for increased radiation-induced cardiac toxicity?. Critical Reviews in Oncology/Hematology 76:3, 186-195
CrossRef267
Allan Lipton, Wolfgang J. Köstler, Kim Leitzel, Suhail M. Ali, Jeff Sperinde, Jodi Weidler, Agnes Paquet, Thomas Sherwood, Weidong Huang, Michael Bates. (2010) Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Cancer 116:22, 5168-5178
CrossRef268
Mathieu Beaulieu, Simon de Denus, Jean Lachaine. (2010) Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics 11:11, 1573-1590
CrossRef269
Rita Nahta, Ruth M. O'Regan. (2010) Evolving Strategies for Overcoming Resistance to HER2-Directed Therapy: Targeting the PI3K/Akt/mTOR Pathway. Clinical Breast Cancer 10:0, S72-S78
CrossRef270
Baohui Liu, Daofeng Tian, Wei Yi, Liquan Wu, Qiang Cai, Huimin Dong, Heng Shen, Baowei Ji, Long Wang, Shenqi Zhang, Dong Ruan, Qianxue Chen. (2010) Effect of Bone Morphogenetic Protein 4 in the Human Brain Glioma Cell Line U251. Cell Biochemistry and Biophysics 58:2, 91-96
CrossRef271
Geoffrey J. Yoon, Melinda L. Telli, David P. Kao, Kelly Y. Matsuda, Robert W. Carlson, Ronald M. Witteles. (2010) Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies. Journal of the American College of Cardiology 56:20, 1644-1650
CrossRef272
Hatem A Azim Jr, Hamdy Azim, Fedro A Peccatori. (2010) Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Review of Clinical Immunology 6:6, 821-826
CrossRef273
Giuseppe Viale, Mariacristina Ghioni, Mauro G Mastropasqua. (2010) Traditional molecular markers and response to adjuvant endocrine or trastuzumab-based therapies. Current Opinion in Oncology 22:6, 541-546
CrossRef274
R. B. Costa, G. Kurra, L. Greenberg, C. E. Geyer. (2010) Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Annals of Oncology 21:11, 2153-2160
CrossRef275
Zsolt Gabos, John Thoms, Sunita Ghosh, John Hanson, Jean Deschênes, Siham Sabri, Bassam Abdulkarim. (2010) The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Research and Treatment 124:1, 187-194
CrossRef276
Fredika M. Robertson, Melissa Bondy, Wei Yang, Hideko Yamauchi, Shannon Wiggins, Samira Kamrudin, Savitri Krishnamurthy, Huong Le-Petross, Luc Bidaut, Audrey N. Player, Sanford H. Barsky, Wendy A. Woodward, Thomas Buchholz, Anthony Lucci, Naoto Ueno, Massimo Cristofanilli. (2010) Inflammatory Breast Cancer: The Disease, the Biology, the Treatment. CA: A Cancer Journal for Clinicians 60:6, 351-375
CrossRef277
Patricia R. Blank, Matthias Schwenkglenks, Holger Moch, Thomas D. Szucs. (2010) Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost–effectiveness analysis of different predictive assay strategies. Breast Cancer Research and Treatment 124:2, 497-507
CrossRef278
V. Guarneri, E. Barbieri, M.V. Dieci, F. Piacentini, P. Conte. (2010) Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treatment Reviews 36, S62-S66
CrossRef279
M. HOOPMANN, K. SACHSE, M.M. VALTER, M. BECKER, R. NEUMANN, M. ORTMANN, U.-J. GÖHRING, A. THOMAS, P. MALLMANN, T. SCHÖNDORF. (2010) Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients. European Journal of Cancer Care 19:6, 809-815
CrossRef280
Stacy Moulder. (2010) Intrinsic resistance to chemotherapy in breast cancer. Women's Health 6:6, 821-830
CrossRef281
Toshihiko Fukamachi, Yoshie Chiba, Xin Wang, Hiromi Saito, Masatoshi Tagawa, Hiroshi Kobayashi. (2010) Tumor specific low pH environments enhance the cytotoxicity of lovastatin and cantharidin. Cancer Letters 297:2, 182-189
CrossRef282
S Guiu, M Gauthier, B Coudert, F Bonnetain, L Favier, S Ladoire, H Tixier, B Guiu, F Penault-Llorca, F Ettore, P Fumoleau, L Arnould. (2010) Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer. British Journal of Cancer 103:9, 1335-1342
CrossRef283
Xianglin L. Du, Rui Xia, Keith Burau, Chih-Chin Liu. (2010) Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005. Medical Oncology
CrossRef284
Stephane Ederhy, Christophe Massard, Ghislaine Dufaitre, Ratio Balheda, Catherine Meuleman, Carlos Gomez Rocca, Hassane Izzedine, Ariel Cohen, Jean-Charles Soria. (2010) Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials. Investigational New Drugs
CrossRef285
Francisco J. Esteva, Hua Guo, Siyuan Zhang, Cesar Santa-Maria, Steven Stone, Jerry S. Lanchbury, Aysegul A. Sahin, Gabriel N. Hortobagyi, Dihua Yu. (2010) PTEN, PIK3CA, p-AKT, and p-p70S6K Status. The American Journal of Pathology 177:4, 1647-1656
CrossRef286
Masataka Sawaki, Hiroji Iwata, Yasuyuki Sato, Masaki Wada, Tatsuya Toyama, Eiichi Sasaki, Yasushi Yatabe, Tsuneo Imai, Yasuo Ohashi. (2010) Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer. The Breast 19:5, 370-376
CrossRef287
Lori M. Minasian, William R. Carpenter, Bryan J. Weiner, Darrell E. Anderson, Worta McCaskill-Stevens, Stefanie Nelson, Cynthia Whitman, Joseph Kelaghan, Ann M. O'Mara, Arnold D. Kaluzny. (2010) Translating research into evidence-based practice. Cancer 116:19, 4440-4449
CrossRef288
Sabine Riethdorf, Klaus Pantel. (2010) Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells. Annals of the New York Academy of Sciences 1210:1, 66-77
CrossRef289
J. Baselga. (2010) Treatment of HER2-overexpressing breast cancer. Annals of Oncology 21:Supplement 7, vii36-vii40
CrossRef290
Cynthia Frankel. (2010) Trastuzumab Cardio-Oncology: Lessons Learned. Clinical Journal of Oncology Nursing 14:5, 630-640
CrossRef291
I. Brana, J. Tabernero. (2010) Cardiotoxicity. Annals of Oncology 21:Supplement 7, vii173-vii179
CrossRef292
Elisabetta Munzone, Franco Nolé, Aron Goldhirsch, Edoardo Botteri, Angela Esposito, Laura Zorzino, Giuseppe Curigliano, Ida Minchella, Laura Adamoli, Maria Cristina Cassatella, Chiara Casadio, Maria Teresa Sandri. (2010) Changes of HER2 Status in Circulating Tumor Cells Compared With the Primary Tumor During Treatment for Advanced Breast Cancer. Clinical Breast Cancer 10:5, 392-397
CrossRef293
C. Oakman, A. Sapino, C. Marchio, M. Pestrin, L. Biganzoli, A. Di Leo. (2010) Chemotherapy with or without trastuzumab. Annals of Oncology 21:Supplement 7, vii112-vii119
CrossRef294
Julie A. Y. Billar, Amylou C. Dueck, Chee-Chee H. Stucky, Richard J. Gray, Nabil Wasif, Donald W. Northfelt, Ann E. McCullough, Barbara A. Pockaj. (2010) Triple-Negative Breast Cancers: Unique Clinical Presentations and Outcomes. Annals of Surgical Oncology 17:S3, 384-390
CrossRef295
P. Maroun, J. Gligorov, J. Ohnona, C. Murariu, Y. Belkacémi. (2010) Détermination de HER2 dans les adénocarcinomes pour établir le pronostic et prédire la réponse aux traitements. Bio tribune magazine 36:1, 30-35
CrossRef296
Christian Bolenz, Shahrokh F. Shariat, Pierre I. Karakiewicz, Raheela Ashfaq, Richard Ho, Arthur I. Sagalowsky, Yair Lotan. (2010) Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU International 106:8, 1216-1222
CrossRef297
L.J. Murray, S. Ramakrishnan, L. O'Toole, I.H. Manifold, O.P. Purohit, R.E. Coleman. (2010) Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery. The Breast 19:5, 339-344
CrossRef298
Kathleen A. Cronin, Linda C. Harlan, Kevin W. Dodd, Jeffrey S. Abrams, Rachel Ballard-Barbash. (2010) Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US. Cancer Investigation 28:9, 963-968
CrossRef299
Thaer Khoury, Kazunori Kanehira, Dan Wang, Foluso Ademuyiwa, Wilfrido Mojica, Richard Cheney, Carl Morrison, Jeffrey Conroy, Norma Nowak, Song Liu. (2010) Breast carcinoma with amplified HER2: a gene expression signature specific for trastuzumab resistance and poor prognosis. Modern Pathology 23:10, 1364-1378
CrossRef300
Anusheel Munshi, Kaustav Talapatra, Debanarayan Dutta. (2010) Breast cancer radiotherapy and cardiac risk. Oncology Reviews 4:3, 137-146
CrossRef301
Stacy L. Moulder. (2010) Novel Cytotoxic Backbones and Targeted Therapies: Recent Data and Ongoing Clinical Trials. Clinical Breast Cancer 10:0, S30-S40
CrossRef302
De-Xing Hou, Takuma Kumamoto. (2010) Flavonoids as Protein Kinase Inhibitors for Cancer Chemoprevention: Direct Binding and Molecular Modeling. Antioxidants & Redox Signaling 13:5, 691-719
CrossRef303
Jean-Philippe Theurillat, Birgit Dreier, Gabriela Nagy-Davidescu, Burkhardt Seifert, Silvia Behnke, Ursina Zürrer-Härdi, Fabienne Ingold, Andreas Plückthun, Holger Moch. (2010) Designed ankyrin repeat proteins: a novel tool for testing epidermal growth factor receptor 2 expression in breast cancer. Modern Pathology 23:9, 1289-1297
CrossRef304
Joseph R. Carver. (2010) Management of Trastuzumab-Related Cardiac Dysfunction. Progress in Cardiovascular Diseases 53:2, 130-139
CrossRef305
Susana Banerjee, Stan B. Kaye, Alan Ashworth. (2010) Making the best of PARP inhibitors in ovarian cancer. Nature Reviews Clinical Oncology 7:9, 508-519
CrossRef306
Jean-Jacques Monsuez, Jean-Christophe Charniot, Noëlle Vignat, Jean-Yves Artigou. (2010) Cardiac side-effects of cancer chemotherapy. International Journal of Cardiology 144:1, 3-15
CrossRef307
Denise Yardley, Howard Burris, Nancy Peacock, Eric Raefsky, Marianne Melnik, Roger Inhorn, Dianna Shipley, John Hainsworth. (2010) A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer. Breast Cancer Research and Treatment 123:2, 471-475
CrossRef308
Giuseppe Curigliano, Erica L. Mayer, Harold J. Burstein, Eric P. Winer, Aron Goldhirsch. (2010) Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review. Progress in Cardiovascular Diseases 53:2, 94-104
CrossRef309
Isabell Witzel, Sibylle Loibl, Gunter Minckwitz, Christoph Mundhenke, Jens Huober, Claus Hanusch, Stephan Henschen, Maik Hauschild, Tilmann Lantzsch, Hans Tesch, Kunibert Latos, Marianne Just, Jörn Hilfrich, Jana Barinoff, Christine zu Eulenburg, Marc Roller, Michael Untch, Volkmar Müller. (2010) Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Research and Treatment 123:2, 437-445
CrossRef310
Gerald M Higa, Vikramjit Singh, Jame Abraham. (2010) Biological considerations and clinical applications of new HER2-targeted agents. Expert Review of Anticancer Therapy 10:9, 1497-1509
CrossRef311
Michael R. Mallmann, Andrea Staratschek-Jox, Christian Rudlowski, Michael Braun, Andrea Gaarz, Matthias Wolfgarten, Walther Kuhn, Joachim L. Schultze. (2010) Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients. The EPMA Journal 1:3, 421-437
CrossRef312
Otto Metzger Filho, Kamal S. Saini, Hatem A. Azim, Ahmad Awada. (2010) Prevention and management of major side effects of targeted agents in breast cancer. Critical Reviews in Oncology/Hematology
CrossRef313
Klaus Pantel, Catherine Alix-Panabières. (2010) Circulating tumour cells in cancer patients: challenges and perspectives. Trends in Molecular Medicine 16:9, 398-406
CrossRef314
C A Purdie, L Baker, A Ashfield, S Chatterjee, L B Jordan, P Quinlan, D J A Adamson, J A Dewar, A M Thompson. (2010) Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study. British Journal of Cancer 103:4, 475-481
CrossRef315
Nicole Schneiderhan-Marra, Georg Sauer, Cornelia Kazmaier, Hsin-Yun Hsu, Karin Koretz, Helmut Deissler, Thomas O. Joos. (2010) Multiplexed immunoassays for the analysis of breast cancer biopsies. Analytical and Bioanalytical Chemistry 397:8, 3329-3338
CrossRef316
Yeon Hee Park, Soohyeon Lee, Eun Yoon Cho, Yoon La Choi, Jeong Eon Lee, Seok Jin Nam, Jung-Hyun Yang, Jin Seok Ahn, Young-Hyuck Im. (2010) Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status. Cancer Chemotherapy and Pharmacology 66:3, 507-516
CrossRef317
Daniel S.-W. Tan, Marco Gerlinger, Bin-Tean Teh, Charles Swanton. (2010) Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference. European Journal of Cancer 46:12, 2166-2177
CrossRef318
Gianluca Tomasello, Philippe L. Bedard, Evandro de Azambuja, Dominique Lossignol, Daniel Devriendt, Martine J. Piccart-Gebhart. (2010) Brain metastases in HER2-positive breast cancer: The evolving role of lapatinib. Critical Reviews in Oncology/Hematology 75:2, 110-121
CrossRef319
D.G. Power, J.V. Reynolds. (2010) Localized adenocarcinoma of the esophagogastric junction – Is there a standard of care?. Cancer Treatment Reviews 36:5, 400-409
CrossRef320
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh, Giuseppe Aprile, Evgeny Kulikov, Julie Hill, Michaela Lehle, Josef Rüschoff, Yoon-Koo Kang. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet 376:9742, 687-697
CrossRef321
Hirofumi Mukai. (2010) Treatment strategy for HER2-positive breast cancer. International Journal of Clinical Oncology 15:4, 335-340
CrossRef322
Jeffrey M. Albert, Ana M. Gonzalez-Angulo, Merih Guray, Aysegul Sahin, Eric A. Strom, Welela Tereffe, Wendy A. Woodward, Susan L. Tucker, Kelly K. Hunt, Gabriel N. Hortobagyi, Thomas A. Buchholz. (2010) Estrogen/Progesterone Receptor Negativity and HER2 Positivity Predict Locoregional Recurrence in Patients With T1a,bN0 Breast Cancer. International Journal of Radiation Oncology*Biology*Physics 77:5, 1296-1302
CrossRef323
Ulla Wilking, Bengt Jönsson, Nils Wilking, Jonas Bergh. (2010) Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden. Acta Oncologica 49:6, 844-850
CrossRef324
Guillermo Gervasini, Julio Benítez, Juan Antonio Carrillo. (2010) Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. European Journal of Clinical Pharmacology 66:8, 755-774
CrossRef325
Juan de la Haba-Rodriguez, Rosario González Mancha, Gumersindo Pérez Manga, Enrique Aranda Aguilar, José Manuel Baena Cañada, Pedro Sánchez Rovira, Emilio Alba Conejo. (2010) Exemestane and Chemotherapy as First-line Treatment of Metastatic Breast Cancer: Results of a Phase II Study. Clinical Breast Cancer 10:4, 313-317
CrossRef326
Miguel Martín, Álvaro Rodríguez-Lescure, Amparo Ruiz, Emilio Alba, Lourdes Calvo, Manuel Ruiz-Borrego, Ana Santaballa, César A. Rodríguez, Carmen Crespo, Mar Abad, Severina Domínguez, Jesús Florián, Cristina Llorca, Miguel Méndez, María Godes, Ricardo Cubedo, Adolfo Murias, Norberto Batista, María José García, Rosalía Caballero, Enrique Álava. (2010) Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment 123:1, 149-157
CrossRef327
SaeGwang Park, Zhujun Jiang, Eric D. Mortenson, Liufu Deng, Olga Radkevich-Brown, Xuanming Yang, Husain Sattar, Yang Wang, Nicholas K. Brown, Mark Greene, Yang Liu, Jie Tang, Shengdian Wang, Yang-Xin Fu. (2010) The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity. Cancer Cell 18:2, 160-170
CrossRef328
Neil K. Taunk, Sharad Goyal, Meena S. Moran, Qifeng Yang, Rahul Parikh, Bruce G. Haffty. (2010) Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy. Radiotherapy and Oncology 96:2, 204-208
CrossRef329
Sophie Otter, Alistair Ring. (2010) Outcomes following adjuvant therapy for HER2-positive early breast cancer in the elderly. Expert Review of Anticancer Therapy 10:8, 1265-1272
CrossRef330
Susana Banerjee, David Cunningham. (2010) Targeted Therapies as Adjuvant Treatment for Early-Stage Colorectal Cancer: First Impressions and Clinical Questions. Clinical Colorectal Cancer 9:0, S28-S35
CrossRef331
George W. Sledge, Aparna C. Jotwani, Lida Mina. (2010) Targeted Therapies in Early-Stage Breast Cancer: Achievements and Promises. Surgical Oncology Clinics of North America 19:3, 669-679
CrossRef332
Anna-Karin Falck, Mårten Fernö, Pär-Ola Bendahl, Lisa Rydén. (2010) Does Analysis of Biomarkers in Tumor Cells in Lymph Node Metastases Give Additional Prognostic Information in Primary Breast Cancer?. World Journal of Surgery 34:7, 1434-1441
CrossRef333
Catherine M. Kelly, Gabriel N. Hortobagyi. (2010) Adjuvant Chemotherapy in Early-Stage Breast Cancer: What, When, and for Whom?. Surgical Oncology Clinics of North America 19:3, 649-668
CrossRef334
K. Kast, W. Distler. (2010) ErbB2 (HER2)-positives Mammakarzinom. Der Gynäkologe 43:7, 574-578
CrossRef335
Valentina Macrinici, Edward Romond. (2010) Clinical Updates on EGFR/HER Targeted Agents in Early-Stage Breast Cancer. Clinical Breast Cancer 10:0, E38-E46
CrossRef336
Alicia F.C. Okines, David Cunningham. (2010) Trastuzumab in gastric cancer. European Journal of Cancer 46:11, 1949-1959
CrossRef337
K. Aoyama, T. Kamio, T. Nishikawa, S. Kameoka. (2010) A Comparison of HER2/neu Gene Amplification and Its Protein Overexpression Between Primary Breast Cancer and Metastatic Lymph Nodes. Japanese Journal of Clinical Oncology 40:7, 613-619
CrossRef338
Yuki Ando, Toshimitsu Hamasaki. (2010) Practical issues and lessons learned from multi-regional clinical trials via case examples: a Japanese perspective. Pharmaceutical Statistics 9:3, 190-200
CrossRef339
E. Fenton. (2010) Making Fair Funding Decisions for High Cost Cancer Care: The Case of Herceptin in New Zealand. Public Health Ethics 3:2, 137-146
CrossRef340
P. Maroun, J. Gligorov, J. Ohnona, C. Murariu, Y. Belkacémi. (2010) Détermination de HER2 dans les adénocarcinomes pour établir le pronostic et prédire la réponse aux traitements. Oncologie 12:7, 416-421
CrossRef341
Patricia S Kho, Wei Chua, Melissa M Moore, Stephen J Clarke. (2010) Is it prime time for personalized medicine in cancer treatment?. Personalized Medicine 7:4, 387-397
CrossRef342
Heidrun Karlic, Harald Herrmann, Axel Schulenburg, Thomas W. Grunt, Sylvia Laffer, Irina Mirkina, Rainer Hubmann, Medhat Shehata, Brigitte Marian, Edgar Selzer, Michael Pfeilstöcker, Elisabeth Pittermann, Ulrich Jäger, Hubert Pehamberger, Christoph Zielinski, Peter Valent. (2010) Tumor-Stammzellforschung – Basis und Herausforderung für Diagnostik und Therapie. Wiener klinische Wochenschrift 122:13-14, 423-436
CrossRef343
W. Chris Taylor, Hyman B. Muss. (2010) Recent Advances. The Cancer Journal 16:4, 289-293
CrossRef344
Efrat Dotan, Lori J. Goldstein. (2010) Optimizing Chemotherapy Regimens for Patients With Early-Stage Breast Cancer. Clinical Breast Cancer 10:0, E8-E15
CrossRef345
Shaheenah Dawood. (2010) Novel biomarkers of metastatic cancer. Expert Review of Molecular Diagnostics 10:5, 581-590
CrossRef346
Helena R. Chang. (2010) Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer 116:12, 2856-2867
CrossRef347
Patrice Viens, Carole Tarpin, Henri Roche, François Bertucci. (2010) Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies. Cancer 116:S11, 2829-2836
CrossRef348
Karen E. Hoffman, Thomas A. Buchholz. (2010) How Improved Local-Regional Therapy Impacts Survival. Current Breast Cancer Reports 2:2, 83-89
CrossRef349
Marc Buyse, Daniel J. Sargent, Axel Grothey, Alastair Matheson, Aimery de Gramont. (2010) Biomarkers and surrogate end points—the challenge of statistical validation. Nature Reviews Clinical Oncology 7:6, 309-317
CrossRef350
Christina A. Saurel, Tejal A. Patel, Edith A. Perez. (2010) Changes to Adjuvant Systemic Therapy in Breast Cancer: A Decade in Review. Clinical Breast Cancer 10:3, 196-208
CrossRef351
Per E. Lønning. (2010) Molecular basis for therapy resistance. Molecular Oncology 4:3, 284-300
CrossRef352
Kai-Keen Shiu, Rachael Natrajan, Felipe C Geyer, Alan Ashworth, Jorge S Reis-Filho. (2010) DNA amplifications in breast cancer: genotypic–phenotypic correlations. Future Oncology 6:6, 967-984
CrossRef353
F. Grudé, M. Campone, A. Lortholary, R. Delva, P. Soulie, P. Kerbrat, G. Ganem, H. Bourgeois, S. Hulst, E. Vuillemin, A.-C. Hardy-Bessard, M.-J. Goudier, H. Simon, B. Lucas, F. Priou, C. Riché, E. Gamelin. (2010) Étude de phase IV de pharmacovigilance portant sur la toxicité cardiaque du trastuzumab en néoadjuvant et adjuvant dans le cancer du sein. Analyse conduite par l’Observatoire des Médicaments et des Innovations Thérapeutiques de Bretagne et des Pays de la Loire (OMIT B PL). Oncologie 12:5-6, 362-368
CrossRef354
Brigitte A.B. Essers, Shanley C. Seferina, Vivianne C.G. Tjan-Heijnen, Johan L. Severens, Annoesjka Novák, Marjolein Pompen, Ulrich H. Oron, Manuela A. Joore. (2010) Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands. Value in Health 13:4, 375-380
CrossRef355
Karly P. Garnock-Jones, Gillian M. Keating, Lesley J. Scott. (2010) Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer†. BioDrugs 24:3, 207-209
CrossRef356
Lisa A. Carey. (2010) Through a Glass Darkly: Advances in Understanding Breast Cancer Biology, 2000-2010. Clinical Breast Cancer 10:3, 188-195
CrossRef357
Cristina Oliveras-Ferraros, Alejandro Vazquez-Martin, Begoña Martin-Castillo, Silvia Cufí, Sonia Del Barco, Eugeni Lopez-Bonet, Joan Brunet, Javier A. Menendez. (2010) Dynamic emergence of the mesenchymal CD44posCD24neg/low phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochemical and Biophysical Research Communications 397:1, 27-33
CrossRef358
Frances M. Palmieri, Charlyn V. Myatt, Edith A. Perez. (2010) Adjuvant Trastuzumab for HER2-Positive Early Breast Cancer. Clinical Journal of Oncology Nursing 14:3, 326-336
CrossRef359
Laura S. Dominici, Elizabeth A. Mittendorf, Tse-Kuan Yu, Isabelle Bedrosian. (2010) Impact of Breast Cancer Subtypes on Local-Regional Outcomes. Current Breast Cancer Reports 2:2, 107-113
CrossRef360
Massimo Cristofanilli. (2010) Novel targeted therapies in inflammatory breast cancer. Cancer 116:S11, 2837-2839
CrossRef361
Patrick G Morris, Heather L McArthur, Clifford Hudis, Larry Norton. (2010) Dose-dense chemotherapy for breast cancer: what does the future hold?. Future Oncology 6:6, 951-965
CrossRef362
G. Masci, L. Di Tommaso, I. Del Prato, S. Orefice, A. Rubino, G. Gullo, M. Zuradelli, R. Sacco, M. Alloisio, M. Eboli, M. Incarbone, L. Giordano, M. Roncalli, A. Santoro. (2010) Sinusal localization of nodal micrometastases is a prognostic factor in breast cancer. Annals of Oncology 21:6, 1228-1232
CrossRef363
Connie G. Chiu, Hamid Masoudi, Samuel Leung, David K. Voduc, Blake Gilks, David G. Huntsman, Sam M. Wiseman. (2010) HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival. Annals of Surgery 251:6, 1107-1116
CrossRef364
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Muss, Hyman B., D'Alessandro, Helen Anne, Brachtel, Elena F., . (2010) Case 15-2010. New England Journal of Medicine 362:20, 1921-1928
Full Text365
S. Aebi, T. Davidson, G. Gruber, M. Castiglione, . (2010) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v9-v14
CrossRef366
R.W. Glynn, N. Miller, M.J. Kerin. (2010) 17q12-21 – The pursuit of targeted therapy in breast cancer. Cancer Treatment Reviews 36:3, 224-229
CrossRef367
Geoffrey Y. Ku, David H. Ilson. (2010) Esophagogastric cancer: Targeted agents. Cancer Treatment Reviews 36:3, 235-248
CrossRef368
Volkmar Müller, Catherine Alix-Panabières, Klaus Pantel. (2010) Insights into minimal residual disease in cancer patients: Implications for anti-cancer therapies. European Journal of Cancer 46:7, 1189-1197
CrossRef369
E C Dijkers, T H Oude Munnink, J G Kosterink, A H Brouwers, P L Jager, J R de Jong, G A van Dongen, C P Schröder, M N Lub-de Hooge, E G de Vries. (2010) Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer. Clinical Pharmacology & Therapeutics 87:5, 586-592
CrossRef370
W. Kwan, A. J. Al-Tourah, C. Speers, R. Woods, H. Kennecke, I. A. Olivotto. (2010) Does HER2 status influence locoregional failure rates in breast cancer patients treated with mastectomy for pT1-2pN0 disease?. Annals of Oncology 21:5, 988-993
CrossRef371
Colin A Purdie, Lee B Jordan, Jean B McCullough, Sharon L Edwards, Joan Cunningham, Miriam Walsh, Andrew Grant, Norman Pratt, Alastair M Thompson. (2010) HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma. Histopathology 56:6, 702-707
CrossRef372
Jennifer Y. Wo, Alphonse G. Taghian, Paul L. Nguyen, Rita Abi Raad, Meera Sreedhara, Jennifer R. Bellon, Julia S. Wong, Michele A. Gadd, Barbara L. Smith, Jay R. Harris. (2010) The Association Between Biological Subtype and Isolated Regional Nodal Failure After Breast-Conserving Therapy. International Journal of Radiation Oncology*Biology*Physics 77:1, 188-196
CrossRef373
Jan Jørgensen. 2010. Pharmacodiagnostics and Personalized Medicine in Cancer. , 325-344.
CrossRef374
Rebecca Scully, Steven E. Lipshultz. 2010. Cardiovascular Toxicity of Antitumor Drugs: Dimensions of the Problem in Children. , 97-126.
CrossRef375
Timo T. Purmonen, Päivi K. Auvinen, Janne A. Martikainen. (2010) Budget impact analysis of trastuzumab in early breast cancer: A hospital district perspective. International Journal of Technology Assessment in Health Care 26:02, 163
CrossRef376
Tim J. Kruser, Deric L. Wheeler. (2010) Mechanisms of resistance to HER family targeting antibodies. Experimental Cell Research 316:7, 1083-1100
CrossRef377
Huixiao Hong, Federico Goodsaid, Leming Shi, Weida Tong. (2010) Molecular biomarkers: a US FDA effort. Biomarkers in Medicine 4:2, 215-225
CrossRef378
Emad A. Rakha, Jorge S. Reis-Filho, Ian O. Ellis. (2010) Combinatorial biomarker expression in breast cancer. Breast Cancer Research and Treatment 120:2, 293-308
CrossRef379
Yoshinari Asaoka, Motohisa Tada, Tsuneo Ikenoue, Motoko Seto, Mitsuho Imai, Koji Miyabayashi, Keisuke Yamamoto, Shinzo Yamamoto, Yotaro Kudo, Dai Mohri, Yoshihiro Isomura, Hideaki Ijichi, Keisuke Tateishi, Fumihiko Kanai, Seishi Ogawa, Masao Omata, Kazuhiko Koike. (2010) Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. Biochemical and Biophysical Research Communications 394:4, 1042-1046
CrossRef380
Li Ma, Ferenc Reinhardt, Elizabeth Pan, Jürgen Soutschek, Balkrishen Bhat, Eric G Marcusson, Julie Teruya-Feldstein, George W Bell, Robert A Weinberg. (2010) Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nature Biotechnology 28:4, 341-347
CrossRef381
Kant M Matsuda, Joon-Yong Chung, Stephen M Hewitt. (2010) Histo-proteomic profiling of formalin-fixed, paraffin-embedded tissue. Expert Review of Proteomics 7:2, 227-237
CrossRef382
V. Girardi, G. Carbognin, L. Camera, M. Tonegutti, F. Bonetti, E. Manfrin, R. Pozzi Mucelli. (2010) Fischer’s score criteria correlating with histopathological prognostic factors in invasive breast cancer. La radiologia medica 115:3, 421-433
CrossRef383
Fabrício F T Barros, Desmond G Powe, Ian O Ellis, Andrew R Green. (2010) Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology 56:5, 560-572
CrossRef384
S Kulkarni, K B Reddy, F J Esteva, H C F Moore, G T Budd, R R Tubbs. (2010) Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer. Oncogene 29:9, 1339-1350
CrossRef385
Q. Ghafoor, P. Sanghera, R.J. Grieve. (2010) A Study of Medical Intervention in Routine Breast Cancer Follow-up. Clinical Oncology 22:2, 91-96
CrossRef386
April Davoli, Barbara A. Hocevar, Thomas L. Brown. (2010) Progression and treatment of HER2-positive breast cancer. Cancer Chemotherapy and Pharmacology 65:4, 611-623
CrossRef387
K Ichimaru, S Toyoshima, Y Uyama. (2010) Effective Global Drug Development Strategy for Obtaining Regulatory Approval in Japan in the Context of Ethnicity-Related Drug Response Factors. Clinical Pharmacology & Therapeutics 87:3, 362-366
CrossRef388
Windy Dean-Colomb, Francisco J. Esteva. (2010) Treatment of Her2-Positive Breast Cancer: What’s on the Horizon. Current Breast Cancer Reports 2:1, 42-52
CrossRef389
Chitta Ranjan Patra, Resham Bhattacharya, Debabrata Mukhopadhyay, Priyabrata Mukherjee. (2010) Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Advanced Drug Delivery Reviews 62:3, 346-361
CrossRef390
Tomás García-Caballero, Dorthe Grabau, Andrew R Green, John Gregory, Arno Schad, Elke Kohlwes, Ian O Ellis, Sarah Watts, Jens Mollerup. (2010) Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology 56:4, 472-480
CrossRef391
Y. Nadler, A. M. Gonzalez, R. L. Camp, D. L. Rimm, H. M. Kluger, Y. Kluger. (2010) Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer. Annals of Oncology 21:3, 466-473
CrossRef392
Brigette BY Ma, Herbert Loong. (2010) Personalized cancer therapy coming of age: clinical highlights in 2009 and future directions. Personalized Medicine 7:2, 121-124
CrossRef393
Helen M. Heneghan, Nicola Miller, Aoife J. Lowery, Karl J. Sweeney, John Newell, Michael J. Kerin. (2010) Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer. Annals of Surgery 251:3, 499-505
CrossRef394
Serena T. Wong, Deborah Toppmeyer. (2010) Adjuvant Chemotherapy for Early Stage Breast Cancer: Current Trends and Future Directions. Current Breast Cancer Reports 2:1, 16-24
CrossRef395
Mary E. Abusief, Stacey A. Missmer, Elizabeth S. Ginsburg, Jane C. Weeks, Ann H. Partridge. (2010) The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 116:4, 791-798
CrossRef396
Masaaki Iwatsuki, Koshi Mimori, Takehiko Yokobori, Hideshi Ishi, Toru Beppu, Shoji Nakamori, Hideo Baba, Masaki Mori. (2010) Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Science 101:2, 293-299
CrossRef397
Nikolas H. Stoecklein, Christoph A. Klein. (2010) Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. International Journal of Cancer 126:3, 589-598
CrossRef398
Leo A Niemeier, David J Dabbs, Sushil Beriwal, Joan M Striebel, Rohit Bhargava. (2010) Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Modern Pathology 23:2, 205-212
CrossRef399
Yeon Hee Park, Seung Tae Kim, Eun Yoon Cho, Yoon La Choi, Oh-Nam Ok, Hae Jin Baek, Jeong Eon Lee, Seok Jin Nam, Jung-Hyun Yang, Won Park, Doo Ho Choi, Seung Jae Huh, Jin Seok Ahn, Young-Hyuck Im. (2010) A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?. Breast Cancer Research and Treatment 119:3, 653-661
CrossRef400
Dimitrios H Roukos, Dimosthenis Ziogas. (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Review of Anticancer Therapy 10:2, 123-128
CrossRef401
, Paula Manchon, Josep M. Borràs, Tàrsila Ferro, Josep Alfons Espinàs. (2010) Breast cancer OncoGuia. Clinical and Translational Oncology 12:2, 113-137
CrossRef402
Emanuel Raschi, Valentina Vasina, Maria Grazia Ursino, Giuseppe Boriani, Andrea Martoni, Fabrizio De Ponti. (2010) Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. Pharmacology & Therapeutics 125:2, 196-218
CrossRef403
Y. Kataoka, T. Mukohara, H. Shimada, N. Saijo, M. Hirai, H. Minami. (2010) Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Annals of Oncology 21:2, 255-262
CrossRef404
Elizabeth Bilodeau, Faizan Alawi, Bernard J. Costello, Joanne L. Prasad. (2010) Molecular Diagnostics for Head and Neck Pathology. Oral and Maxillofacial Surgery Clinics of North America 22:1, 183-194
CrossRef405
Francisco J. Esteva, Dihua Yu, Mien-Chie Hung, Gabriel N. Hortobagyi. (2010) Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nature Reviews Clinical Oncology 7:2, 98-107
CrossRef406
Augusto Villanueva, Beatriz Minguez, Alejandro Forner, Maria Reig, Josep M. Llovet. (2010) Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy. Annual Review of Medicine 61:1, 317-328
CrossRef407
Alba A Brandes, Enrico Franceschi, Alicia Tosoni, Roberta Degli Esposti. (2010) Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls. Expert Review of Anticancer Therapy 10:2, 179-184
CrossRef408
Joseph A. Sparano, Gabriel N. Hortobagyi, Julie R. Gralow, Edith A. Perez, Robert L. Comis. (2010) Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization. Breast Cancer Research and Treatment 119:3, 511-527
CrossRef409
Shaheenah Dawood. (2010) Biology and management of inflammatory breast cancer. Expert Review of Anticancer Therapy 10:2, 209-220
CrossRef410
Tommaso Susini, Cecilia Bussani, Giulia Marini, Jacopo Nori, Simone Olivieri, Cecilia Molino, Simonetta Bianchi, Vania Vezzosi, Milena Paglierani, Massimo Giachi, Elena Borrani, Gianfranco Scarselli. (2010) Preoperative assessment of HER-2/neu status in breast carcinoma: The role of quantitative real-time PCR on core-biopsy specimens. Gynecologic Oncology 116:2, 234-239
CrossRef411
Kan Yonemori, Koji Tsuta, Makiko Ono, Chikako Shimizu, Akihiro Hirakawa, Tadashi Hasegawa, Yutaka Hatanaka, Yoshitaka Narita, Soichiro Shibui, Yasuhiro Fujiwara. (2010) Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu -positive breast cancer. Cancer 116:2, 302-308
CrossRef412
Ana M. Gonzalez-Angulo. (2010) Defining the Lower Limit of Risk, Stage, or Tumor Size for Trastuzumab-Based Adjuvant Chemotherapy for HER2-Positive Breast Cancer. Breast Diseases: A Year Book Quarterly 21:2, 112-115
CrossRef413
Sumanta K. Pal, Barrett H. Childs, Mark Pegram. (2010) Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer. Breast Cancer Research and Treatment 119:1, 25-32
CrossRef414
Dimitrios H Roukos, Dimosthenis E Ziogas, Christos Katsios. (2010) Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks. Expert Review of Anticancer Therapy 10:8, 1187
CrossRef415
Petra Harris, Andrea Takeda, Emma Loveman, Debbie Hartwell. (2010) Time to full publication of studies of anticancer drugs for breast cancer, and the potential for publication bias. International Journal of Technology Assessment in Health Care 26:01, 110
CrossRef416
Kan Yonemori, Koji Tsuta, Chikako Shimizu, Yutaka Hatanaka, Akihiro Hirakawa, Makiko Ono, Tsutomu Kouno, Noriyuki Katsumata, Masashi Ando, Kenji Tamura, Tadashi Hasegawa, Takayuki Kinoshita, Yasuhiro Fujiwara. (2010) Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. Journal of Surgical Oncologyn/a-n/a
CrossRef417
J.R. Bellon. (2010) Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. Breast Diseases: A Year Book Quarterly 21:4, 373-375
CrossRef418
H. M. Heneghan, N. Miller, A. J. Lowery, K. J. Sweeney, M. J. Kerin. (2010) MicroRNAs as Novel Biomarkers for Breast Cancer. Journal of Oncology 2010, 1-7
CrossRef419
Brian Thiessen, Clinton Stewart, Ming Tsao, Suzanne Kamel-Reid, Paula Schaiquevich, Warren Mason, Jacob Easaw, Karl Belanger, Peter Forsyth, Lynn McIntosh, Elizabeth Eisenhauer. (2010) A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemotherapy and Pharmacology 65:2, 353-361
CrossRef420
Bruce Hough, Adam Brufsky, Suzanne Lentzsch. (2010) Metastatic Breast Cancer or Multiple Myeloma? Camouflage by Lytic Lesions. Journal of Oncology 2010, 1-3
CrossRef421
Yazid Belkacémi, Joseph Gligorov. (2010) Concurrent trastuzumab – Internal mammary irradiation for HER2 positive breast cancer: “It hurts to be on the cutting edge”. Radiotherapy and Oncology 94:1, 119-120
CrossRef422
Sebastian Szmit, Marcin Kurzyna, Renata Glówczynska, Marcin Grabowski, Jaroslaw Kober, Justyna Czerniawska, Krzysztof J Filipiak, Grzegorz Opolski, Cezary Szczylik. (2010) Manageability of Acute Severe Heart Failure Complicated With Left Ventricular Thrombosis During Therapy for Breast Cancer. International Heart Journal 51:2, 141-145
CrossRef423
Major Kenneth Lee IV, Anupama Sharma, Brian J Czerniecki. (2010) It’s all in for the HER family in tumorigenesis. Expert Review of Vaccines 9:1, 29-34
CrossRef424
Woo Sang Ryu, Gil Soo Son. (2010) Cancer Vaccines Targeting HER2/neu for Early Breast Cancer. Journal of Breast Cancer 13:1, 5
CrossRef425
Karly P. Garnock-Jones, Gillian M. Keating, Lesley J. Scott. (2010) Trastuzumab. Drugs 70:2, 215-239
CrossRef426
Manabu Minami, Shigemi Matsumoto, Hisanori Horiuchi. (2010) Cardiovascular Side-Effects of Modern Cancer Therapy. Circulation Journal 74:9, 1779-1786
CrossRef427
Cathy B Moelans, Roel A de Weger, Marja TM van Blokland, Elsken van der Wall, Paul J van Diest. (2010) Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Modern Pathology 23:1, 62-70
CrossRef428
J.S. Ross. (2010) Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1Year of Trastuzumab: The HERA Trial. Breast Diseases: A Year Book Quarterly 21:4, 378-380
CrossRef429
Yasunori SATO, Kengo NAGASHIMA, Chikuma HAMADA. (2010) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 41:6, 291-300
CrossRef430
Ruchi Saxena, Anila Dwivedi. (2010) ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective. Medicinal Research Reviewsn/a-n/a
CrossRef431
Tatjana Ivkovic-Kapicl, Slavica Knezevic-Usaj. (2010) Human epidermal growth factor receptor 2 testing in breast cancer. Medicinski pregled 63:1-2, 69-74
CrossRef432
Aziz Alami Chentoufi, Anthony B. Nesburn, Lbachir BenMohamed. (2009) Recent advances in multivalent self adjuvanting glycolipopeptide vaccine strategies against breast cancer. Archivum Immunologiae et Therapiae Experimentalis 57:6, 409-423
CrossRef433
O. Gluz, C. Liedtke, N. Gottschalk, L. Pusztai, U. Nitz, N. Harbeck. (2009) Triple-negative breast cancer--current status and future directions. Annals of Oncology 20:12, 1913-1927
CrossRef434
Yi Wang, Xinrong Liu, Ling Chen, Dengfeng Cheng, Mary Rusckowski, Donald J. Hnatowich. (2009) Tumor delivery of antisense oligomer using trastuzumab within a streptavidin nanoparticle. European Journal of Nuclear Medicine and Molecular Imaging 36:12, 1977-1986
CrossRef435
Austin Duffy, Shivaani Kummar. (2009) Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors. Targeted Oncology 4:4, 267-273
CrossRef436
Anna Bergamaschi, Geir Olav Hjortland, Tiziana Triulzi, Therese Sørlie, Hilde Johnsen, Anne Hansen Ree, Hege Giercksky Russnes, Sigurd Tronnes, Gunhild M. Mælandsmo, Oystein Fodstad, Anne-Lise Borresen-Dale, Olav Engebraaten. (2009) Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Molecular Oncology 3:5-6, 469-482
CrossRef437
Thomas R. Geiger, Daniel S. Peeper. (2009) Metastasis mechanisms. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1796:2, 293-308
CrossRef438
Alberto Ocaña, Eitan Amir. (2009) Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions. Cancer Treatment Reviews 35:8, 685-691
CrossRef439
Thoralf Christoffersen, Tormod K. Guren, Karen-Lise Garm Spindler, Olav Dahl, Per Eystein Lønning, Bjørn Tore Gjertsen. (2009) Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. European Journal of Pharmacology 625:1-3, 6-22
CrossRef440
Paul Sabbatini. (2009) Consolidation Therapy in Ovarian Cancer. International Journal of Gynecological Cancer 19:Suppl 2, S35-S39
CrossRef441
Janneke E. Jaspers, Sven Rottenberg, Jos Jonkers. (2009) Therapeutic options for triple-negative breast cancers with defective homologous recombination. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1796:2, 266-280
CrossRef442
Roisin Connolly, Vered Stearns. (2009) The role of pharmacogenetics in selection of breast cancer treatment. Current Breast Cancer Reports 1:4, 190-197
CrossRef443
Franz Porzsolt, Ian Curi Bonotto de Oliveira Costa, Tania Gouvêa Thomaz. (2009) Section Original article. Journal of Public Health 17:6, 425-432
CrossRef444
S. E. Taube, G. M. Clark, J. E. Dancey, L. M. McShane, C. C. Sigman, S. I. Gutman. (2009) A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment. JNCI Journal of the National Cancer Institute 101:21, 1453-1463
CrossRef445
Nan Soon Wong, Benjamin O Anderson, Kei Siong Khoo, Peng Tiam Ang, Cheng Har Yip, Yen-Shen Lu, Narind Voravud, Zhi-Ming Shao, Kathleen I Pritchard. (2009) Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009. The Lancet Oncology 10:11, 1077-1085
CrossRef446
X Liu, J Wu, S Zhang, C Li, Q Huang. (2009) Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy. Cancer Gene Therapy 16:11, 861-872
CrossRef447
Karen Y. Wonders, David S. Hydock, Stephanie Greufe, Carole M. Schneider, Reid Hayward. (2009) Endurance exercise training preserves cardiac function in rats receiving doxorubicin and the HER-2 inhibitor GW2974. Cancer Chemotherapy and Pharmacology 64:6, 1105-1113
CrossRef448
Hamdy Azim, Hatem A. Azim, Bernard Escudier. (2009) Trastuzumab versus lapatinib: The cardiac side of the story. Cancer Treatment Reviews 35:7, 633-638
CrossRef449
Xiaoming Shen, Brian Mailey, Joshua D. I. Ellenhorn, Peiguo G. Chu, Andrew M. Lowy, Joseph Kim. (2009) CC Chemokine Receptor 9 Enhances Proliferation in Pancreatic Intraepithelial Neoplasia and Pancreatic Cancer Cells. Journal of Gastrointestinal Surgery 13:11, 1955-1962
CrossRef450
M. D. Green, P. A. Francis, V. Gebski, V. Harvey, C. Karapetis, A. Chan, R. Snyder, A. Fong, R. Basser, J. F. Forbes, . (2009) Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Annals of Oncology 20:11, 1813-1817
CrossRef451
Carol A. Parise, Katrina R. Bauer, Monica M. Brown, Vincent Caggiano. (2009) Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004. The Breast Journal 15:6, 593-602
CrossRef452
Timothy E. Kute, Lori Savage, John R. Stehle, Jung W. Kim-Shapiro, Michael J. Blanks, James Wood, James P. Vaughn. (2009) Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing. Cancer Immunology, Immunotherapy 58:11, 1887-1896
CrossRef453
D. Collins, A.D.K. Hill, L. Young. (2009) Lapatinib: A competitor or companion to trastuzumab?. Cancer Treatment Reviews 35:7, 574-581
CrossRef454
Wen Chen, Zefei Jiang, Zhimin Shao, Qiang Sun, Kunwei Shen. (2009) An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer. Value in Health 12, S82-S84
CrossRef455
J-S Frenel, E Bourbouloux, D Berton-Rigaud, S Sadot-Lebouvier, A Zanetti, M Campone. (2009) Lapatinib in metastatic breast cancer. Women's Health 5:6, 603-612
CrossRef456
(2009) Le cancer du sein chez la femme âgée (hors situation métastatique). Oncologie 11:11, 533-551
CrossRef457
S. Beslija, J. Bonneterre, H. J. Burstein, V. Cocquyt, M. Gnant, V. Heinemann, J. Jassem, W. J. Kostler, M. Krainer, S. Menard, T. Petit, L. Petruzelka, K. Possinger, P. Schmid, E. Stadtmauer, M. Stockler, S. Van Belle, C. Vogel, N. Wilcken, C. Wiltschke, C. C. Zielinski, H. Zwierzina, . (2009) Third consensus on medical treatment of metastatic breast cancer. Annals of Oncology 20:11, 1771-1785
CrossRef458
Giovanna Damia, Maurizio D’Incalci. (2009) Contemporary pre-clinical development of anticancer agents – What are the optimal preclinical models?. European Journal of Cancer 45:16, 2768-2781
CrossRef459
M E Montañez-Wiscovich, D D Seachrist, M D Landis, J Visvader, B Andersen, R A Keri. (2009) LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression. Oncogene 28:41, 3608-3618
CrossRef460
Xiaolei Zhou, David Cella, David Cameron, Mayur M. Amonkar, Anthony Segreti, Steven Stein, Mel Walker, Charles E. Geyer. (2009) Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Research and Treatment 117:3, 577-589
CrossRef461
Susan Bahl, Robert E. Roses, Anupama Sharma, Ursula Koldovsky, Shuwen Xu, Susan Weinstein, Harvey Nisenbaum, Kevin Fox, Theresa Pasha, Paul Zhang, Louis Araujo, Joseph Carver, Brian J. Czerniecki. (2009) Asymptomatic changes in cardiac function can occur in ductal carcinoma-in-situ patients following treatment with HER-2/neu–pulsed dendritic cell vaccines. The American Journal of Surgery 198:4, 488-494
CrossRef462
David M. Boruta, Paola A. Gehrig, Amanda Nickles Fader, Alexander B. Olawaiye. (2009) Management of women with uterine papillary serous cancer: A Society of Gynecologic Oncology (SGO) review. Gynecologic Oncology 115:1, 142-153
CrossRef463
Kathryn E. Huber, Lisa A. Carey, David E. Wazer. (2009) Breast Cancer Molecular Subtypes in Patients With Locally Advanced Disease: Impact on Prognosis, Patterns of Recurrence, and Response to Therapy. Seminars in Radiation Oncology 19:4, 204-210
CrossRef464
Nathan M. Shumway, Nuhad Ibrahim, Sathibalan Ponniah, George E. Peoples, James L. Murray. (2009) Therapeutic Breast Cancer Vaccines. BioDrugs 23:5, 277-287
CrossRef465
Richard D. Gelber, Shari Gelber. (2009) Facilitating consensus by examining patterns of treatment effects. The Breast 18, S2-S8
CrossRef466
Shani Paluch-Shimon, Noa Ben-Baruch, Ido Wolf, Lior Zach, Juri Kopolovic, Anna Kruglikova, Tami Modiano, Ady Yosepovich, Raphael Catane, Bella Kaufman. (2009) Hormone Receptor Expression Is Associated With a Unique Pattern of Metastatic Spread and Increased Survival Among HER2-Overexpressing Breast Cancer Patients. American Journal of Clinical Oncology 32:5, 504-508
CrossRef467
Felipe C. Geyer, Maria A. Lopez-Garcia, Maryou B. Lambros, Jorge S. Reis-Filho. (2009) Genetic characterization of breast cancer and implications for clinical management. Journal of Cellular and Molecular Medicine 13:10, 4090-4103
CrossRef468
Alfonso Sánchez-Muñoz, Elisabeth Pérez-Ruiz, Begoña Jiménez, Nuria Ribelles, Antonia Márquez, Isabel García-Ríos, Emilio Alba Conejo. (2009) Targeted therapy of metastatic breast cancer. Clinical and Translational Oncology 11:10, 643-650
CrossRef469
Larissa J. Lee, Jay R. Harris. (2009) Innovations in radiation therapy (RT) for breast cancer. The Breast 18, S103-S111
CrossRef470
Maya Guglin, Gregory Hartlage, Christopher Reynolds, Ren Chen, Vinod Patel. (2009) Trastuzumab-Induced Cardiomyopathy: Not as Benign as it Looks? A Retrospective Study. Journal of Cardiac Failure 15:8, 651-657
CrossRef471
Wendy A. Woodward, Massimo Cristofanilli. (2009) Inflammatory Breast Cancer. Seminars in Radiation Oncology 19:4, 256-265
CrossRef472
Carole Perez-Ellis, Anthony Goncalves, Jocelyne Jacquemier, Michel Marty, Véronique Girre, Henri Roché, Etienne Brain, Jean-Paul Moatti, Patrice Viens, Anne-Gaëlle Le Corroller-Soriano. (2009) Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer. American Journal of Clinical Oncology 32:5, 492-498
CrossRef473
Lisa Wiechmann, Michelle Sampson, Michelle Stempel, Lindsay M. Jacks, Sujata M. Patil, Tari King, Monica Morrow. (2009) Presenting Features of Breast Cancer Differ by Molecular Subtype. Annals of Surgical Oncology 16:10, 2705-2710
CrossRef474
Mikiya Ishihara, Hirofumi Mukai, Shunji Nagai, Toru Mukohara. (2009) Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer. International Journal of Clinical Oncology 14:5, 431-435
CrossRef475
J. Boone, R. van Hillegersberg, G. J. A. Offerhaus, P. J. van Diest, I. H. M. Borel Rinkes, F. J. W. ten Kate. (2009) Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. Diseases of the Esophagus 22:6, 496-504
CrossRef476
Alison K. Ramsay, Hing Y. Leung. (2009) Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy. Clinical Science 117:6, 209-228
CrossRef477
Deepa Wadhwa, Nazanin Fallah-Rad, Debjani Grenier, Marianne Krahn, Tielan Fang, Roien Ahmadie, Jonathan R. Walker, Danica Lister, Rakesh C. Arora, Ivan Barac, Andrew Morris, Davinder S. Jassal. (2009) Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Research and Treatment 117:2, 357-364
CrossRef478
Giuseppe Viale. (2009) Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer. The Journal of Pathology 219:1, 1-2
CrossRef479
Chung-Ming Tu, Kai-Ming Chu, Shin-Ping Yang, Shu-Mung Cheng, Wen-been Wang. (2009) Trastuzumab (Herceptin)–associated cardiomyopathy presented as new onset of complete left bundle-branch block mimicking acute coronary syndrome: a case report and literature review. The American Journal of Emergency Medicine 27:7, 903.e1-903.e3
CrossRef480
Daniel S. W. Tan, George V. Thomas, Michelle D. Garrett, Udai Banerji, Johann S. de Bono, Stan B. Kaye, Paul Workman. (2009) Biomarker-Driven Early Clinical Trials in Oncology. The Cancer Journal 15:5, 406-420
CrossRef481
Irfan Cicin, Hakan Karagol, Ufuk Usta, Atakan Sezer, Sernaz Uzunoglu, Rusen Alas-Cosar, Tarkan Yetisyigit, Kazim Uygun. (2009) Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer. Medical Oncology 26:3, 335-343
CrossRef482
Amani Asnacios, Sylvie Naveau, Gabriel Perlemuter. (2009) Gastrointestinal toxicities of novel agents in cancer therapy. European Journal of Cancer 45, 332-342
CrossRef483
Toru Mukohara, Hiroyuki Shimada, Naomi Ogasawara, Ryoko Wanikawa, Manami Shimomura, Tetsuya Nakatsura, Genichiro Ishii, Joon Oh Park, Pasi A. Jänne, Nagahiro Saijo, Hironobu Minami. (2009) Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression. Cancer Letters 282:1, 14-24
CrossRef484
Kan Yonemori, Koji Tsuta, Chikako Shimizu, Yutaka Hatanaka, Kaoru Hashizume, Makiko Ono, Tsutomu Kouno, Masashi Ando, Kenji Tamura, Noriyuki Katsumata, Tadashi Hasegawa, Takayuki Kinoshita, Yasuhiro Fujiwara. (2009) Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. Medical Oncology 26:3, 344-349
CrossRef485
T. Fojo, C. Grady. (2009) How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. JNCI Journal of the National Cancer Institute 101:15, 1044-1048
CrossRef486
Pelagia G. Tsoutsou, Michael I. Koukourakis, David Azria, Yazid Belkacémi. (2009) Optimal timing for adjuvant radiation therapy in breast cancerA comprehensive review and perspectives. Critical Reviews in Oncology/Hematology 71:2, 102-116
CrossRef487
Y. H. Choi, J. H. Ahn, S.-B. Kim, K.-H. Jung, G.-Y. Gong, M.-J. Kim, B.-H. Son, S.-H. Ahn, W. K. Kim. (2009) Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis. Annals of Oncology 20:8, 1337-1343
CrossRef488
Michael Montejo, Theresa L. Werner, David Gaffney. (2009) Current challenges in clinical management of endometrial cancer. Advanced Drug Delivery Reviews 61:10, 883-889
CrossRef489
David Dodwell, Helen Thorpe, Robert Coleman. (2009) Refining systemic therapy for early breast cancer: difficulties with subtraction. The Lancet Oncology 10:8, 738-739
CrossRef490
R.C.F. Leonard, S. Williams, A. Tulpule, A.M. Levine, S. Oliveros. (2009) Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (Myocet™). The Breast 18:4, 218-224
CrossRef491
A. Goldhirsch, J. N. Ingle, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, . (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Annals of Oncology 20:8, 1319-1329
CrossRef492
Leopoldo Perez de Isla, Alberto de Agustin, Jose Luis Rodrigo, Carlos Almeria, Maria del Carmen Manzano, Enrique Rodríguez, Ana García, Carlos Macaya, José Zamorano. (2009) Chronic Mitral Regurgitation: A Pilot Study to Assess Preoperative Left Ventricular Contractile Function Using Speckle-Tracking Echocardiography. Journal of the American Society of Echocardiography 22:7, 831-838
CrossRef493
Fernando Schmitt. (2009) HER2+ breast cancer: How to evaluate?. Advances in Therapy 26:S1, 1-8
CrossRef494
Chris Skedgel, Daniel Rayson, Tallal Younis. (2009) The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial. Value in Health 12:5, 641-648
CrossRef495
Tyler Lahusen, Ralf T. Henke, Benjamin L. Kagan, Anton Wellstein, Anna T. Riegel. (2009) The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Research and Treatment 116:2, 225-237
CrossRef496
Hideko Yamauchi, Massimo Cristofanilli, Seigo Nakamura, Gabriel N. Hortobagyi, Naoto T. Ueno. (2009) Molecular targets for treatment of inflammatory breast cancer. Nature Reviews Clinical Oncology 6:7, 387-394
CrossRef497
Dimosthenis Ziogas, Dimitrios H. Roukos. (2009) Genetics and Personal Genomics for Personalized Breast Cancer Surgery: Progress and Challenges in Research and Clinical Practice. Annals of Surgical Oncology 16:7, 1771-1782
CrossRef498
Manuela Fiúza. (2009) Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer. Advances in Therapy 26:S1, 9-17
CrossRef499
Shelby D. Reed, Kevin A. Schulman. (2009) Cost Utility of Sequential Adjuvant Trastuzumab for HER2/Neu-Positive Breast Cancer. Value in Health 12:5, 637-640
CrossRef500
José Baselga, Sandra M. Swain. (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer 9:7, 463-475
CrossRef501
Peter S Hall, Jaishree Bhosle, David A Cameron. (2009) Lapatinib in the management of breast cancer. Therapy 6:4, 553-568
CrossRef502
D. R. Rhodes, B. Ateeq, Q. Cao, S. A. Tomlins, R. Mehra, B. Laxman, S. Kalyana-Sundaram, R. J. Lonigro, B. E. Helgeson, M. S. Bhojani, A. Rehemtulla, C. G. Kleer, D. F. Hayes, P. C. Lucas, S. Varambally, A. M. Chinnaiyan. (2009) AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proceedings of the National Academy of Sciences 106:25, 10284-10289
CrossRef503
Evandro Azambuja, Philippe L. Bedard, Thomas Suter, Martine Piccart-Gebhart. (2009) Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?. Targeted Oncology 4:2, 77-88
CrossRef504
H. Masmoudi, S.M. Hewitt, N. Petrick, K.J. Myers, M.A. Gavrielides. (2009) Automated Quantitative Assessment of HER-2/neu Immunohistochemical Expression in Breast Cancer. IEEE Transactions on Medical Imaging 28:6, 916-925
CrossRef505
Klaus Pantel, Catherine Alix-Panabières, Sabine Riethdorf. (2009) Cancer micrometastases. Nature Reviews Clinical Oncology 6:6, 339-351
CrossRef506
I. Pauporté, C. Faure, X. Pivot. (2009) Impulser la recherche clinique française dans le cancer du sein: l’exemple de l’essai PHARE. Oncologie 11:6, 348-352
CrossRef507
H. Boyle, V. Girre, C. Mertens, C. Falandry, F. Gouttenoire, G. Freyer, E. G. C. Brain. (2009) Recherche clinique en oncogériatrie. Oncologie 11:6, 331-336
CrossRef508
2009. Early Symptomatic Breast Cancer. , 1-67.
CrossRef509
Joan Albanell, Xavier Andreu, María José Calasanz, Ángel Concha, José María Corominas, Tomás García-Caballero, José Antonio López, Fernando López-Ríos, Santiago Ramón y Cajal, Francisco J. Vera-Sempere, Ramón Colomer, Miguel Martín, Emilio Alba, Antonio González-Martín, Antonio Llombart, Ana Lluch, José Palacios. (2009) Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). Clinical and Translational Oncology 11:6, 363-375
CrossRef510
Bin Chen, Bin Su, Shiuan Chen. (2009) A COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms. Biochemical Pharmacology 77:12, 1787-1794
CrossRef511
David Jamieson, Nicola Cresti, Mark W Verrill, Alan V. Boddy. (2009) Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma. Journal of Immunological Methods 345:1-2, 106-111
CrossRef512
W. Willenbacher. (2009) The Best is yet to come – New drugs in Haematology. memo - Magazine of European Medical Oncology 2:2, 61-62
CrossRef513
B. Ejlertsen, M.-B. Jensen, F. Rank, B. B. Rasmussen, P. Christiansen, N. Kroman, M. E. Kvistgaard, M. Overgaard, D. B. Toftdahl, H. T. Mouridsen, . (2009) Population-Based Study of Peritumoral Lymphovascular Invasion and Outcome Among Patients With Operable Breast Cancer. JNCI Journal of the National Cancer Institute 101:10, 729-735
CrossRef514
L. Quaye, D. Dafou, S. J. Ramus, H. Song, A. G. Maharaj, M. Notaridou, E. Hogdall, S. K. Kjaer, L. Christensen, C. Hogdall, D. F. Easton, I. Jacobs, U. Menon, P. D.P. Pharoah, S. A. Gayther. (2009) Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. Human Molecular Genetics 18:10, 1869-1878
CrossRef515
C. Dreyer, E. Raymond, S. Faivre. (2009) Les thérapies ciblées et leurs indications dans les tumeurs solides. La Revue de Médecine Interne 30:5, 416-424
CrossRef516
Christina Justenhoven, Christiane B. Pierl, Susanne Haas, Hans-Peter Fischer, Ute Hamann, Christian Baisch, Volker Harth, Anne Spickenheuer, Sylvia Rabstein, Caren Vollmert, Thomas Illig, Beate Pesch, Thomas Brüning, Jürgen Dippon, Yon-Dschun Ko, Hiltrud Brauch. (2009) Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors. International Journal of Cancer 124:9, 2077-2081
CrossRef517
Maura N. Dickler, Melody A. Cobleigh, Kathy D. Miller, Pamela M. Klein, Eric P. Winer. (2009) Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Research and Treatment 115:1, 115-121
CrossRef518
V. Kataja, M. Castiglione, . (2009) Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 20:Supplement 4, iv10-iv14
CrossRef519
Wen-Jin Yin, Jin-Song Lu, Gen-Hong Di, Yan-Ping Lin, Li-Heng Zhou, Guang-Yu Liu, Jiong Wu, Kun-Wei Shen, Qi-Xia Han, Zhen-Zhou Shen, Zhi-Ming Shao. (2009) Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Research and Treatment 115:2, 325-333
CrossRef520
Sumanta Kumar Pal, Joanne Mortimer. (2009) Adjuvant systemic therapy for older adults with early-stage breast cancer. Women's Health 5:3, 251-262
CrossRef521
Michael Z. Gilcrease, Wendy A. Woodward, Marlo M. Nicolas, Lynda J. Corley, Gregory N. Fuller, Francisco J. Esteva, Susan L. Tucker, Thomas A. Buchholz. (2009) Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer. The American Journal of Surgical Pathology 33:5, 759-767
CrossRef522
Ming Hui Chen. (2009) Cardiac dysfunction induced by novel targeted anticancer therapy: An emerging issue. Current Cardiology Reports 11:3, 167-174
CrossRef523
Maysa M. Abu-Khalaf, Lyndsay Harris. (2009) The prognostic and predictive values of circulating HER-2/neu extracellular domain in patients with metastatic breast cancer. Breast Cancer Research and Treatment 114:3, 513-515
CrossRef524
Vladimir Tolmachev, Eskender Mume, Stefan Sjöberg, Fredrik Y. Frejd, Anna Orlova. (2009) Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. European Journal of Nuclear Medicine and Molecular Imaging 36:4, 692-701
CrossRef525
Tianqian Zhang, Dorothee Herlyn. (2009) Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunology, Immunotherapy 58:4, 475-492
CrossRef526
Heather-Jane Au, Kamran Golmohammadi, Tallal Younis, Shailendra Verma, Stephen Chia, Konrad Fassbender, Philip Jacobs. (2009) Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects. Breast Cancer Research and Treatment 114:3, 579-587
CrossRef527
Laura Pentassuglia, Michael Graf, Heidi Lane, Yukio Kuramochi, Gregory Cote, Francesco Timolati, Douglas B. Sawyer, Christian Zuppinger, Thomas M. Suter. (2009) Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Experimental Cell Research 315:7, 1302-1312
CrossRef528
Davinder S. Jassal, Song-Yee Han, Cecilia Hans, Anita Sharma, Tielan Fang, Roien Ahmadie, Matthew Lytwyn, Jonathan R. Walker, Raveen S. Bhalla, Andrew Czarnecki, Tarek Moussa, Pawan K. Singal. (2009) Utility of Tissue Doppler and Strain Rate Imaging in the Early Detection of Trastuzumab and Anthracycline Mediated Cardiomyopathy. Journal of the American Society of Echocardiography 22:4, 418-424
CrossRef529
Vivien H. C. Bramwell, Gordon S. Doig, Alan B. Tuck, Sylvia M. Wilson, Katia S. Tonkin, Anna Tomiak, Francisco Perera, Theodore A. Vandenberg, Ann F. Chambers. (2009) Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. Breast Cancer Research and Treatment 114:3, 503-511
CrossRef530
Hagop M. Kantarjian. (2009) Introduction: Targeting Different Pathways to Prevent Tumor Cell Development. Seminars in Oncology 36, S1-S5
CrossRef531
Noor Al-Dasooqi, Joanne M. Bowen, Rachel J. Gibson, Thomas Sullivan, Jude Lees, Dorothy M. Keefe. (2009) Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. Investigational New Drugs 27:2, 173-178
CrossRef532
Oumar Camara, Cornelia Jörke, Ulrike Hammer, Anne Egbe, Carola Rabenstein, Ingo B. Runnebaum, Klaus Hoeffken, Katharina Pachmann. (2009) Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment. Journal of Cancer Research and Clinical Oncology 135:4, 643-647
CrossRef533
Dimitrios H Roukos. (2009) Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Review of Molecular Diagnostics 9:3, 217-221
CrossRef534
Christoph A. Klein. (2009) Parallel progression of primary tumours and metastases. Nature Reviews Cancer 9:4, 302-312
CrossRef535
John Mackey, Deanna McLeod, Joseph Ragaz, Karen Gelmon, Sunil Verma, Kathleen Pritchard, Kara Laing, Louise Provencher, Lauren F. Charbonneau. (2009) Adjuvant targeted therapy in early breast cancer. Cancer 115:6, 1154-1168
CrossRef536
A L Jones, M Barlow, P J Barrett-Lee, P A Canney, I M Gilmour, S D Robb, C J Plummer, A M Wardley, M W Verrill. (2009) Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. British Journal of Cancer 100:5, 684-692
CrossRef537
K. Tipples, A. Robinson. (2009) Optimising Care of Elderly Breast Cancer Patients: a Challenging Priority. Clinical Oncology 21:2, 118-130
CrossRef538
Christine Desmedt, Jeff Sperinde, Fanny Piette, Weidong Huang, Xueguang Jin, Yuping Tan, Virginie Durbecq, Denis Larsimont, Rosa Giuliani, Colombe Chappey, Marc Buyse, John Winslow, Martine Piccart, Christos Sotiriou, Christos Petropoulos, Michael Bates. (2009) Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH. Diagnostic Molecular Pathology 18:1, 22-29
CrossRef539
Philippe L. Bedard, Fatima Cardoso, Martine J. Piccart-Gebhart. (2009) Stemming Resistance to HER-2 Targeted Therapy. Journal of Mammary Gland Biology and Neoplasia 14:1, 55-66
CrossRef540
F.C. Geyer, T. Decker, J.S. Reis-Filho. (2009) Genomweite Expressionsprofile als klinische Entscheidungshilfe. Der Pathologe 30:2, 141-146
CrossRef541
Dana Faratian, Ashley Graham, Frances Rae, Jeremy Thomas. (2009) Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service. Histopathology 54:4, 428-432
CrossRef542
Ilia L Ferrusi, Deborah A Marshall, Nathalie A Kulin, Natasha B Leighl, Kathryn A Phillips. (2009) Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses. Personalized Medicine 6:2, 193-215
CrossRef543
Ayuko A. Iverson, Cheryl Gillett, Paul Cane, Christopher D. Santini, Thomas M. Vess, Lauren Kam-Morgan, Alice Wang, Marcia Eisenberg, Charles M. Rowland, Janice J. Hessling, Samuel E. Broder, John J. Sninsky, Andrew Tutt, Steven Anderson, Sheng-Yung P. Chang. (2009) A Single-Tube Quantitative Assay for mRNA Levels of Hormonal and Growth Factor Receptors in Breast Cancer Specimens. The Journal of Molecular Diagnostics 11:2, 117-130
CrossRef544
Costanza De Rossi, Antonella Brunello, Giuseppe Jirillo, Antonio Jirillo. (2009) When an interim analysis of randomized trial changes the practice in oncology: the lesson of adjuvant Trastuzumab and the HERA trial. Immunopharmacology and Immunotoxicology 31:1, 30-31
CrossRef545
J. Rüschoff, I. Nagelmeier, M. Hofmann, Th. Henkel, O. Stoss. (2009) Aktuelles zur ErbB2-Diagnostik beim Mammakarzinom. Der Pathologe 30:2, 147-155
CrossRef546
Alice Nicol, Mike Avison, Mark Harbinson, Steve Jeans, Wendy Waddington, Simon Woldman. (2009) Procedure guideline for planar radionuclide cardiac ventriculogram for the assessment of left ventricular systolic function. Nuclear Medicine Communications 30:3, 245-252
CrossRef547
Bushra Haq, Charles E Geyer. (2009) Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer. Women's Health 5:2, 135-147
CrossRef548
Heather McArthur. (2009) An overview of HER-targeted therapy with lapatinib in breast cancer. Advances in Therapy 26:3, 263-271
CrossRef549
M Scaltriti, C Verma, M Guzman, J Jimenez, J L Parra, K Pedersen, D J Smith, S Landolfi, S Ramon y Cajal, J Arribas, J Baselga. (2009) Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28:6, 803-814
CrossRef550
J D Barros-Silva, D Leitão, L Afonso, J Vieira, M Dinis-Ribeiro, M Fragoso, M J Bento, L Santos, P Ferreira, S Rêgo, C Brandão, F Carneiro, C Lopes, F Schmitt, M R Teixeira. (2009) Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. British Journal of Cancer 100:3, 487-493
CrossRef551
Gabriella Mariani, Angelica Fasolo, Elena De Benedictis, Luca Gianni. (2009) Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nature Clinical Practice Oncology 6:2, 93-104
CrossRef552
Richard M. Eglen, Terry Reisine. (2009) The Current Status of Drug Discovery Against the Human Kinome. ASSAY and Drug Development Technologies 7:1, 22-43
CrossRef553
Christopher P. Evans. (2009) Identification of molecular targets in urologic oncology. World Journal of Urology 27:1, 3-8
CrossRef554
Melissa C. Hulvat, Nora M. Hansen, Jacqueline S. Jeruss. (2009) Multidisciplinary Care for Patients with Breast Cancer. Surgical Clinics of North America 89:1, 133-176
CrossRef555
M. J. Pepels, K. A. Boomars, R. Kimmenade, P. S. Hupperets. (2009) Life-threatening interstitial lung disease associated with trastuzumab: case report. Breast Cancer Research and Treatment 113:3, 609-612
CrossRef556
A. Spitale, P. Mazzola, D. Soldini, L. Mazzucchelli, A. Bordoni. (2009) Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Annals of Oncology 20:4, 628-635
CrossRef557
S Shousha, D Peston, B Amo-Takyi, M Morgan, B Jasani. (2009) Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Histopathology 54:2, 248-253
CrossRef558
Michael S. Sabel. 2009. Principles of Adjuvant Chemotherapy for Breast Cancer. , 247-266.
CrossRef559
Rachel E Payne, Ernesto Yagüe, Martin J Slade, Christos Apostolopoulos, Long R Jiao, Becky Ward, R Charles Coombes, Justin Stebbing. (2009) Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics 10:1, 51-57
CrossRef560
K.E. Hoffman, J.R. Harris. (2009) Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer. Breast Diseases: A Year Book Quarterly 20:2, 172-174
CrossRef561
Ian E. Krop, Eric P. Winer. (2009) Ten years of HER2-directed therapy: still questions after all these years. Breast Cancer Research and Treatment 113:2, 207-209
CrossRef562
C.T. Dang. (2009) Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials. Breast Diseases: A Year Book Quarterly 20:4, 424-426
CrossRef563
W. F. Anderson, S. Luo, N. Chatterjee, P. S. Rosenberg, R. K. Matsuno, M. T. Goodman, B. Y. Hernandez, M. Reichman, M. P. Dolled-Filhart, R. M. O’Regan, M. Garcia-Closas, C. M. Perou, I. Jatoi, R. W. Cartun, M. E. Sherman. (2009) Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program. Breast Cancer Research and Treatment 113:1, 189-196
CrossRef564
Carolyn Straehle, Fatima Cardoso, Evandro Azambuja, Stella Dolci, Livia Meirsman, Kris Vantongelen, Michalis Ignatiadis, Christos Sotiriou, Martine J. Piccart-Gebhart. (2009) Better translation from bench to bedside: Breakthroughs in the individualized treatment of cancer. Critical Care Medicine 37:Supplement, S22-S29
CrossRef565
Daphne W Bell. (2009) Our changing view of the genomic landscape of cancer. The Journal of Pathologyn/a-n/a
CrossRef566
Heather McArthur. (2009) An overview of HER-targeted therapy with lapatinib in breast cancer. Advances in Therapy 26:3, 263
CrossRef567
Peter S. Hall, David A. Cameron. (2009) Current perspective – Trastuzumab. European Journal of Cancer 45:1, 12-18
CrossRef568
2009. BIBLIOGRAPHIE. , 176-189.
CrossRef569
Antoni Hurtado, Kelly A. Holmes, Timothy R. Geistlinger, Iain R. Hutcheson, Robert I. Nicholson, Myles Brown, Jie Jiang, William J. Howat, Simak Ali, Jason S. Carroll. (2008) Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen. Nature 456:7222, 663-666
CrossRef570
C Marchiò, R Natrajan, KK Shiu, MBK Lambros, SM Rodriguez-Pinilla, DSP Tan, CJ Lord, D Hungermann, K Fenwick, N Tamber, A Mackay, J Palacios, A Sapino, H Buerger, A Ashworth, JS Reis-Filho. (2008) The genomic profile of HER2 -amplified breast cancers: the influence of ER status. The Journal of Pathology 216:4, 399-407
CrossRef571
C. C. Zielinski. (2008) Treatment of metastatic breast cancer: a historical perspective. memo - Magazine of European Medical Oncology 1:4, 227-234
CrossRef572
Serena Di Cosimo, José Baselga. (2008) Targeted therapies in breast cancer: Where are we now?. European Journal of Cancer 44:18, 2781-2790
CrossRef573
Hyoungsuk Ko, Hyesil Seol, Wook Youn Kim, Seock-Ah Im, Wonshik Han, Dong-Young Noh, Yoon Kyung Jeon, In Ae Park. (2008) Ongoing debates in the assessment of the HER2 status in breast cancer: A comparative analysis by immunohistochemistry and FISH using original FDA and ASCO/CAP guidelines. Basic and Applied Pathology 1:4, 182-188
CrossRef574
Alicia Tosoni, Enrico Franceschi, Alba A. Brandes. (2008) Chemotherapy in breast cancer patients with brain metastases: Have new chemotherapic agents changed the clinical outcome?. Critical Reviews in Oncology/Hematology 68:3, 212-221
CrossRef575
Windy Dean-Colomb, Francisco J. Esteva. (2008) Her2-positive breast cancer: Herceptin and beyond. European Journal of Cancer 44:18, 2806-2812
CrossRef576
Emilio Bria, Federica Cuppone, Michele Milella, Sunil Verma, Paolo Carlini, Cecilia Nisticò, Vanja Vaccaro, Antonio Rossi, Giuseppe Tonini, Francesco Cognetti, Edmondo Terzoli. (2008) Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues. Expert Opinion on Biological Therapy 8:12, 1963-1971
CrossRef577
Christian F. Singer, Wolfgang J. Köstler, Gernot Hudelist. (2008) Predicting the efficacy of trastuzumab-based therapy in breast cancer: Current standards and future strategies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1786:2, 105-113
CrossRef578
Sandro Barni, Mary Cabiddu, F Petrelli. (2008) Toxicity of targeted therapies in elderly patients. Expert Review of Anticancer Therapy 8:12, 1965-1976
CrossRef579
Dimosthenis Ziogas, Eleftheria Ignatiadou, Dimitrios Roukos, Efstathios Lykoudis. (2008) HER2 and Trastuzumab: Impact of a New Standard Agent on Local Control and Surgery for Breast Cancer. Annals of Surgical Oncology 15:12, 3614-3615
CrossRef580
Asna Amin, Linda C. Benavides, Jarrod P. Holmes, Jeremy D. Gates, Mark G. Carmichael, Matthew T. Hueman, Elizabeth A. Mittendorf, Catherine E. Storrer, Yusuf H. Jama, Dianna Craig, Alex Stojadinovic, Sathibalan Ponniah, George E. Peoples. (2008) Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunology, Immunotherapy 57:12, 1817-1825
CrossRef581
K. C. Jensen, D. A. Turbin, S. Leung, M. A. Miller, K. Johnson, B. Norris, T. Hastie, S. McKinney, T. O. Nielsen, D. G. Huntsman, C. B. Gilks, R. B. West. (2008) New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up. Breast Cancer Research and Treatment 112:3, 453-459
CrossRef582
Kan Yonemori, Koji Tsuta, Chikako Shimizu, Yutaka Hatanaka, Kaoru Hashizume, Makiko Ono, Yukihiro Nakanishi, Tadashi Hasegawa, Yasuji Miyakita, Yoshitaka Narita, Soichiro Shibui, Yasuhiro Fujiwara. (2008) Immunohistochemical profiles of brain metastases from breast cancer. Journal of Neuro-Oncology 90:2, 223-228
CrossRef583
BuHyun Youn, Hag Dong Kim, Joon Kim. (2008) Nm23-H1/nucleoside diphosphate kinase as a key molecule in breast tumor angiogenesis. Expert Opinion on Therapeutic Targets 12:11, 1419-1430
CrossRef584
Don S Dizon, Sharmila Makhija. (2008) HER dimerization inhibitors: developing pertuzumab as an anticancer agent in women's oncology. Expert Opinion on Drug Discovery 3:11, 1363-1369
CrossRef585
H. B. Muss. (2008) Adjuvant chemotherapy for older women with breast cancer. Breast Cancer Online 11:11,
CrossRef586
Fátima Carneiro, Carla Oliveira, Marina Leite, Raquel Seruca. (2008) Molecular targets and biological modifiers in gastric cancer. Seminars in Diagnostic Pathology 25:4, 274-287
CrossRef587
Masahide Kondo, Shu Ling Hoshi, Hiroshi Ishiguro, Hiroshi Yoshibayashi, Masakazu Toi. (2008) Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan. Breast Cancer Research and Treatment 112:1, 175-187
CrossRef588
Antonino Carbone, Gerardo Botti, Annunziata Gloghini, Gianni Simone, Mauro Truini, Maria Pia Curcio, Patrizia Gasparini, Anita Mangia, Tiziana Perin, Sandra Salvi, Adele Testi, Paolo Verderio. (2008) Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists. The Journal of Molecular Diagnostics 10:6, 527-536
CrossRef589
P. SINGH, C.L. SMITH, G. CHEETHAM, T.J. DODD, M.L.J. DAVY. (2008) Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation. International Journal of Gynecological Cancer 18:6, 1344-1351
CrossRef590
Isao TABEI, Shigeki NISHIYAMA, Shigeo YAMASHITA, Hisashi HASHIMOTO, Toshiaki TACHIBANA, Ken UCHIDA, Hiroshi ISHIKAWA. (2008) Establishment and characterization of HER2-positive cell line derived from pleural effusion of human breast scirrhous carcinoma. Human Cell 21:4, 105-112
CrossRef591
Sabine Riethdorf, Harriet Wikman, Klaus Pantel. (2008) Review: Biological relevance of disseminated tumor cells in cancer patients. International Journal of Cancer 123:9, 1991-2006
CrossRef592
Federico Rojo, Joan Albanell, Ana Rovira, Josep Maria Corominas, Felix Manzarbeitia. (2008) Targeted therapies in breast cancer. Seminars in Diagnostic Pathology 25:4, 245-261
CrossRef593
Phuong Dinh, Evandro de Azambuja, Fatima Cardoso, Martine J Piccart-Gebhart. (2008) Facts and controversies in the use of trastuzumab in the adjuvant setting. Nature Clinical Practice Oncology 5:11, 645-654
CrossRef594
Hiroo Nakajima, Ikuya Fujiwara, Naruhiko Mizuta, Koichi Sakaguchi, Yasushi Hachimine, Eiichi Konishi, Akio Yanagisawa, Junji Magae. (2008) Prognosis of Japanese Breast Cancer Based on Hormone Receptor and HER2 Expression Determined by Immunohistochemical Staining. World Journal of Surgery 32:11, 2477-2482
CrossRef595
J. Stagg, J. Sharkey, S. Pommey, R. Young, K. Takeda, H. Yagita, R. W. Johnstone, M. J. Smyth. (2008) Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proceedings of the National Academy of Sciences 105:42, 16254-16259
CrossRef596
A. Anton, A. Ruiz, M. A. Segui, L. Calvo, M. Munoz, J. Lao, F. Sancho, L. Fernandez. (2008) Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Annals of Oncology 20:3, 454-459
CrossRef597
H-J Ko, Y-J Kim, Y-S Kim, J-M Kim, S-H Ho, J-G Jeong, S-M Oh, J-A Chae, C-Y Kim, P-S Lee, C-Y Kang. (2008) Immunogenicity and safety profiles of genetic vaccines against human Her-2/neu in cynomolgus monkeys. Gene Therapy 15:20, 1351-1360
CrossRef598
Dehong Yang, Hong Liu, Jing Zhao. (2008) Analysis of the clinicopathologic features and prognosis in triple-negative breast cancer. Chinese Journal of Clinical Oncology 5:5, 387-390
CrossRef599
Shun’e Yang, Bing Zhao. (2008) Research progress in the use of drugs for breast cancer targeted therapy. Chinese Journal of Clinical Oncology 5:5, 320-325
CrossRef600
John H. Sampson, Gary E. Archer, Duane A. Mitchell, Amy B. Heimberger, Darell D. Bigner. (2008) Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Seminars in Immunology 20:5, 267-275
CrossRef601
Yolanda Madarnas, Maureen Trudeau, Jacob A. Franek, David McCready, Kathleen I. Pritchard, Hans Messersmith. (2008) Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review. Cancer Treatment Reviews 34:6, 539-557
CrossRef602
Peng H Tan, Amrit S Lota. (2008) Interaction of current cancer treatments and the immune system: implications for breast cancer therapeutics. Expert Opinion on Pharmacotherapy 9:15, 2639-2660
CrossRef603
Grace K. Dy, Alex A. Adjei. (2008) Systemic cancer therapy: Evolution over the last 60 years. Cancer 113:S7, 1857-1887
CrossRef604
Kristopher J. Kimball, T. Michael Numnum, Tyler O. Kirby, William C. Zamboni, Jacob M. Estes, Mack N. Barnes, Daniela E. Matei, Kevin M. Koch, Ronald D. Alvarez. (2008) A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. Gynecologic Oncology 111:1, 95-101
CrossRef605
M. A. Pantaleo, S. Fanti, M. Nannini, S. Boschi, C. Nanni, A. Maleddu, D. Rubello, G. Biasco. (2008) What oncologists need and require from nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging 35:10, 1761-1765
CrossRef606
Tallal Younis, Chris Skedgel. (2008) Is trastuzumab a cost-effective treatment for breast cancer?. Expert Review of Pharmacoeconomics & Outcomes Research 8:5, 433-442
CrossRef607
Philipp Kiewe, Eckhard Thiel. (2008) Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opinion on Investigational Drugs 17:10, 1553-1558
CrossRef608
Allen M Gown, Lynn C Goldstein, Todd S Barry, Steven J Kussick, Patricia L Kandalaft, Patricia M Kim, Christopher C Tse. (2008) High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Modern Pathology 21:10, 1271-1277
CrossRef609
Ann H. Rosendahl, Jeff M.P. Holly, Mona Celander, Göran Forsberg. (2008) Systemic IGF‐I administration stimulates the in vivo growth of early, but not advanced, renal cell carcinoma. International Journal of Cancer 123:6, 1286-1291
CrossRef610
Andrew Z. Wang, Vaishali Bagalkot, Christophoros C. Vasilliou, Frank Gu, Frank Alexis, Liangfang Zhang, Mariam Shaikh, Kai Yuet, Michael J. Cima, Robert Langer, Philip W. Kantoff, Neil H. Bander, Sangyong Jon, Omid C. Farokhzad. (2008) Superparamagnetic Iron Oxide Nanoparticle-Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy. ChemMedChem 3:9, 1311-1315
CrossRef611
J. Qin, R. C. Jones, R. Ramakrishnan. (2008) Studying copy number variations using a nanofluidic platform. Nucleic Acids Research 36:18, e116-e116
CrossRef612
Claudia D’Alessandro, Silvia Dellapasqua, Laura Orlando, Luigi Santoro, Patrick Maisonneuve, Rosalba Torrisi, Alessandra Balduzzi, Eloise Scarano, Raffaella Ghisini, Giulia Peruzzotti, Aron Goldhirsch, Marco Colleoni. (2008) Role of Endocrine Responsiveness and HER2/neu Overexpression in Inflammatory Breast Cancer Treated with Multimodality Preoperative Therapy. The Breast Journal 14:5, 435-441
CrossRef613
Henry G. Kaplan, Judith A. Malmgren. (2008) Impact of Triple Negative Phenotype on Breast Cancer Prognosis. The Breast Journal 14:5, 456-463
CrossRef614
Thomas Force, Risto Kerkelä. (2008) Cardiotoxicity of the new cancer therapeutics – mechanisms of, and approaches to, the problem. Drug Discovery Today 13:17-18, 778-784
CrossRef615
Sundus Ozair, Shabana Iqbal. (2008) Efficacy and safety of aromatase inhibitors in early breast cancer. Expert Opinion on Drug Safety 7:5, 547-558
CrossRef616
Josep Maria del Campo, Aleix Prat, Antonio Gil-Moreno, José Pérez, Marta Parera. (2008) Update on novel therapeutic agents for cervical cancer. Gynecologic Oncology 110:3, S72-S76
CrossRef617
Aleix Prat, José Baselga. (2008) The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nature Clinical Practice Oncology 5:9, 531-542
CrossRef618
Aaron P. Brown, Deborah E. Citrin, Kevin A. Camphausen. (2008) Clinical biomarkers of angiogenesis inhibition. Cancer and Metastasis Reviews 27:3, 415-434
CrossRef619
Juan Haba-Rodriguez, Emilio Alba, Agustí Barnadas, Eloisa Bayo, Antonio Llombart, Ana Lluch, Miguel Martín, José Andrés Moreno-Nogueira, Gumersindo Pérez Manga, Álvaro Rodríguez-Lescure, Enrique Aranda. (2008) Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007. Clinical and Translational Oncology 10:9, 552-559
CrossRef620
Robert M. Sharkey, David M. Goldenberg. (2008) Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Advanced Drug Delivery Reviews 60:12, 1407-1420
CrossRef621
Dimitrios H Roukos. (2008) Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Review of Molecular Diagnostics 8:5, 587-597
CrossRef622
Kai-Keen Shiu, David SP Tan, Jorge S Reis-Filho. (2008) Development of therapeutic approaches to ‘triple negative’ phenotype breast cancer. Expert Opinion on Therapeutic Targets 12:9, 1123-1137
CrossRef623
Angela L.W. Meisner, M. Houman Fekrazad, Melanie E. Royce. (2008) Breast Disease: Benign and Malignant. Medical Clinics of North America 92:5, 1115-1141
CrossRef624
B. Gril, D. Palmieri, J. L. Bronder, J. M. Herring, E. Vega-Valle, L. Feigenbaum, D. J. Liewehr, S. M. Steinberg, M. J. Merino, S. D. Rubin, P. S. Steeg. (2008) Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain. JNCI Journal of the National Cancer Institute 100:15, 1092-1103
CrossRef625
Monica Morrow. (2008) Margins in breast-conserving therapy: have we lost sight of the big picture?. Expert Review of Anticancer Therapy 8:8, 1193-1196
CrossRef626
John C. Mansour, Roderich E. Schwarz. (2008) Molecular Mechanisms for Individualized Cancer Care. Journal of the American College of Surgeons 207:2, 250-258
CrossRef627
F. Peintinger, A. U. Buzdar, H. M. Kuerer, J. A. Mejia, C. Hatzis, A. M. Gonzalez-Angulo, L. Pusztai, F. J. Esteva, S. S. Dawood, M. C. Green, G. N. Hortobagyi, W. F. Symmans. (2008) Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Annals of Oncology 19:12, 2020-2025
CrossRef628
Augusto Villanueva, Sara Toffanin, Josep M Llovet. (2008) Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Current Opinion in Oncology 20:4, 444-453
CrossRef629
Barrett W. Newsome, Marc S. Ernstoff. (2008) The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?. British Journal of Clinical Pharmacology 66:1, 6-19
CrossRef630
Rachel Rosenthal, Carsten T. Viehl, Ulrich Guller, Walter P. Weber, Michel Adamina, Giulio C. Spagnoli, Michael Heberer, Markus Zuber. (2008) Active Specific Immunotherapy Phase III Trials for Malignant Melanoma: Systematic Analysis and Critical Appraisal. Journal of the American College of Surgeons 207:1, 95-105
CrossRef631
Richard Simon. (2008) Interpretation of Genomic Data: Questions and Answers. Seminars in Hematology 45:3, 196-204
CrossRef632
T. FEHM, V. MUELLER, R. MARCHES, G. KLEIN, B. GUECKEL, H. NEUBAUER, E. SOLOMAYER, S. BECKER. (2008) Tumor cell dormancy: implications for the biology and treatment of breast cancer . APMIS 116:7-8, 742-753
CrossRef633
Ivo M. Hennig, Chris Twelves. (2008) Loading doses for costly cancer biologicals: A cause for concern or tilting at windmills?. European Journal of Cancer 44:11, 1493-1496
CrossRef634
Graziella Pratesi, Giovanna Petrangolini, Monica Tortoreto, Alessandro Addis, Franco Zunino, Claudia Calcaterra, Andrea Merlo, Elda Tagliabue, Sylvie Menard, Andrea Balsari. (2008) Antitumor Efficacy of Trastuzumab in Nude Mice Orthotopically Xenografted With Human Pancreatic Tumor Cells Expressing Low Levels of HER-2/neu. Journal of Immunotherapy 31:6, 537-544
CrossRef635
HARRIET WIKMAN, ROBERT VESSELLA, KLAUS PANTEL. (2008) Cancer micrometastasis and tumour dormancy . APMIS 116:7-8, 754-770
CrossRef636
Finn, Olivera J., . (2008) Cancer Immunology. New England Journal of Medicine 358:25, 2704-2715
Full Text637
Martine Piccart-Gebhardt, Francoise Meunier. 2008. European Organization for Research and Treatment of Cancer (EORTC). .
CrossRef638
S. Menard, A. Balsari, E. Tagliabue, T. Camerini, P. Casalini, R. Bufalino, F. Castiglioni, M. L. Carcangiu, A. Gloghini, S. Scalone, P. Querzoli, M. Lunardi, A. Molino, M. Mandara, M. Mottolese, F. Marandino, M. Venturini, C. Bighin, G. Cancello, E. Montagna, F. Perrone, A. De Matteis, A. Sapino, M. Donadio, N. Battelli, A. Santinelli, L. Pavesi, A. Lanza, F. A. Zito, A. Labriola, R. A. Aiello, M. Caruso, F. Zanconati, G. Mustacchi, M. Barbareschi, M. Frisinghelli, R. Russo, G. Carrillo, . (2008) Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. Annals of Oncology 19:10, 1706-1712
CrossRef639
Maya Guglin, Raymond Cutro, Joseph D. Mishkin. (2008) Trastuzumab-Induced Cardiomyopathy. Journal of Cardiac Failure 14:5, 437-444
CrossRef640
Richard Simon. (2008) Designs and adaptive analysis plans for pivotal clinical trials of therapeutics and companion diagnostics. Expert Opinion on Medical Diagnostics 2:6, 721-729
CrossRef641
M Hofmann, O Stoss, D Shi, R Büttner, M van de Vijver, W Kim, A Ochiai, J Rüschoff, T Henkel. (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52:7, 797-805
CrossRef642
Swati Kulkarni, David G. Hicks. (2008) HER2-Positive Early Breast Cancer and Trastuzumab: A Surgeon’s Perspective. Annals of Surgical Oncology 15:6, 1677-1688
CrossRef643
Klaus Strebhardt, Axel Ullrich. (2008) Paul Ehrlich's magic bullet concept: 100 years of progress. Nature Reviews Cancer 8:6, 473-480
CrossRef644
A D Graham, D Faratian, F Rae, J St J Thomas. (2008) Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology 52:7, 847-855
CrossRef645
R. Bartsch, G. G. Steger. (2008) Adjuvant chemotherapy in breast cancer. memo - Magazine of European Medical Oncology 1:2, 91-98
CrossRef646
David F. Stern. (2008) ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer. Journal of Mammary Gland Biology and Neoplasia 13:2, 215-223
CrossRef647
Takeru Shiroiwa, Takashi Fukuda, Kojiro Shimozuma, Yasuo Ohashi, Kiichiro Tsutani. (2008) The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Research and Treatment 109:3, 559-566
CrossRef648
Feng Guo, Stephen P. Letrent, Pamela N. Munster, Carolyn D. Britten, Karen Gelmon, Anthony W. Tolcher, Amarnath Sharma. (2008) Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety. Cancer Chemotherapy and Pharmacology 62:1, 97-109
CrossRef649
Edith A. Perez, Maria Koehler, Julie Byrne, Alaknanda J. Preston, Erica Rappold, Michael S. Ewer. (2008) Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials. Mayo Clinic Proceedings 83:6, 679-686
CrossRef650
E. A. Perez, M. Koehler, J. Byrne, A. J. Preston, E. Rappold, M. S. Ewer. (2008) Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials. Mayo Clinic Proceedings 83:6, 679-686
CrossRef651
D. Rayson, D. Richel, S. Chia, C. Jackisch, S. van der Vegt, T. Suter. (2008) Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Annals of Oncology 19:9, 1530-1539
CrossRef652
X. Li, M. T. Lewis, J. Huang, C. Gutierrez, C. K. Osborne, M.-F. Wu, S. G. Hilsenbeck, A. Pavlick, X. Zhang, G. C. Chamness, H. Wong, J. Rosen, J. C. Chang. (2008) Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy. JNCI Journal of the National Cancer Institute 100:9, 672-679
CrossRef653
M Hermes, W Schormann, M Brulport, K Uhlemann, F Lupatsch, L C Horn, A Schumann, C Allgaier, M Weishaupt, K Engeland, G A Müller, J Mössner, A Bauer, I B Schiffer, S Gebhard, M Schmidt, E Lausch, D Prawitt, C Wilhelm, J G Hengstler. (2008) Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model. British Journal of Cancer 98:9, 1525-1532
CrossRef654
Bindi Dhesy-Thind, Kathleen I. Pritchard, Hans Messersmith, Frances O’Malley, Leela Elavathil, Maureen Trudeau. (2008) HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Research and Treatment 109:2, 209-229
CrossRef655
Carsten T. Viehl, Daniel M. Frey, Chanpheng Phommaly, Tingting Chen, Timothy P. Fleming, William E. Gillanders, Timothy J. Eberlein, Peter S. Goedegebuure. (2008) Generation of mammaglobin-A-specific CD4 T cells and identification of candidate CD4 epitopes for breast cancer vaccine strategies. Breast Cancer Research and Treatment 109:2, 305-314
CrossRef656
C. Thomssen, J. Huober. (2008) Primäre und adjuvante Systemtherapie des operablen Mammakarzinoms. Der Onkologe 14:5, 504-513
CrossRef657
Emilio Bria, Federica Cuppone, Monica Fornier, Cecilia Nisticò, Paolo Carlini, Michele Milella, Isabella Sperduti, Edmondo Terzoli, Francesco Cognetti, Diana Giannarelli. (2008) Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Research and Treatment 109:2, 231-239
CrossRef658
Klaus Pantel, Ruud H. Brakenhoff, Burkhard Brandt. (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nature Reviews Cancer 8:5, 329-340
CrossRef659
Scott Metcalfe, Carl Burgess, George Laking, Jackie Evans, Susan Wells, Steffan Crausaz. (2008) Trastuzumab: possible publication bias. The Lancet 371:9625, 1646-1648
CrossRef660
Allen M Gown. (2008) Current issues in ER and HER2 testing by IHC in breast cancer. Modern Pathology 21, S8-S15
CrossRef661
Edurne Arriola, Caterina Marchio, David SP Tan, Suzanne C Drury, Maryou B Lambros, Rachael Natrajan, Socorro Maria Rodriguez-Pinilla, Alan Mackay, Narinder Tamber, Kerry Fenwick, Chris Jones, Mitch Dowsett, Alan Ashworth, Jorge S Reis-Filho. (2008) Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Laboratory Investigation 88:5, 491-503
CrossRef662
Li Yan, Karl Hsu, Robert A. Beckman. (2008) Antibody-Based Therapy for Solid Tumors. The Cancer Journal 14:3, 178-183
CrossRef663
Minetta C. Liu, George D. Demetri, Donald A. Berry, Larry Norton, Gloria Broadwater, Nicholas J. Robert, David Duggan, Daniel F. Hayes, I. Craig Henderson, Alan Lyss, Judith Hopkins, Peter A. Kaufman, P. Kelly Marcom, Jerry Younger, Nancy Lin, Katherine Tkaczuk, Eric P. Winer, Clifford A. Hudis. (2008) Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treatment Reviews 34:3, 223-230
CrossRef664
C. Wilhelm, A. Neubauer. (2008) Molekulare Tumortherapie. Der Internist 49:5, 581-592
CrossRef665
N. V. Zhukov, S. A. Tjulandin. (2008) Targeted therapy in the treatment of solid tumors: Practice contradicts theory. Biochemistry (Moscow) 73:5, 605-618
CrossRef666
I. Judson, J. Barriuso. (2008) Molecularly targeted therapy and cancer surgery. British Journal of Surgery 95:5, 537-538
CrossRef667
Lisa Rydén, Göran Landberg, Olle Stål, Bo Nordenskjöld, Mårten Fernö, Pär-Ola Bendahl. (2008) HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Breast Cancer Research and Treatment 109:2, 351-357
CrossRef668
George Lazaridis, George Pentheroudakis, Nicholas Pavlidis. (2008) Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: Accumulating evidence of efficacy, synergy and safety. Critical Reviews in Oncology/Hematology 66:1, 31-41
CrossRef669
Grant Sellar, John D Alvarez, Frank Loganzo, Richat Abbas, Fred Immermann, Maha Karnoub, Giora Z Feuerstein, Michael E Burczynski, Christina M Coughlin. (2008) Opportunities posed by novel patient selection biomarker approaches in oncology drug development: going beyond the cytotoxics. Biomarkers in Medicine 2:2, 147-153
CrossRef670
I. Überall, Z. Kolář, R. Trojanec, J. Berkovcová, M. Hajdúch. (2008) The status and role of ErbB receptors in human cancer. Experimental and Molecular Pathology 84:2, 79-89
CrossRef671
Quyen D. Chu, Neal Holm, Kerry Byrnes, Benjamin D. Li. (2008) Translational Research in Breast Cancer. Surgical Oncology Clinics of North America 17:2, 421-438
CrossRef672
Olivera J. Finn. (2008) Tumor immunology top 10 list. Immunological Reviews 222:1, 5-8
CrossRef673
Constantin N Baxevanis. (2008) Antibody-based cancer therapy. Expert Opinion on Drug Discovery 3:4, 441-452
CrossRef674
Patricia S Steeg, Dan Theodorescu. (2008) Metastasis: a therapeutic target for cancer. Nature Clinical Practice Oncology 5:4, 206-219
CrossRef675
Søren M. Bentzen. (2008) From Cellular to High-Throughput Predictive Assays in Radiation Oncology: Challenges and Opportunities. Seminars in Radiation Oncology 18:2, 75-88
CrossRef676
Gerald M. Higa. (2008) Targeting HER 1 and 2 in breast cancer with lapatinib. Oncology Reviews 2:1, 21-28
CrossRef677
Chikako Shimizu, Yasuhiro Fujiwara. (2008) Personalized systemic treatment for breast cancer patients: is it a reality?. Breast Cancer 15:2, 141-144
CrossRef678
Sanjay Popat, Ian E Smith. (2008) Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects. Nature Clinical Practice Oncology
CrossRef679
F. Trotta, G. Apolone, S. Garattini, G. Tafuri. (2008) Stopping a trial early in oncology: for patients or for industry?. Annals of Oncology 19:7, 1347-1353
CrossRef680
J. King, J. Waxman, H. Stauss. (2008) Advances in tumour immunotherapy. QJM 101:9, 675-683
CrossRef681
Alfredo Santinelli, Eleonora Pisa, Daniela Stramazzotti, Guidalberto Fabris. (2008) HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. International Journal of Cancer 122:5, 999-1004
CrossRef682
Ahmad Awada, Martine J. Piccart-Gebhart. (2008) Management of HER-2/neu-positive metastatic breast cancer. European Journal of Cancer Supplements 6:4, 2-9
CrossRef683
Primož Drev, Snježana Frković Grazio, Matej Bračko. (2008) Tissue Microarrays for Routine Diagnostic Assessment of HER2 Status in Breast Carcinoma. Applied Immunohistochemistry & Molecular Morphology 16:2, 179-184
CrossRef684
Karin Jöhrer, Lisa Pleyer, Angelika Olivier, Eva Maizner, Claudia Zelle-Rieser, Richard Greil. (2008) Tumour-immune cell interactions modulated by chemokines. Expert Opinion on Biological Therapy 8:3, 269-290
CrossRef685
Paul Wheatley-Price, Frances A Shepherd. (2008) Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Current Opinion in Oncology 20:2, 162-175
CrossRef686
Ian N Olver. (2008) Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when. Future Oncology 4:1, 125-131
CrossRef687
Shaheenah Dawood, Naoto T. Ueno, Massimo Cristofanilli. (2008) The Medical Treatment of Inflammatory Breast Cancer. Seminars in Oncology 35:1, 64-71
CrossRef688
Márk Barok, Margit Balázs, Péter Nagy, Zsuzsa Rákosy, Andrea Treszl, Enikő Tóth, István Juhász, John W. Park, Jorma Isola, György Vereb, János Szöllősi. (2008) Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. Cancer Letters 260:1-2, 198-208
CrossRef689
Ginny Mason, Owen Johnson. (2008) Inflammatory Breast Cancer: Patient Advocate View. Seminars in Oncology 35:1, 87-91
CrossRef690
M. Brian Hemphill, Julia A. Lawrence. (2008) Current Therapeutic Options for Breast Cancer Central Nervous System Metastases. Current Treatment Options in Oncology 9:1, 41-50
CrossRef691
Tristin Abair, Jennifer Klem, Susan Peck, Joyce O'Shaughnessy. (2008) 2007 Highlights from: The 2007 San Antonio Breast Cancer Symposium San Antonio, TX December 13-16, 2007. Clinical Breast Cancer 8:1, 26-32
CrossRef692
I.H. Kunkler, P. Canney, G. van Tienhoven, N.S. Russell. (2008) Elucidating the Role of Chest Wall Irradiation in ‘Intermediate-risk’ Breast Cancer: the MRC/EORTC SUPREMO Trial. Clinical Oncology 20:1, 31-34
CrossRef693
Daniela D. Rosa, Gustavo Ismael, Lissandra Dal Lago, Ahmad Awada. (2008) Molecular-targeted therapies: Lessons from years of clinical development. Cancer Treatment Reviews 34:1, 61-80
CrossRef694
Carlos Camps, Cristina Caballero, Rafael Sirera, Ana Blasco, Diego Cayuela, Mireia Gil, Xavier Badía. (2008) Can the Spanish care system assume the new costs of medications against cancer?. Clinical and Translational Oncology 10:2, 96-101
CrossRef695
Partho P. Sengupta, Donald W. Northfelt, Federico Gentile, Jose L. Zamorano, Bijoy K. Khandheria. (2008) Trastuzumab-Induced Cardiotoxicity: Heart Failure at the Crossroads. Mayo Clinic Proceedings 83:2, 197-203
CrossRef696
P. P. Sengupta, D. W. Northfelt, F. Gentile, J. L. Zamorano, B. K. Khandheria. (2008) Trastuzumab-Induced Cardiotoxicity: Heart Failure at the Crossroads. Mayo Clinic Proceedings 83:2, 197-203
CrossRef697
(2008) HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. New England Journal of Medicine 358:2, 197-199
Full Text698
Reiki Nishimura, Yasuhiro Okumura, Nobuyuki Arima. (2008) Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival. Breast Cancer 15:1, 57-64
CrossRef699
Gabriel N. Hortobagyi. (2008) The Future of Breast Cancer Management: Teamwork and Team Science. Breast Diseases: A Year Book Quarterly 18:4, 331-332
CrossRef700
Ji Won Lee, Woo Chul Noh, Min Suk Kim, Hyun-Ah Kim, Yoon Hwan Chang, Young Joon Hong, Seok Il Hong, Jin Kyung Lee. (2008) Availability of Fine Needle Aspirates for the Assessment of HER2 Gene Amplification in Invasive Breast Cancer Patients. The Korean Journal of Laboratory Medicine 28:5, 392
CrossRef701
Wolfgang Janni, Gunter von Minckwitz, Volker Möbus, Ulrike Nitz. (2008) Adjuvant and Neoadjuvant Therapy with Lapatinib in ErbB2-Overexpressing Breast Cancer. Breast Care 3:1, 17-20
CrossRef702
Patricia M. LoRusso, B. Nebiyou Bekele, Scott A. Boerner, Darren W. Davis, Jeffrey L. Evelhoch, Roy S. Herbst. 2008. Phase 1 Trials Today. , 553-570.
CrossRef703
Nancy U. Lin. (2008) Treatment of HER2-Positive Breast Cancer: New Approaches, New Opportunities. Breast Diseases: A Year Book Quarterly 18:4, 336-338
CrossRef704
Hiroyoshi Doihara, Naruto Taira. (2008) Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 119:3, 273-283
CrossRef705
Yong-Seok Kim, Yong Sung Won, Kyung Shin Park, Byung Joo Song, Jeong Soo Kim, Se Jeong Oh, Hae Myung Jeon, Sang Seol Jung, Woo-Chan Park. (2008) Prognostic Significance of HER2 Gene Amplification According to Stage of Breast Cancer. Journal of Korean Medical Science 23:3, 414
CrossRef706
Jan Trøst Jørgensen. (2008) From blockbuster medicine to personalized medicine. Personalized Medicine 5:1, 55-63
CrossRef707
Steven M Ewer, Michael S Ewer. (2008) Cardiotoxicity Profile of Trastuzumab. Drug Safety 31:6, 459-467
CrossRef708
Dimitrios Chatsiproios, Renate Haidinger, Thomas Suter. (2008) Practical Management Recommendations for Anti-ErbB2 Therapy with Lapatinib. Breast Care 3:1, 13-16
CrossRef709
María Sereno, Antonella Brunello, Alberto Chiappori, Jorge Barriuso, Enrique Casado, Cristóbal Belda, Javier Castro, Jaime Feliu, Manuel González-Barón. (2008) Cardiac toxicity: old and new issues in anti-cancer drugs. Clinical and Translational Oncology 10:1, 35-46
CrossRef710
S Moulder, GN Hortobagyi. (2008) Advances in the Treatment of Breast Cancer. Clinical Pharmacology & Therapeutics 83:1, 26-36
CrossRef711
Danielle M. Doyle, Kathy D. Miller. (2008) Development of new targeted therapies for breast cancer. Breast Cancer 15:1, 49-56
CrossRef712
Eun Seog Kim, Doo Ho Choi, So Young Jin, Dong Wha Lee, Hee Sook Park, Min Hyuk Lee, Jong Ho Won, Yong Ho Kim, Kyu Taek Lee, Sung Yong Kim. (2008) The Role of Immunohistochemical Biomarkers as Prognostic Factors by the Use of a Tissue Microarray in Breast Cancer Patients Under 45-years-old. The Journal of the Korean Society for Therapeutic Radiology and Oncology 26:1, 45
CrossRef713
V. Craig Jordan. (2008) Tamoxifen: Catalyst for the change to targeted therapy. European Journal of Cancer 44:1, 30-38
CrossRef714
A. Rab Razzak, Nancy U. Lin, Eric P. Winer. (2008) Heterogeneity of breast cancer and implications of adjuvant chemotherapy. Breast Cancer 15:1, 31-34
CrossRef715
Frank Alexis, June-Wha Rhee, Jerome P. Richie, Aleksandar F. Radovic-Moreno, Robert Langer, Omid C. Farokhzad. (2008) New frontiers in nanotechnology for cancer treatment. Urologic Oncology: Seminars and Original Investigations 26:1, 74-85
CrossRef716
Steven Simoens. (2008) Trastuzumab in Early-Stage Breast Cancer. PharmacoEconomics 26:10, 807-809
CrossRef717
Wendy A. Woodward, James D. Cox. 2008. Molecular Basis of Radiation Therapy. , 593-604.
CrossRef718
Isabelle Madelaine, Pierre Faure, Pierre Faure, Julie Berthou. 2008. Traitement des cancers bronchique, colorectal, du sein et de l'ovaire. , 621-644.
CrossRef719
Yuriko Kitano, Shinobu Umemura, Hirokazu Ohbayashi, Masato Takenaga, Robert Yoshiyuki Osamura. (2007) Assessment of a New Anti-HER2 Monoclonal Antibody, SV2-61γ: A Best Concordance With HER2 FISH. Applied Immunohistochemistry & Molecular Morphology 15:4, 389-393
CrossRef720
Patrick J Perik, Maarten Alexander de Korte, Dirk J van Veldhuisen, Jourik A Gietema, Dirk T Sleijfer, Elisabeth GE de Vries. (2007) Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. Expert Review of Anticancer Therapy 7:12, 1763-1771
CrossRef721
Cynthia Frankel. (2007) Choosing the Appropriate Breast Cancer Therapy for Today's Breast Cancer Patient. Seminars in Oncology Nursing 23, S3-S9
CrossRef722
Zeina Nahleh, Azadeh Namakydoust, Rania Bakkar, John Bishop. (2007) Trastuzumab not for ductal carcinoma in situ?. Anti-Cancer Drugs 18:10, 1231-1235
CrossRef723
H. Labrosse, B. Favier, J. Fayette. (2007) Pharmacologie des thérapeutiques ciblées. Oncologie 9:11, 773-777
CrossRef724
Catherine Alix-Panabières, Volkmar Müller, Klaus Pantel. (2007) Current status in human breast cancer micrometastasis. Current Opinion in Oncology 19:6, 558-563
CrossRef725
Josep M. Llovet. (2007) Clinical and molecular classification of hepatocellular carcinoma. Liver Transplantation 13:S2, S13-S16
CrossRef726
C Ginestier, J Adélaïde, A Gonçalvès, L Repellini, F Sircoulomb, A Letessier, P Finetti, J Geneix, E Charafe-Jauffret, F Bertucci, J Jacquemier, P Viens, D Birnbaum. (2007) ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene 26:50, 7163-7169
CrossRef727
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Winer, Eric P., Harris, Jay R., Smith, Barbara L., D'Alessandro, Helen Anne, Brachtel, Elena F., . (2007) Case 32-2007. New England Journal of Medicine 357:16, 1640-1648
Full Text728
Bharat B. Aggarwal, Gautam Sethi, Veera Baladandayuthapani, Sunil Krishnan, Shishir Shishodia. (2007) Targeting cell signaling pathways for drug discovery: An old lock needs a new key. Journal of Cellular Biochemistry 102:3, 580-592
CrossRef729
M M Moasser. (2007) Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 26:46, 6577-6592
CrossRef730
Hayes, Daniel F., Thor, Ann D., Dressler, Lynn G., Weaver, Donald, Edgerton, Susan, Cowan, David, Broadwater, Gloria, Goldstein, Lori J., Martino, Silvana, Ingle, James N., Henderson, I. Craig, Norton, Larry, Winer, Eric P., Hudis, Clifford A., Ellis, Matthew J., Berry, Donald A., . (2007) HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. New England Journal of Medicine 357:15, 1496-1506
Full Text731
Moore, Anne, . (2007) Breast-Cancer Therapy — Looking Back to the Future. New England Journal of Medicine 357:15, 1547-1549
Full Text732
Sumanta Kumar Pal, Mark Pegram. (2007) HER2 targeted therapy in breast cancer...beyond Herceptin. Reviews in Endocrine and Metabolic Disorders 8:3, 269-277
CrossRef733
Tristin Abair, Zachary Moore, Joyce A. O'Shaughnessy. (2007) 2007 Highlights from: The 2007 American Society of Clinical Oncology Breast Cancer Symposium; San Francisco, CA; September 7–8, 2007. Clinical Breast Cancer 7:10, 734-738
CrossRef734
Arash Naeim, Rishi Sawhney, Catherine H. MacLean, Homayoon Sanati. (2007) Quality Indicators for the Care of Breast Cancer in Vulnerable Elders. Journal of the American Geriatrics Society 55, S258-S269
CrossRef735
Sanraj K. Basi, John R. Mackey. (2007) Anastrozole Plus Trastuzumab Prolongs Progression-Free Survival in Postmenopausal Patients with HER2-Positive and Hormone Receptor–Positive Metastatic Breast Cancer: A Review of the TAnDEM Study. Breast Diseases: A Year Book Quarterly 18:3, 236-237
CrossRef736
Daphne R. Friedman, Amy P. Abernethy. (2007) <I>REVIEW</I>. Progress in Palliative Care 15:5, 225-232
CrossRef737
Paolo Pedrazzoli, Giovanni Rosti, Simona Secondino, Ornella Carminati, Taner Demirer. (2007) High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Support for Solid Tumors in Adults. Seminars in Hematology 44:4, 286-295
CrossRef738
Lee W. Jones, Mark J. Haykowsky, Jonas J. Swartz, Pamela S. Douglas, John R. Mackey. (2007) Early Breast Cancer Therapy and Cardiovascular Injury. Journal of the American College of Cardiology 50:15, 1435-1441
CrossRef739
T. Mieghem, K. Leunen, N. Pochet, B. Moor, F. Smet, F. Amant, P. Berteloot, D. Timmerman, I. Vanden Bempt, R. Drijkoningen, H. Wildiers, R. Paridaens, A. Smeets, W. Hendrickx, E. Limbergen, M. R. Christiaens, I. Vergote, P. Neven. (2007) Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age. Breast Cancer Research and Treatment 106:1, 127-133
CrossRef740
Richard S. Finn, Judy Dering, Charles Ginther, Cindy A. Wilson, Padraic Glaspy, Nishan Tchekmedyian, Dennis J. Slamon. (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Research and Treatment 105:3, 319-326
CrossRef741
Shaheenah Dawood, Ana M. Gonzalez-Angulo, Florentia Peintinger, Kristine Broglio, William F. Symmans, Shu-Wan Kau, Rabiul Islam, Gabriel N. Hortobagyi, Aman U. Buzdar. (2007) Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin. Cancer 110:6, 1195-1200
CrossRef742
Feng Guo, Stephen P. Letrent, Amarnath Sharma. (2007) Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors. Cancer Chemotherapy and Pharmacology 60:6, 799-809
CrossRef743
Anna Kanerva, Mari Raki, Akseli Hemminki. (2007) Gene therapy of gynaecological diseases. Expert Opinion on Biological Therapy 7:9, 1347-1361
CrossRef744
M. Mimeault, R. Hauke, P. P. Mehta, S. K. Batra. (2007) Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. Journal of Cellular and Molecular Medicine 11:5, 981-1011
CrossRef745
M.A. de Korte, E.G.E. de Vries, M.N. Lub-de Hooge, P.L. Jager, J.A. Gietema, W.T.A. van der Graaf, W.J. Sluiter, D.J. van Veldhuisen, T.M. Suter, D.T. Sleijfer, P.J. Perik. (2007) 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. European Journal of Cancer 43:14, 2046-2051
CrossRef746
Gerald M Higa, Jame Abraham. (2007) Lapatinib in the treatment of breast cancer. Expert Review of Anticancer Therapy 7:9, 1183-1192
CrossRef747
Gaston Demonty. (2007) Docetaxel plus trastuzumab as treatment for HER-2 positive metastatic breast cancer: review of the existing evidence. Women's Health 3:5, 523-528
CrossRef748
Susanne Briest, Antonio C Wolff. (2007) Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer. Expert Review of Anticancer Therapy 7:9, 1243-1253
CrossRef749
Peter C. Black, Piyush K. Agarwal, Colin P.N. Dinney. (2007) Targeted therapies in bladder cancer—an update. Urologic Oncology: Seminars and Original Investigations 25:5, 433-438
CrossRef750
D.A. Cameron. (2007) Herceptin – from bedside to bench to clinic?. European Journal of Cancer Supplements 5:5, 372-374
CrossRef751
Susana Banerjee, Mitch Dowsett, Alan Ashworth, Lesley-Ann Martin. (2007) Mechanisms of Disease: angiogenesis and the management of breast cancer. Nature Clinical Practice Oncology 4:9, 536-550
CrossRef752
Min A Kim, Eun Ji Jung, Hye Seung Lee, Hee Eun Lee, Yoon Kyung Jeon, Han-Kwang Yang, Woo Ho Kim. (2007) Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Human Pathology 38:9, 1386-1393
CrossRef753
Wenfang Shi, Cunye Qu, Qijun Qian. (2007) Trends in therapeutic monoclonal antibodies of cancer. Expert Opinion on Therapeutic Patents 17:9, 1047-1059
CrossRef754
Hervé Bonnefoi. (2007) To bury TNM classification in breast cancer or to praise it?. European Journal of Cancer Supplements 5:5, 23-29
CrossRef755
S. Pruthi, J. C. Boughey, K. R. Brandt, A. C. Degnim, G. K. Dy, M. P. Goetz, E. A. Perez, C. A. Reynolds, P. J. Schomberg, J. N. Ingle. (2007) A Multidisciplinary Approach to the Management of Breast Cancer, Part 2: Therapeutic Considerations. Mayo Clinic Proceedings 82:9, 1131-1140
CrossRef756
Jean-Philippe Theurillat, Ursina Zürrer-Härdi, Zsuzsanna Varga, Martina Storz, Nicole M. Probst-Hensch, Burkhardt Seifert, Mathias K. Fehr, Daniel Fink, Soldano Ferrone, Bernhard Pestalozzi, Achim A. Jungbluth, Yao-Tseng Chen, Dirk Jäger, Alexander Knuth, Holger Moch. (2007) NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. Cancer Immunology, Immunotherapy 56:11, 1723-1731
CrossRef757
John Mathers. 2007. Toward Personalized Nutrition for the Prevention and Treatment of Cancer. , 75-87.
CrossRef758
Dmitriy Kedrin, Jacco Rheenen, Lorena Hernandez, John Condeelis, Jeffrey E. Segall. (2007) Cell Motility and Cytoskeletal Regulation in Invasion and Metastasis. Journal of Mammary Gland Biology and Neoplasia 12:2-3, 143-152
CrossRef759
Kouzou NINOMIYA, Satoshi OHI, Isao TABEI, Song JIN, Toshiaki TACHIBANA, Shigeo YAMASHITA, Katsuhiko YANAGA, Hisashi HASHIMOTO. (2007) Establishment and characterization of a cell line (BTIC) including HER-2-positive cells derived from pleural effusion of recurrent breast invasive ductal carcinoma, scirrhous type. Human Cell 20:3, 85-90
CrossRef760
Louis P. Garrison, Deborah Lubeck, Deepa Lalla, Virginia Paton, Amylou Dueck, Edith A. Perez. (2007) Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 110:3, 489-498
CrossRef761
E. D. Rossmann, A. Liljegren, J. Bergh. (2007) Male breast cancer – how to treat?. Breast Cancer Online 10:08,
CrossRef762
Debu Tripathy, Debu Tripathy. (2007) 2007 Highlights from: The 43rd Annual Meeting of the American Society of Clinical Oncology; Chicago, IL, June 2007. Clinical Breast Cancer 7:9, 660-669
CrossRef763
Per E. Lønning, Jürgen Geisler. (2007) Aromatase inhibitors—Socioeconomical issues. The Journal of Steroid Biochemistry and Molecular Biology 106:1-5, 55-61
CrossRef764
Daniela Matei. (2007) Novel agents in ovarian cancer. Expert Opinion on Investigational Drugs 16:8, 1227-1239
CrossRef765
Yu Zhou, Daryl C. Drummond, Hao Zou, Mark E. Hayes, Gregory P. Adams, Dmitri B. Kirpotin, James D. Marks. (2007) Impact of Single-chain Fv Antibody Fragment Affinity on Nanoparticle Targeting of Epidermal Growth Factor Receptor-expressing Tumor Cells. Journal of Molecular Biology 371:4, 934-947
CrossRef766
Maryou B.K. Lambros, Rachael Natrajan, Jorge S. Reis-Filho. (2007) Chromogenic and fluorescent in situ hybridization in breast cancer. Human Pathology 38:8, 1105-1122
CrossRef767
McArthur, Heather L., , Chia, Stephen, . (2007) Cardiotoxicity of Trastuzumab in Clinical Practice. New England Journal of Medicine 357:1, 94-95
Full Text768
I Craig Henderson, Vinona Bhatia. (2007) Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Review of Anticancer Therapy 7:7, 919-943
CrossRef769
Philip Poortmans. (2007) Evidence based radiation oncology: Breast cancer. Radiotherapy and Oncology 84:1, 84-101
CrossRef770
Christian Widakowich, Evandro de Azambuja, Thierry Gil, Fatima Cardoso, Phuong Dinh, Ahmad Awada, Martine Piccart-Gebhart. (2007) Molecular targeted therapies in breast cancer: Where are we now?. The International Journal of Biochemistry & Cell Biology 39:7-8, 1375-1387
CrossRef771
Daniel R. Budman, Julia Tai, Anthony Calabro. (2007) Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro. Breast Cancer Research and Treatment 104:1, 93-101
CrossRef772
Christian Zuppinger, Francesco Timolati, Thomas M. Suter. (2007) Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovascular Toxicology 7:2, 61-66
CrossRef773
Jean-Philippe Theurillat, Fabienne Ingold, Claudia Frei, Alfred Zippelius, Zsuzsanna Varga, Burkhardt Seifert, Yao-Tseng Chen, Dirk Jäger, Alexander Knuth, Holger Moch. (2007) NY-ESO-1 protein expression in primary breast carcinoma and metastases—correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. International Journal of Cancer 120:11, 2411-2417
CrossRef774
L. G. Estévez, M. Martín, E. Alba, R. Colomer, F. Lobo, A. Lluch, E. Adrover, J. Albanell, A. Barnadas, J. García-Mata, A. Llombart, M. Muñoz, C. Rodríguez, P. Sánchez-Rovira, M. A. Seguí, I. Tusquets. (2007) Current controversies in the management of early breast cancer. Clinical and Translational Oncology 9:6, 375-384
CrossRef775
Frank X. Gu, Rohit Karnik, Andrew Z. Wang, Frank Alexis, Etgar Levy-Nissenbaum, Seungpyo Hong, Robert S. Langer, Omid C. Farokhzad. (2007) Targeted nanoparticles for cancer therapy. Nano Today 2:3, 14-21
CrossRef776
Aleix Prat, Josep Baselga. (2007) Bioterapia: aplicaciones actuales y futuras en oncología. Medicina Clínica 129:5, 184-193
CrossRef777
Eiji Suzuki, Masakazu Toi. (2007) Improving the efficacy of trastuzumab in breast cancer. Cancer Science 98:6, 767-771
CrossRef778
Patricia A. Fetsch, Andrea Abati. (2007) The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature. Diagnostic Cytopathology 35:6, 319-328
CrossRef779
W. Janni, K. Friese, R. Kreienberg, K. Diedrich, D. Wallwiener, W. Jonat. (2007) Adjuvante Systemtherapie des Mammakarzinoms. Der Gynäkologe 40:6, 455-462
CrossRef780
Tsipi Ben-Kasus, Bilha Schechter, Michael Sela, Yosef Yarden. (2007) Cancer therapeutic antibodies come of age: Targeting minimal residual disease. Molecular Oncology 1:1, 42-54
CrossRef781
Petros I. Rafailidis, Ourania K. Kakisi, Konstantinos Vardakas, Matthew E. Falagas. (2007) Infectious complications of monoclonal antibodies used in cancer therapy. Cancer 109:11, 2182-2189
CrossRef782
Beverly Moy, Peter Kirkpatrick, Santwana Kar, Paul Goss. (2007) Lapatinib. Nature Reviews Drug Discovery 6:6, 431-432
CrossRef783
Elly Barry, Jorge A Alvarez, Rebecca E Scully, Tracie L Miller, Steven E Lipshultz. (2007) Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opinion on Pharmacotherapy 8:8, 1039-1058
CrossRef784
R Nahta, F J Esteva. (2007) Trastuzumab: triumphs and tribulations. Oncogene 26:25, 3637-3643
CrossRef785
Filippo Montemurro, Laura Martincich, Ivana Sarotto, Ilaria Bertotto, Riccardo Ponzone, Lisa Cellini, Stefania Redana, Piero Sismondi, Massimo Aglietta, Daniele Regge. (2007) Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer. European Radiology 17:6, 1490-1497
CrossRef786
G. Arpino, C. Gutierrez, H. Weiss, M. Rimawi, S. Massarweh, L. Bharwani, S. De Placido, C. K. Osborne, R. Schiff. (2007) Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy. JNCI Journal of the National Cancer Institute 99:9, 694-705
CrossRef787
Susanne Briest, Vered Stearns. (2007) Advances in the adjuvant and neoadjuvant treatment of breast cancer. Women's Health 3:3, 325-339
CrossRef788
Josie Ursini-Siegel, Babette Schade, Robert D. Cardiff, William J. Muller. (2007) Insights from transgenic mouse models of ERBB2-induced breast cancer. Nature Reviews Cancer 7:5, 389-397
CrossRef789
K. Qu, A. Abi Haidar, J. Fan, L. Ensman, K. Tuncay, M. Jolly, P. Ortoleva. (2007) Cancer onset and progression: A genome-wide, nonlinear dynamical systems perspective on onconetworks. Journal of Theoretical Biology 246:2, 234-244
CrossRef790
Mitch Dowsett, Wedad M Hanna, Mark Kockx, Frederique Penault-Llorca, Josef Rüschoff, Thorsten Gutjahr, Kai Habben, Marc J van de Vijver. (2007) Standardization of HER2 testing: results of an international proficiency-testing ring study. Modern Pathology 20:5, 584-591
CrossRef791
Heather L. McArthur, Clifford A. Hudis. (2007) Breast Cancer Chemotherapy. The Cancer Journal 13:3, 141-147
CrossRef792
Michael J. Duffy. (2007) Role of tumor markers in patients with solid cancers: A critical review. European Journal of Internal Medicine 18:3, 175-184
CrossRef793
Laura Pentassuglia, Francesco Timolati, Franziska Seifriz, Kaisaier Abudukadier, Thomas M. Suter, Christian Zuppinger. (2007) Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes. Experimental Cell Research 313:8, 1588-1601
CrossRef794
T Macarulla, J Tabernero. 2007. Safety of targeted therapies. , 141-155.
CrossRef795
Thomas Force, Daniela S. Krause, Richard A. Van Etten. (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Reviews Cancer 7:5, 332-344
CrossRef796
Raymond Ng, Michael D Green. (2007) Managing cardiotoxicity in anthracycline-treated breast cancers. Expert Opinion on Drug Safety 6:3, 315-321
CrossRef797
Barbara S. Craft, Gabriel N. Hortobagyi, Stacy L. Moulder. (2007) Adjuvant Biologic Therapy for Breast Cancer. The Cancer Journal 13:3, 156-161
CrossRef798
Evian Gordon. (2007) Integrating genomics and neuromarkers for the era of brain-related personalized medicine. Personalized Medicine 4:2, 201-215
CrossRef799
M. Scaltriti, F. Rojo, A. Ocana, J. Anido, M. Guzman, J. Cortes, S. Di Cosimo, X. Matias-Guiu, S. Ramon y Cajal, J. Arribas, J. Baselga. (2007) Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer. JNCI Journal of the National Cancer Institute 99:8, 628-638
CrossRef800
Sven A. Lang, Andreas Gaumann, Gudrun E. Koehl, Ulrike Seidel, Frauke Bataille, Dagmar Klein, Lee M. Ellis, Ulrich Bolder, Ferdinand Hofstaedter, Hans-Jürgen Schlitt, Edward K. Geissler, Oliver Stoeltzing. (2007) Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. International Journal of Cancer 120:8, 1803-1810
CrossRef801
Simon Chowdhury, Lisa M. Pickering, Paul A. Ellis. (2007) Lapatinib: a novel dual tyrosine kinase inhibitor. Targeted Oncology 2:2, 107-112
CrossRef802
Yoshinori Ito, Nahomi Tokudome, Tsutomu Sugihara, Shunji Takahashi, Kiyohiko Hatake. (2007) Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?. Breast Cancer 14:2, 156-162
CrossRef803
Marie Catherine Lee, Lisa A. Newman. (2007) Management of Patients with Locally Advanced Breast Cancer. Surgical Clinics of North America 87:2, 379-398
CrossRef804
M. Vanhuyse, P.L. Bedard, J. Sheiner, B. Fitzgerald, M. Clemons. (2007) Transfer of Follow-up Care to Family Physicians for Early-stage Breast Cancer. Clinical Oncology 19:3, 172-176
CrossRef805
Jennifer Klem, Zachary Moore, Susan Peck, Debu Tripathy, Joyce O'Shaughnessy. (2007) 2007 Highlights from: The 29th Annual San Antonio Breast Cancer Symposium; San Antonio, TX, December 2006. Clinical Breast Cancer 7:7, 535-542
CrossRef806
Molly Yancovitz, Joanne Yoon, Maryann Mikhail, Weiming Gai, Richard L. Shapiro, Russell S. Berman, Anna C. Pavlick, Paul B. Chapman, Iman Osman, David Polsky. (2007) Detection of Mutant BRAF Alleles in the Plasma of Patients with Metastatic Melanoma. The Journal of Molecular Diagnostics 9:2, 178-183
CrossRef807
Thomas A. Buchholz. (2007) Integrating Trastuzumab and Radiation into the Adjuvant Treatments of Breast Cancer. Breast Diseases: A Year Book Quarterly 18:1, 18-20
CrossRef808
Laura Biganzoli, Wederson M. Claudino, Marta Pestrin, Daniele Pozzessere, Angelo Di Leo. (2007) Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: Where do we stand?. Critical Reviews in Oncology/Hematology 62:1, 1-8
CrossRef809
Hiroji Iwata. (2007) Perspective of trastuzumab treatment. Breast Cancer 14:2, 150-155
CrossRef810
Gustavo Ismael, Daniela Dornelles Rosa, Evandro de Azambuja, Sofia Braga, Martine Piccart-Gebhart. (2007) Trastuzumab (Herceptin) for Early-Stage Breast Cancer. Hematology/Oncology Clinics of North America 21:2, 239-256
CrossRef811
Thomas W. Flaig, Steven K. Nordeen, M. Scott Lucia, Gail S. Harrison, L. Michael Glodé. (2007) Conference Report and Review: Current Status of Biomarkers Potentially Associated With Prostate Cancer Outcomes. The Journal of Urology 177:4, 1229-1237
CrossRef812
Erwin P. Bottinger. (2007) Foundations, promises and uncertainties of personalized medicine. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 74:1, 15-21
CrossRef813
Heather L. McArthur, Clifford A. Hudis. (2007) Adjuvant Chemotherapy for Early-Stage Breast Cancer. Hematology/Oncology Clinics of North America 21:2, 207-222
CrossRef814
Hannah M Simonds, David Miles. (2007) Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor. Expert Opinion on Biological Therapy 7:4, 487-491
CrossRef815
Lisa A. Newman, S. Eva Singletary. (2007) Overview of Adjuvant Systemic Therapy in Early Stage Breast Cancer. Surgical Clinics of North America 87:2, 499-509
CrossRef816
Kaori Fujimoto-Ouchi, Fumiko Sekiguchi, Hideyuki Yasuno, Yoichiro Moriya, Kazushige Mori, Yutaka Tanaka. (2007) Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemotherapy and Pharmacology 59:6, 795-805
CrossRef817
Martine Piccart, Aron Goldhirsch, William Wood, Kathleen Pritchard, José Baselga, Linda Reaby, Ingrid Kössler, Stella Kyriakides, Larry Norton, Alan Coates. (2007) Keeping faith with trial volunteers. Nature 446:7132, 137-138
CrossRef818
V. C. Jordan. (2007) SERMs: Meeting the Promise of Multifunctional Medicines. JNCI Journal of the National Cancer Institute 99:5, 350-356
CrossRef819
William C. Powell, David G. Hicks, Nichole Prescott, Shannon M. Tarr, Simas Laniauskas, Tristin Williams, Sarah Short, James Pettay, Raymond B. Nagle, David J. Dabbs, Katherine M. Scott, Richard W. Brown, Thomas Grogan, Patrick C. Roche, Raymond R. Tubbs. (2007) A New Rabbit Monoclonal Antibody (4B5) for the Immunohistochemical (IHC) Determination of the HER2 Status in Breast Cancer: Comparison With CB11, Fluorescence In Situ Hybridization (FISH), and Interlaboratory Reproducibility. Applied Immunohistochemistry & Molecular Morphology 15:1, 94-102
CrossRef820
Anthony S.-Y. Leong, Zenobia Haffajee, Megan Clarke. (2007) Microwave Enhancement of CISH for HER2 Oncogene. Applied Immunohistochemistry & Molecular Morphology 15:1, 88-93
CrossRef821
Luc Bonneux. (2007) Mammographic screening from age 40 years. The Lancet 369:9563, 737
CrossRef822
Rebecca L. Olin, Shashank S. Desai, Kevin Fox, Rebecca Davidson. (2007) Non-Myopathic Cardiac Events in Two Patients Treated with Trastuzumab. The Breast Journal 13:2, 211-212
CrossRef823
P. Kelly Marcom, Claudine Isaacs, Lyndsay Harris, Zee Wang Wong, Aruna Kommarreddy, Nellie Novielli, Gretchen Mann, Yu Tao, Matthew J. Ellis. (2007) The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Research and Treatment 102:1, 43-49
CrossRef824
Sudhir Srivastava, Paul D Wagner. (2007) Risk-based and diagnostics-linked personalized medicine for cancer. Personalized Medicine 4:1, 33-43
CrossRef825
Aarati Ranganathan, Zachary Moore, Joyce A. O'Shaughnessy. (2007) 2007 Highlights from: The 29th Annual San Antonio Breast Cancer Symposium San Antonio, TX, December 2006. Clinical Breast Cancer 7:6, 445-454
CrossRef826
K-F Becker, C Schott, S Hipp, V Metzger, P Porschewski, R Beck, J Nährig, I Becker, H Höfler. (2007) Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. The Journal of Pathology 211:3, 370-378
CrossRef827
Max S. Mano, Daniela D. Rosa, Evandro De Azambuja, Gustavo F.V. Ismael, Virginie Durbecq. (2007) The 17q12-q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours. Cancer Treatment Reviews 33:1, 64-77
CrossRef828
Gianluigi Ferretti, Alessandra Felici, Paola Papaldo, Alessandra Fabi, Francesco Cognetti. (2007) HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Current Opinion in Obstetrics and Gynecology 19:1, 56-62
CrossRef829
Filippo Montemurro, Giorgio Valabrega, Massimo Aglietta. (2007) Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opinion on Biological Therapy 7:2, 257-268
CrossRef830
Howard Safran, Thomas DiPetrillo, Paul Akerman, Thomas Ng, Devon Evans, Margaret Steinhoff, David Benton, John Purviance, Lisa Goldstein, Umadevi Tantravahi, Teresa Kennedy. (2007) Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. International Journal of Radiation Oncology*Biology*Physics 67:2, 405-409
CrossRef831
Gurusher Singh Panjrath, Diwakar Jain. (2007) Trastuzumab-induced cardiac dysfunction. Nuclear Medicine Communications 28:2, 69-73
CrossRef832
Biyun Qian, Dan Su, Herbert Yu. (2007) Clinical oncology—A new era. Chinese Journal of Clinical Oncology 4:1, 6-8
CrossRef833
Shigeru Imoto, Noriaki Wada, Takahiro Hasebe, Atsushi Ochiai, Takashi Kitoh. (2007) Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast. International Journal of Cancer 120:2, 357-361
CrossRef834
Steven Simoens. (2007) Economic Evaluation and Decision Making. PharmacoEconomics 25:3, 181-185
CrossRef835
Christoph Thomssen, Ingo Bauerfeind, Joachim Bischoff, Jens Uwe Blohmer, Klaus Brunnert, Serban D. Costa, Peter Dall, Ingo J. Diel, Nikos Fersis, Michael Friedrich, Kay Friedrichs, Bernd Gerber, Uwe-Jochen Göhring, Volker Hanf, Nadia Harbeck, Jens Huober, Christian Jackisch, Wolfgang Janni, Walter Jonat, Manfred Kaufmann, Hans-Joachim Lück, Nicolai Maass, Volker Möbus, Ulrike Nitz, Carsten Oberhoff, Mahdi Rezai, Gerhard Schaller, Anton Scharl, Rita Schmutzler, Andreas Schneeweiß, Ingrid Schreer, H. Kreipe, Peter Sinn, Erich F. Solomayer, Rainer Souchon, Elmar Stickeler, Christoph Thomssen, Michael Untch, Gunter von Minckwitz. (2007) AGO Recommendations for the Diagnosis and Therapy of Breast Cancer. Breast Care 2:4, 244-250
CrossRef836
Meredith M. Regan, Richard D. Gelber. (2007) Using clinical trial data to tailor adjuvant treatments for individual patients. The Breast 16, 98-104
CrossRef837
Richard Theriault, Karin Hahn. (2007) Management of breast cancer in pregnancy. Current Oncology Reports 9:1, 17-21
CrossRef838
Kathleen I. Pritchard. (2007) Adjuvant therapy of the very young woman. The Breast 16, 136-146
CrossRef839
Joyce O'Shaughnessy. (2007) Developments in the systemic therapy of early-stage breast cancer. European Journal of Cancer Supplements 5:1, 3-10
CrossRef840
Stefan Aebi, Olivia Pagani. (2007) Treatment of Premenopausal Women with Early Breast Cancer. Drugs 67:10, 1393-1401
CrossRef841
Christian Jackisch, Michael Untch. (2007) Trastuzumab in the Treatment of Breast Cancer – New Developments. Breast Care 2:2, 90-93
CrossRef842
Daniel Hind, Hazel Pilgrim, Sue Ward. (2007) Questions about adjuvant trastuzumab still remain. The Lancet 369:9555, 3-5
CrossRef843
H.B. Muss. (2007) Adjuvant treatment of elderly breast cancer patients. The Breast 16, 159-165
CrossRef844
Peter H. Johnson, Francisco J. Esteva. (2007) The use of HER2 modulation in the adjuvant setting. Current Oncology Reports 9:1, 9-16
CrossRef845
J Alasdair Millar, Michael J Millward. (2007) Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer. PharmacoEconomics 25:5, 429-442
CrossRef846
Rupert Bartsch, Catharina Wenzel, Christoph C Zielinski, Guenther G Steger. (2007) HER-2-Positive Breast Cancer. BioDrugs 21:2, 69-77
CrossRef847
Hiroo NAKAJIMA, Naruhiko MIZUTA, Ikuya FUJIWARA, Koichi SAKAGUCHI, Katsuhiko NAKATSUKASA, Aya KOBAYASHI. (2007) Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons) 32:4, 643-647
CrossRef848
Raveendra Dayam, Fedora Grande, Laith Q Al-Mawsawi, Nouri Neamati. (2007) Recent advances in the design and discovery of small-molecule therapeutics targeting HER2/neu. Expert Opinion on Therapeutic Patents 17:1, 83-102
CrossRef849
Vladimir Baltić. (2007) Application of Genomics in Clinical Oncology. Journal of Medical Biochemistry 26:2, 79-93
CrossRef850
Alison K. Conlin, Andrew D. Seidman. (2007) Taxanes in breast cancer: An update. Current Oncology Reports 9:1, 22-30
CrossRef851
Sean O. Ryan, Kira R. Gantt, Olivera J. Finn. (2007) Tumor Antigen-Based Immunotherapy and Immunoprevention of Cancer. International Archives of Allergy and Immunology 142:3, 179-189
CrossRef852
Damien Downing. (2007) Herceptin madness. Journal of Nutritional and Environmental Medicine 16:1, 1-9
CrossRef853
Jennifer Laudadio, Denise I Quigley, Raymond Tubbs, Daynna J Wolff. (2007) HER2 testing: a review of detection methodologies and their clinical performance. Expert Review of Molecular Diagnostics 7:1, 53-64
CrossRef854
Phuong Dinh, Christos Sotiriou, Martine J. Piccart. (2007) The evolution of treatment strategies: Aiming at the target. The Breast 16, 10-16
CrossRef855
Keisei TAKU, Narikazu BOKU. (2007) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 38:6, 393-400
CrossRef856
Ian Smith, Marion Procter, Richard D Gelber, Sébastien Guillaume, Andrea Feyereislova, Mitch Dowsett, Aron Goldhirsch, Michael Untch, Gabriella Mariani, Jose Baselga, Manfred Kaufmann, David Cameron, Richard Bell, Jonas Bergh, Robert Coleman, Andrew Wardley, Nadia Harbeck, Roberto I Lopez, Peter Mallmann, Karen Gelmon, Nicholas Wilcken, Erik Wist, Pedro Sánchez Rovira, Martine J Piccart-Gebhart. (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. The Lancet 369:9555, 29-36
CrossRef857
Hiroo NAKAJIMA, Ikuya FUJIWARA, Naruhiko MIZUTA, Koichi SAKAGUCHI, Yasushi HACHIMINE, Katsuhiko NAKATSUKASA, Miho ICHIDA, Eiichi KONISHI, Akio YANAGISAWA. (2007) INVESTIGATION OF THE PROGNOSIS OF BREAST CANCER FROM THE VIEW POINT OF PRESENTATION OF ESTROGEN RECEPTOR AND HER2 IN IMMUNOHISTOCHEMICAL STAINING. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 68:9, 2171-2177
CrossRef858
Edith A. Perez, Mansoina. Baweja. 2007. HER2-Positive Breast Cancer: Current Treatment Strategies. , 189-202.
CrossRef859
B.C. John Cho, David R. McCready. (2007) Oncologic Principles in Breast Reconstruction. Clinics in Plastic Surgery 34:1, 1-13
CrossRef860
Stephan Braun, Florian D. Vogl, Alois Schneitter, Daniel Egle, Doris Auer, Margarete Lang, Christian Marth. (2007) Disseminated tumor cells: Are they ready for clinical use?. The Breast 16, 51-54
CrossRef861
Michail Ignatiadis, Christine Desmedt. (2007) Predicting risk of breast cancer recurrence using gene-expression profiling. Pharmacogenomics 8:1, 101-111
CrossRef862
Muss, Hyman B., . (2006) Targeted Therapy for Metastatic Breast Cancer. New England Journal of Medicine 355:26, 2783-2785
Full Text863
Geyer, Charles E., Forster, John, Lindquist, Deborah, Chan, Stephen, Romieu, C. Gilles, Pienkowski, Tadeusz, Jagiello-Gruszfeld, Agnieszka, Crown, John, Chan, Arlene, Kaufman, Bella, Skarlos, Dimosthenis, Campone, Mario, Davidson, Neville, Berger, Mark, Oliva, Cristina, Rubin, Stephen D., Stein, Steven, Cameron, David, . (2006) Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine 355:26, 2733-2743
Full Text864
R. T. Chlebowski, G. L. Blackburn, C. A. Thomson, D. W. Nixon, A. Shapiro, M. K. Hoy, M. T. Goodman, A. E. Giuliano, N. Karanja, P. McAndrew, C. Hudis, J. Butler, D. Merkel, A. Kristal, B. Caan, R. Michaelson, V. Vinciguerra, S. Del Prete, M. Winkler, R. Hall, M. Simon, B. L. Winters, R. M. Elashoff. (2006) Dietary Fat Reduction and Breast Cancer Outcome: Interim Efficacy Results From the Women's Intervention Nutrition Study. JNCI Journal of the National Cancer Institute 98:24, 1767-1776
CrossRef865
F. Stenner-Liewen, A. Zippelius, B. C. Pestalozzi, A. Knuth. (2006) Molekular zielgerichtete Therapie. Der Chirurg 77:12, 1118-1125
CrossRef866
L. Michael Glodé. (2006) The Case for Adjuvant Therapy for Prostate Cancer. The Journal of Urology 176:6, S30-S33
CrossRef867
Stefan Aebi. (2006) Chemotherapy - overview and future perspectives. The Breast 15, S11-S14
CrossRef868
Anthony S-Y Leong, Mark Formby, Zenobia Haffajee, Megan Clarke, Adrienne Morey. (2006) Refinement of Immunohistologic Parameters for Her2/neu Scoring Validation by FISH and CISH. Applied Immunohistochemistry & Molecular Morphology 14:4, 384-389
CrossRef869
J. Eucker, A. Emde, K. Possinger. (2006) Therapie des Mammakarzinoms. Der Internist 47:12, 1223-1228
CrossRef870
Ivan P Uray, Powel H Brown. (2006) Prevention of breast cancer: current state of the science and future opportunities. Expert Opinion on Investigational Drugs 15:12, 1583-1600
CrossRef871
S Esseghir, JS Reis-Filho, A Kennedy, M James, MJ O'Hare, R Jeffery, R Poulsom, CM Isacke. (2006) Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts. The Journal of Pathology 210:4, 420-430
CrossRef872
Joseph P. Crowe, Rebecca J. Patrick, Lisa A. Rybicki, Pedro F. Escobar, David Weng, G. Thomas Budd, Raymond R. Tubbs, Gary W. Procop, David G. Hicks. (2006) A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution. The Breast 15:6, 728-735
CrossRef873
B. You, V. Trillet-Lenoir. (2006) Thérapeutiques anticancéreuses ciblées. La Revue de Médecine Interne 27, S285-S288
CrossRef874
Christina Richard, Jonathan Yau, John P. H. Th’ng, Wilhelmina C. M. Duivenvoorden. (2006) Naturally occurring resistance of bone marrow mononuclear and metastatic cancer cells to anticancer agents. Clinical & Experimental Metastasis 23:5-6, 249-258
CrossRef875
Axel Schulenburg, Herbert Ulrich-Pur, Dietmar Thurnher, Boban Erovic, Stefan Florian, Wolfgang R. Sperr, Peter Kalhs, Brigitte Marian, Friedrich Wrba, Christoph C. Zielinski, Peter Valent. (2006) Neoplastic stem cells: A novel therapeutic target in clinical oncology. Cancer 107:10, 2512-2520
CrossRef876
Poole, Christopher J., Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, Sarah, Grieve, Robert J., Spooner, David A., Agrawal, Rajiv K., Fernando, Indrajit N., Brunt, A. Murray, O'Reilly, Susan M., Crawford, S. Michael, Rea, Daniel W., Simmonds, Peter, Mansi, Janine L., Stanley, Andrew, Harvey, Peter, McAdam, Karen, Foster, Liz, Leonard, Robert C.F., Twelves, Christopher J., . (2006) Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer. New England Journal of Medicine 355:18, 1851-1862
Full Text877
Paola Queirolo, Mirko Acquati. (2006) Targeted therapies in melanoma. Cancer Treatment Reviews 32:7, 524-531
CrossRef878
Vered Stearns, Bryan Schneider, N. Lynn Henry, Daniel F. Hayes, David A. Flockhart. (2006) Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nature Reviews Cancer 6:11, 886-893
CrossRef879
SM Tovey, JR Reeves, P Stanton, BW Ozanne, JMS Bartlett, TG Cooke. (2006) Low expression of HER2 protein in breast cancer is biologically significant. The Journal of Pathology 210:3, 358-362
CrossRef880
Andrea Rocca, Giulia Peruzzotti, Raffaella Ghisini, Giuseppe Viale, Paolo Veronesi, Alberto Luini, Mattia Intra, Elisabetta Pietri, Giuseppe Curigliano, Filippo Giovanardi, Patrick Maisonneuve, Aron Goldhirsch, Marco Colleoni. (2006) A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. Anti-Cancer Drugs 17:10, 1201-1209
CrossRef881
Jeffrey S Ross, W Fraser Symmans, Lajos Pusztai, Gabriel N Hortobagyi. (2006) Personalized medicine for breast cancer: moving forward and going back. Personalized Medicine 3:4, 363-370
CrossRef882
Michael Davies, Bryan Hennessy, Gordon B Mills. (2006) Point mutations of protein kinases and individualised cancer therapy. Expert Opinion on Pharmacotherapy 7:16, 2243-2261
CrossRef883
S. Arif, P.J. Barrett-Lee, C. Jordan. (2006) The Incidence and Treatment Outcome after Radiotherapy for Brain Metastases in HER-2-positive Metastatic Breast Cancer Patients Treated with Trastuzumab. Clinical Oncology 18:9, 719-720
CrossRef884
G Frasci, G D'Aiuto, P Comella, R Thomas, G Botti, M Di Bonito, V De Rosa, G Iodice, M R Rubulotta, G Comella. (2006) Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study. British Journal of Cancer 95:8, 1005-1012
CrossRef885
Lorenzo Moja, Cinzia Brambilla, Anna Compagnoni, Vanna Pistotti, Lorenzo Moja. 2006. Trastuzumab containing regimens for early breast cancer. .
CrossRef886
M. Namer, J. Gligorov, E. Luporsi, D. Serin, . (2006) Breast cancer clinical practice recommendations from Saint-Paul-de-Vence: excerpts concerning targeted therapies. Targeted Oncology 1:4, 228-238
CrossRef887
J M Cummins, V E Velculescu. (2006) Implications of micro-RNA profiling for cancer diagnosis. Oncogene 25:46, 6220-6227
CrossRef888
Andrea H. Bild, Anil Potti, Joseph R. Nevins. (2006) Linking oncogenic pathways with therapeutic opportunities. Nature Reviews Cancer 6:9, 735-741
CrossRef889
Karen Lisa Smith, Chau Dang, Andrew D Seidman. (2006) Cardiac dysfunction associated with trastuzumab. Expert Opinion on Drug Safety 5:5, 619-629
CrossRef890
M Laakso, M Tanner, J Isola. (2006) Dual-colour chromogenicin situ hybridization for testing ofHER-2 oncogene amplification in archival breast tumours. The Journal of Pathology 210:1, 3-9
CrossRef891
Eleanor E. R. Harris, Wei-Ting Hwang, Eric A. Lee, Keith A. Cengel, Michael D. Feldman, Angela DeMichele, Gary Kao, Lawrence J. Solin. (2006) The Impact of HER-2 Status on Local Recurrence in Women with Stage I?II Breast Cancer Treated with Breast-Conserving Therapy. The Breast Journal 12:5, 431-436
CrossRef892
Michael C Cox, Tu D Dan, Sandra M Swain. (2006) Emerging drugs to replace current leaders in first-line therapy for breast cancer. Expert Opinion on Emerging Drugs 11:3, 489-501
CrossRef893
Trishe Y.-M. Leong, Anthony S.-Y. Leong. (2006) Controversies in the Assessment of HER-2. Advances in Anatomic Pathology 13:5, 263-269
CrossRef894
Kadri Altundag, Mauricio Z. Baptista. (2006) Why Adjuvant Trastuzumab Led to Better Outcomes in Women with High-Risk HER-2-Positive Breast Cancer. The Breast Journal 12:5, 497-498
CrossRef895
Ranee Mehra, Barbara Burtness. (2006) Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials. Expert Opinion on Biological Therapy 6:9, 951-962
CrossRef896
Robin L Jones, Michael S Ewer. (2006) Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Review of Anticancer Therapy 6:9, 1249-1269
CrossRef897
N. Ditsch, S. Kahlert, M. Lenhard, C. Kümper, I. Bauerfeind, M. Untch. (2006) Immunologische Therapie beim Mammakarzinom. Der Onkologe 12:9, 945-954
CrossRef898
(2006) Anthracyclines in Early Breast Cancer. New England Journal of Medicine 355:8, 845-846
Full Text899
O'Shaughnessy, Joyce A., . (2006) Molecular Signatures Predict Outcomes of Breast Cancer. New England Journal of Medicine 355:6, 615-617
Full Text900
I Bernard Weinstein, Andrew K Joe. (2006) Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy. Nature Clinical Practice Oncology 3:8, 448-457
CrossRef901
Patricia S Steeg. (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nature Medicine 12:8, 895-904
CrossRef902
Andrew I. Minchinton, Ian F. Tannock. (2006) Drug penetration in solid tumours. Nature Reviews Cancer 6:8, 583-592
CrossRef903
Risto Kerkelä, Luanda Grazette, Rinat Yacobi, Cezar Iliescu, Richard Patten, Cara Beahm, Brian Walters, Sergei Shevtsov, Stéphanie Pesant, Fred J Clubb, Anthony Rosenzweig, Robert N Salomon, Richard A Van Etten, Joseph Alroy, Jean-Bernard Durand, Thomas Force. (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Medicine 12:8, 908-916
CrossRef904
Huguette Albrecht, Sally J. DeNardo. (2006) Update : Recombinant Antibodies: From the Laboratory to the Clinic. Cancer Biotherapy & Radiopharmaceuticals 21:4, 285-304
CrossRef905
Nickolas Papadopoulos, Kenneth W Kinzler, Bert Vogelstein. (2006) The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nature Biotechnology 24:8, 985-995
CrossRef906
Ute Wölfle, Volkmar Müller, Klaus Pantel. (2006) Disseminated tumor cells in breast cancer: detection, characterization and clinical relevance. Future Oncology 2:4, 553-561
CrossRef907
D K Wilkins, A Mayer. (2006) Development of antibodies for cancer therapy. Expert Opinion on Biological Therapy 6:8, 787-796
CrossRef908
Jan Norum. (2006) The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer. Expert Opinion on Pharmacotherapy 7:12, 1617-1625
CrossRef909
Sofia Braga, Lissandra dal Lago, Chantal Bernard, Fátima Cardoso, Martine Piccart. (2006) Use of trastuzumab for the treatment of early stage breast cancer. Expert Review of Anticancer Therapy 6:8, 1153-1164
CrossRef910
Mark Pegram, Debbie Ngo. (2006) Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin®): A case study. Advanced Drug Delivery Reviews 58:5-6, 723-734
CrossRef911
Tim Byers, Ermilo Barrera, Elizabeth T. H. Fontham, Lisa A. Newman, Carolyn D. Runowicz, Stephen F. Sener, Michael J. Thun, Sara Winborn, Richard C. Wender, . (2006) A midpoint assessment of the American Cancer Society challenge goal to halve the U.S. cancer mortality rates between the years 1990 and 2015. Cancer 107:2, 396-405
CrossRef912
Eriko Tokunaga, Eiji Oki, Kojiro Nishida, Tadashi Koga, Akinori Egashira, Masaru Morita, Yoshihiro Kakeji, Yoshihiko Maehara. (2006) Trastuzumab and breast cancer: developments and current status. International Journal of Clinical Oncology 11:3, 199-208
CrossRef913
Miguel Martin. (2006) Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer. Women's Health 2:4, 527-537
CrossRef914
Melinda Epstein, Yanling Ma, Michael F. Press. (2006) Herceptin (Trastuzumab) in the Adjuvant Setting: The Need for Accurate HER-2 Testing in Breast Cancer. Advances in Anatomic Pathology 13:4, 200-201
CrossRef915
Hitoshi Tsuda. (2006) HER-2 (c-erbB-2) test update: Present status and problems. Breast Cancer 13:3, 236-248
CrossRef916
Nancy E. Hynes, Thomas Schlange. (2006) Targeting ADAMS and ERBBs in lung cancer. Cancer Cell 10:1, 7-11
CrossRef917
Luke A. J. O'Neill. (2006) Targeting signal transduction as a strategy to treat inflammatory diseases. Nature Reviews Drug Discovery 5:7, 549-563
CrossRef918
Niklaus G Schaefer, Bernhard C Pestalozzi, Alexander Knuth, Christoph Renner. (2006) Potential use of humanized antibodies in the treatment of breast cancer. Expert Review of Anticancer Therapy 6:7, 1065-1074
CrossRef919
Tiffany H. Svahn, Robert W. Carlson. (2006) Modest benefits of adjuvant chemotherapy in hormone receptor-positive breast cancer. Breast Cancer Online 9:07,
CrossRef920
L.W.C. Chow, C.C.P. Yiu, A.Y.S. Yip, W.T.Y. Loo. (2006) The future perspectives of breast cancer therapy. Biomedicine & Pharmacotherapy 60:6, 259-262
CrossRef921
Chunfai Lai, Xin Jiang, Xianqiang Li. (2006) Development of Luciferase Reporter-Based Cell Assays. ASSAY and Drug Development Technologies 4:3, 307-315
CrossRef922
M Myat Moe, T Pwint Pwint, RCF Leonard. (2006) Treatment options for older woman with early breast cancer. Expert Review of Anticancer Therapy 6:6, 941-950
CrossRef923
Stan Kaye. (2006) Which drugs for which patients?. Future Oncology 2:3, 317-319
CrossRef924
Ryan P. Million. (2006) Impact of genetic diagnostics on drug development strategy. Nature Reviews Cancer 5:6, 459-462
CrossRef925
C. Jochims, U. Mazitschek, D. Jäger, H. Goldschmidt. (2006) Zielgerichtete Therapie bei soliden Tumoren und in der Hämatoonkologie. Der Internist 47:6, 633-641
CrossRef926
Emilio Bria, Cecilia Nistico, Federica Cuppone, Paolo Carlini, Mariangela Ciccarese, Michele Milella, Guido Natoli, Edmondo Terzoli, Francesco Cognetti, Diana Giannarelli. (2006) Benefit of taxanes as adjuvant chemotherapy for early breast cancer. Cancer 106:11, 2337-2344
CrossRef927
Karin Schreiber, Donald A. Rowley, Gert Riethmüller, Hans Schreiber. (2006) Cancer Immunotherapy and Preclinical Studies: Why We Are Not Wasting Our Time with Animal Experiments. Hematology/Oncology Clinics of North America 20:3, 567-584
CrossRef928
Benny Vittrup Jensen. (2006) Cardiotoxic Consequences of Anthracycline-Containing Therapy in Patients With Breast Cancer. Seminars in Oncology 33, 15-21
CrossRef929
Emer O. Hanrahan, Kristine Broglio, Deborah Frye, Aman U. Buzdar, Richard L. Theriault, Vicente Valero, Daniel J. Booser, Sonja E. Singletary, Eric A. Strom, James L. Gajewski, Richard E. Champlin, Gabriel N. Hortobagyi. (2006) Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma. Cancer 106:11, 2327-2336
CrossRef930
(2006) Trastuzumab Treatment in Breast Cancer. New England Journal of Medicine 354:20, 2186-2186
Full Text931
M.-O. Grimm, F. H. Hartmann, R. Ackermann. (2006) Zukunft der Chemotherapie. Der Urologe 45:5, 567-571
CrossRef932
Rita Nahta, Dihua Yu, Mien-Chie Hung, Gabriel N Hortobagyi, Francisco J Esteva. (2006) Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clinical Practice Oncology 3:5, 269-280
CrossRef933
Thomas Ng, Thomas Dipetrillo, John Purviance, Howard Safran. (2006) Multimodality treatment of esophageal cancer: A review of the current status and future directions. Current Oncology Reports 8:3, 174-182
CrossRef934
Heidi A. Lane, David Lebwohl. (2006) Future Directions in the Treatment of Hormone-Sensitive Advanced Breast Cancer: The RAD001 (Everolimus)-Letrozole Clinical Program. Seminars in Oncology 33, 18-25
CrossRef935
Rebecca Dent, Mark Clemons. (2006) Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence. Cancer Treatment Reviews 32:2, 144-148
CrossRef936
Ahmad Al-Hajj, Ruth O’Regan. (2006) Selection of optimal adjuvant endocrine therapy for early-stage breast cancer. Current Treatment Options in Oncology 7:2, 153-165
CrossRef937
T. B. Y. Liem. (2006) Trastuzumab in combinatie met en na adjuvante chemotherapie bij borstkanker. MFM 44:4, 107-109
CrossRef938
Sheila A Doggrell. (2006) ‘Simply stunning’ – trastuzumab in HER2-positive breast cancer. Expert Opinion on Pharmacotherapy 7:5, 631-634
CrossRef939
H. G. Sayer, H. Schmalenberg. (2006) Versorgungsforschung in Deutschland: Mammakarzinom. Der Onkologe 12:4, 350-355
CrossRef940
Andrew D Seidman. (2006) Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?. Nature Clinical Practice Oncology 3:4, 178-179
CrossRef941
Ruth E Board, Emma J Dean, Claire Mitchell, Andrew M Wardley. (2006) Second-line treatment of postmenopausal women with advanced breast carcinoma. Expert Review of Anticancer Therapy 6:4, 613-624
CrossRef942
Joanne E Mortimer, Sarah L Blair. (2006) Management of early stage breast cancer in the elderly. Aging Health 2:2, 245-251
CrossRef943
Masakazu Toi, Yuichi lino. (2006) Who benefits from hormone therapy?. Breast Cancer 13:2, 117-122
CrossRef944
Koji MATSUMOTO, Chikako SHIMIZU, Yasuhiro FUJIWARA. (2006) The next step to approaching central nervous system metastasis in HER-2-positive metastatic breast cancer patients. Asia-Pacific Journal of Clinical Oncology 2:1, 6-8
CrossRef945
John Bryant, Charles E Geyer. (2006) Trastuzumab for early breast cancer. The Lancet 367:9512, 728
CrossRef946
Dale Chenoweth. (2006) Can single-patient investigational new drug studies hurry slow trains to the fast track?. Drug Discovery Today 11:5-6, 185-186
CrossRef947
(2006) Scientific surgery. British Journal of Surgery 93:3, 378-378
CrossRef948
Steven Khoo, Sathibalan Ponniah, George E Peoples. (2006) HER2/neu vaccines in breast cancer. Women's Health 2:2, 217-223
CrossRef949
Chau T Dang. (2006) Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions. Expert Review of Anticancer Therapy 6:3, 427-436
CrossRef950
D Yee. (2006) Targeting insulin-like growth factor pathways. British Journal of Cancer 94:4, 465-468
CrossRef951
Joensuu, Heikki, Kellokumpu-Lehtinen, Pirkko-Liisa, Bono, Petri, Alanko, Tuomo, Kataja, Vesa, Asola, Raija, Utriainen, Tapio, Kokko, Riitta, Hemminki, Akseli, Tarkkanen, Maija, Turpeenniemi-Hujanen, Taina, Jyrkkiö, Sirkku, Flander, Martti, Helle, Leena, Ingalsuo, Seija, Johansson, Kaisu, Jääskeläinen, Anna-Stina, Pajunen, Marjo, Rauhala, Mervi, Kaleva-Kerola, Jaana, Salminen, Tapio, Leinonen, Mika, Elomaa, Inkeri, Isola, Jorma, . (2006) Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer. New England Journal of Medicine 354:8, 809-820
Full Text952
(2006) Trastuzumab in Breast Cancer. New England Journal of Medicine 354:6, 640-644
Full Text953
E Claire Dees, Robert Z Orlowski. (2006) Targeting the ubiquitin–proteasome pathway in breast cancer therapy. Future Oncology 2:1, 121-135
CrossRef954
Sabeeha Muneer, Aarati Ranganathan, Susan Peck, Latha Shivakumar, Joyce A. O'Shaughnessy. (2006) 2005 Highlights From: The 28th Annual San Antonio Breast Cancer Symposium; San Antonio, TX December 2005. Clinical Breast Cancer 6:6, 481-489
CrossRef955
Raymond Ng, Nathan Better, Michael D. Green. (2006) Anticancer Agents and Cardiotoxicity. Seminars in Oncology 33:1, 2-14
CrossRef956
Tufia Haddad, Douglas Yee. (2006) Targeting the insulin-like growth factor axis as a cancer therapy. Future Oncology 2:1, 101-110
CrossRef957
Mangesh Thorat. (2006) Trastuzumab for early breast cancer. The Lancet 367:9505, 108
CrossRef958
H SWEETLAND. (2006) Adjuvant therapy for breast cancer. Women's Health Medicine 3:1, 36-39
CrossRef959
Peter Littlejohns. (2006) Trastuzumab for early breast cancer: evolution or revolution?. The Lancet Oncology 7:1, 22-23
CrossRef960
Ian E Smith. (2006) Trastuzumab for early breast cancer. The Lancet 367:9505, 107
CrossRef961
Sebastian F. Schoppmann, Raimund Jakesz. (2006) Early-Stage Breast Cancer – Highlights at ASCO 2006. Breast Care 1:4, 265-269
CrossRef962
Alexandra King. (2006) Major developments in adjuvant treatment of early HER2-positive breast cancer. Nature Clinical Practice Oncology 3:1, 10-11
CrossRef963
Nancy E. Hynes, William Gullick. (2006) Therapeutic Targeting of Signal Transduction Pathways and Proteins in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia 11:1, 1-2
CrossRef964
Samuel K. Chan, Mark E. Hill, William J. Gullick. (2006) The Role of the Epidermal Growth Factor Receptor in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia 11:1, 3-11
CrossRef965
Debra Patt, Michelle Gauthier, Sharon Giordano. (2006) Paclitaxel in breast cancer. Women's Health 2:1, 11-21
CrossRef966
N Lynn Henry, Kathleen M Diehl, Daniel F Hayes. (2006) Adjuvant systemic therapy for elderly women with breast cancer. Women's Health 2:1, 75-87
CrossRef967
Nina Ditsch, Sandra Rückert, Carolin Kümper, Miriam Lenhard, Steffen Kahlert, Ingo Bauerfeind, Klaus Friese, Michael Untch. (2006) Trastuzumab (Herceptin<sup>®</sup>): Monoclonal Antibody in the Treatment of HER2/neu-Overexpressing Breast Cancer in the Metastatic and (Neo)adjuvant Situation. Breast Care 1:2, 78-84
CrossRef968
Colleen Sweeney, Jamie K. Miller, David L. Shattuck, Kermit L. Carraway. (2006) ErbB Receptor Negative Regulatory Mechanisms: Implications in Cancer. Journal of Mammary Gland Biology and Neoplasia 11:1, 89-99
CrossRef969
Annette Lebeau. (2006) HER2 Testing in Breast Cancer: Opportunities and Challenges. Breast Care 1:2, 69-76
CrossRef970
Pedram Argani. (2006) Trastuzumab as Adjuvant Therapy for Primary Breast Cancer. Advances in Anatomic Pathology 13:1, 66-67
CrossRef971
Chantal Bernard-Marty, Fabienne Lebrun, Ahmad Awada, Martine J Piccart. (2006) Monoclonal Antibody-Based Targeted Therapy in Breast Cancer. Drugs 66:12, 1577-1591
CrossRef972
Deepali Sachdev, Douglas Yee. (2006) Inhibitors of Insulin-like Growth Factor Signaling: A Therapeutic Approach for Breast Cancer. Journal of Mammary Gland Biology and Neoplasia 11:1, 27-39
CrossRef973
Clifford A Hudis. (2006) Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer. Nature Clinical Practice Oncology 3:1, 12-13
CrossRef974
Volker R. Jacobs. (2006) Current Status of Financing and Reimbursement of Trastuzumab (Herceptin<sup>®</sup>) for Adjuvant and Advanced Therapy of Breast Cancer in Germany. Breast Care 1:2, 86-94
CrossRef975
Christian Jackisch, Andreas Schneeweiss. (2006) Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients. Breast Care 1:4, 242-247
CrossRef976
G. Des Guetz. (2006) The 41st annual ASCO meeting: targeted therapies, Orlando, Florida. Targeted Oncology 1:1, 59-65
CrossRef977
Greg L Plosker, Susan J Keam. (2006) Trastuzumab. Drugs 66:4, 449-475
CrossRef978
Daniele Santini, Bruno Vincenzi, Giuseppe Tonini. (2006) Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?. Women's Health 2:1, 1-3
CrossRef979
Ali Badache, Anthony Gonçalves. (2006) The ErbB2 Signaling Network as a Target for Breast Cancer Therapy. Journal of Mammary Gland Biology and Neoplasia 11:1, 13-25
CrossRef980
Rakesh K Jain, Dan G Duda, Jeffrey W Clark, Jay S Loeffler. (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clinical Practice Oncology 3:1, 24-40
CrossRef981
(2005) News In Brief. Nature Reviews Drug Discovery 4:12, 948-949
CrossRef982
Hortobagyi, Gabriel N., . (2005) Trastuzumab in the Treatment of Breast Cancer. New England Journal of Medicine 353:16, 1734-1736
Full Text983
Burstein, Harold J., . (2005) The Distinctive Nature of HER2-Positive Breast Cancers. New England Journal of Medicine 353:16, 1652-1654
Full Text
- Letters
